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CHAPTER  I   –  
INTRODUCTION 
 
1.1 EPIGENETICS 
 
1.1.1 Background information 
 
“There appear to be about 30,000 – 40,000 protein-coding genes in the human 
genome – only about twice as many as in worm or fly1.”  
 
After the draft sequence of the human genome was published1 in Nature in 2001 
by the International Human Genome Sequencing Consortium (example see Figure 
1), this statement, mentioned above, equals a disillusion for science and the result 
was even revised downwards to 20,000 – 25,000 genes after the publication of the 
final sequence2 in 2004. Previous calculations, for example of Randall Scott3 or 
John Quackenbush4, estimated a range between 130,000 and 140,000 genes – 
approximately the fourfold of the ones actually found. But of what reason the vast 
complexity of humans does not result in significantly more genes than a worm? 
One of the answers is that for most 
gen regulations, and e.g. the 
following cell differentiations, 
epigenetic factors are responsible5. 
 
Figure 1. Protein coding sequence of 
human gene SNTG2 (splice variant 3) 
located on chromosome 2
6
. 
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Conrad Hal Waddington wrote in 1942 in his paper “The Epigenotype” about 
hereditary information concerning the developmental process between genotype 
and phenotype7. For this mechanics of development, Waddington coined the word 
epigenetics7,8, a combination of epigenesis and genetics, referring to the term 
phenogenetics, which was predominantly introduced by Haecker9. Waddington’s 
definition could be understood as a further improvement of the well-known theory 
of epigenesis. 
 
Beside several new definitions for epigenetics along the years, Robin Holliday 
described it, in 1990, as “the study of the mechanism of temporal and spatial 
control of gene activity during the development of complex organisms"10. A more 
defined and generally accepted definition was given in 1996 by Arthur Riggs as 
“the study of mitotically and / or meiotically heritable changes in gene function that 
cannot be explained by changes in DNA sequence"11. 
 
 
 
1.1.2 From DNA to chromosomes 
 
To gain a better insight of how epigenetics affect gene regulations, it is essential to 
understand the structure and the constitution of chromatin (Figure 2), especially of 
DNA and histones12,13. 
 
The double-stranded deoxyribonucleic acid (DNA), built-up of nucleotides, forms a 
right-handed -helix, with its two chains running antiparallel to each other14. The 
complementary nucleobase pairs adenine with thymine and guanine with cytosine 
are located on the inside, while the phosphate-sugar chains of the nucleotides are 
responsible for the polar surface on the outside of the DNA14. 
 
The human DNA, with its approximately 6 billion base pairs – divided into 46 
chromosomes – and a theoretical length of 2 meters, has to be stored into a cell 
nucleus of merely 6 µm in diameter15,16. Next to supercoiling of DNA, done by 
topoisomerases17, histone proteins play an essential role for DNA packing18. 
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Figure 2. Illustration for the build-up of chromosomes
19
. 
 
Histone proteins prefer an octamer as quaternary structure, which is assembled by 
two of each subunit H2A, H2B, H3 and H420. A high density of amino acids 
containing basic side chains, like lysine (K) and arginine (R), lead to a surface 
cluttered with cationic residues21,22. With these side chains on the exterior of the 
histone octamer, DNA – with its negatively charged backbone – gets easily bound 
to it by salt bridges23,24 as well as hydrogen bonds and hydrophobic interactions25. 
These histone proteins, each of them wrapped around with an average of 147 
base pairs (bp) of DNA, are so called nucleosomes, the central module of 
chromatin25. These nucleosomes are connected consecutively with a 20 to 50 bp 
long unwrapped linker DNA26. 
 
Chromatin itself consists of numerous diverse components, including “DNA-
binding factors, the basal transcription machinery and its nascent transcripts, 
replication and repair machineries that copy and maintain DNA, and many other 
molecules that interact with any of these components"27. Furthermore, chromatin 
has to be divided into two states: (1) heterochromatin, which is highly compacted, 
e.g. by linker histones H128, and (2) euchromatin, a relatively open constitution, 
where linker DNA is easily accessible29. 
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1.1.3 Epigenetic marks 
 
There are two important types of epigenetic modifications, how gene regulation is 
enabled in chromatin by nature. On the one hand, methylation of DNA occurs, on 
the other hand, various changes on amino acid side chains of histones take place. 
These post-translational modifications are regulated by three groups of proteins: 
writers, erasers and readers (Figure 3)30,31,32. 
 
(1) Epigenetic writers are responsible for the addition of covalent modifications on 
histones or DNA, for example histone acetyltransferases (HATs), which are 
responsible for acetylation of lysine residues in histones. 
 
(2) Epigenetic erasers, like histone deacetylases (HDACs), remove the 
corresponding epigenetic mark from either the DNA or from histones. 
 
(3) The function of epigenetic readers, represented e.g. by chromodomains or 
bromodomains (BRDs), is the specific recognition of chemically modified 
amino acid side chains by protein-protein interactions. Consequently, they are 
found very often as subunits of eraser or writer proteins, directing and 
stabilizing those on the right location of the histone or DNA. 
 
 
Figure 3. Epigenetic regulators are clustered into three groups: writers, erasers and readers
30
. 
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1.1.3.1 DNA methylation 
 
The most important epigenetic modification of DNA is 5-methylcytosine (5mC), 
which is mainly observed in 5’-deoxycytidine-3’-phosphate-5’-deoxyguanosine-3’ 
(CpG) dinucleotides15,33. However, this heritable methylation has neither an 
influence on the base pairing with guanine nor an effect on the genetic information 
of the DNA34. Thus, the complementary dinucleotide on the opposite DNA strand 
shows the same CpG motif and also contains the 5mC (Figure 4)35. 
 
 
Figure 4. CpG motif of a DNA double strand with both cytosines methylated (red) in 5 position. 
Hydrogen bonds between cytosine und guanine are colored blue. 
 
DNA methyltransferases (DNMTs) are responsible for transferring methyl groups 
onto DNA36. Family members DNMT3a and DNMT3b are able to methylate 
cytosine de novo on both sides of the DNA strand (Figure 5A), whereas the 
function of DNMT1 is the complementation of the methyl pattern of a replicated 
DNA strand (Figure 5B)35,37. DNA methylation pattern, for example, can regulate 
tissue-specific gene transcription and gene silencing37,38. Moreover, a lack of 
DNMTs was observed to lead to lethality of embryonic mice39. 
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Figure 5. (A) Cytosin de novo methylation (blue) of both complementary DNA strands on a CpG 
motif by DNMT3 a/b. (B) DNMT1 complements the missing methyl groups (red) of the newly 
synthesized daughter strand
37
. 
 
 
 
1.1.3.2 Histone modifications 
 
A broader diversity of histone modifications (Figure 7) is given in contrast to simple 
DNA methylation. This includes ubiquitylation (Ub) of lysines (K), isomerization 
(Iso) of prolines (P) and phosphorylation (Ph) of hydroxyl group containing amino 
acids like tyrosine (Y), serine (S) and threonine (T), respectively (Figure 6)40,41.  
 
 
Figure 6. Epigenetic marks attached to amino acid side chains, like an -N-ubiquitylated lysine or a 
phosphorylated tyrosine. Also the isomerization of L-proline into D-proline plays an important role in 
epigenetics. 
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Figure 7. Epigenetic marks on amino acid side chains of histone tails. Methylation (Me), 
phosphorylation (Ph), acetylation (Ac), ubiquitylation (Ub) and proline isomerization (Iso)
40
. 
 
However, these modifications play a secondary role compared to methylation (Me) 
and acetylation (Ac), e.g. of lysine, which are the most intensively studied ones42. 
In 2002, for example, Tachibana et al. showed the necessity of a special lysine 
methylation in euchromatic histones for early embryogenesis43. The terminal  
-amino group of lysine can be monomethylated, dimethylated or trimethylated, 
whereas arginine (R) has two terminal guanidine nitrogens with different options. 
Likewise, a monomethylation of one nitrogen, or a dimethylation of either one 
nitrogen (asymmetric) or of both terminal nitrogens (symmetric)30. 
 
 
 
Figure 8. Dimethylation of arginine can occur either on the same terminal nitrogen (asymmetric 
form), or one methyl group on each terminal nitrogen (symmetric form). 
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Regardless of the respective methylation level, there is no change in the positive 
charge of the side chain in contrast to acetylation of lysine. By the loss of the 
cationic amine species in favor of the resulting uncharged amide, the affinity for 
the DNA phosphate backbone disappears, what allows chromatin to adopt a more 
relaxed structure30,44. 
 
 
 
Figure 9. The positive charge of the protonated -amino group of lysine disappears after 
acetylation by a histone acetyltransferase (HAT). 
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1.2 BROMODOMAINS 
 
1.2.1 An epigenetic recognition module 
 
Besides epigenetic readers and writers, both of which are of enormous interest for 
drug development research and have already yielded promising targets45, also the 
third group – epigenetic readers – extensively gained attention in drug discovery 
over the last couple of years. 
 
A remarkable class of epigenetic readers are bromodomains, so called because 
they were first identified in the Drosophila gene brahma46. They are the main 
protein interaction modules known for a specifically recognition of -N-acetylated 
lysines (Kac)
47. These evolutionary highly conserved units, with a length of about 
120 amino acids, consist of four left-handed -helices (Z, A, B, C), connected 
by the ZA (between Z and A) and the BC loop (between B and C)
48,49. Both 
loops have an essential role in determining binding specificity by lining the Kac 
binding site and marginal variations of their amino acid sequence50. Furthermore, 
in 2000, Owen et al. showed51 by co-crystal structures with proteins, that a 
asparagine residue, present in most BRDs, which is located in a deep hydrophobic 
cavity in between both loops, performs a hydrogen bond to the Kac (Figure 10). 
 
 
Figure 10. (A) Bromodomain BRD4(1) is shown in complex with a short peptide GGKacA from H3. 
(B) Hydrogen bonds between H3 peptide and the asparagine N140 in the hydrophobic cavity of 
BRD4(1) with several water molecules (red) around
52
. 
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Figure 11. Phylogenetic tree of 
bromodomains with all 61 modules 
clustered into eight (using Roman 
numerals I – VIII) distinct families
48
. 
 
 
 
 
 
 
 
 
 
 
46 BRD-containing proteins are encoded by the human genome, comprising one 
to six modules each protein, leading to a total number of 61 bromodomains48,53. 
They were clustered into eight families (Figure 11), using NMR models, high 
resolution crystal structures and additionally secondary structure prediction 
algorithms48,50. Müller et al. summarized54 that among these proteins, ATP-
dependent chromatin-remodeling complexes55 and methyltransferases56,57 were 
identified as well as nuclear proteins (e.g. HATs)58 and transcriptional 
coactivators59,60,61. 
 
As a consequence of the broad distribution in various classes of proteins, 
bromodomains represent a highly interesting target for small molecule inhibitors. 
BRDs are linked to several diverse disease patterns, like HIV transcription, cancer 
and inflammation62. Detailed studies showed a decreased stability and a loss of 
nuclear localization after deletion of a bromodomain in human HBRM63,64 (a 
protein of a remodeling complex), an indispensability of a BRD for the function of 
GCN5 (a histone acetyltransferase) in yeast65,66, and the need of BRDs in Bdf1 
(protein of Saccharomyces cerevisiae) for sporulation and normal mitotic 
growth67,68. In 2011, Dawson et al. already described69 an effective treatment for 
MLL-fusion leukaemia by the inhibition of bromodomains. 
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Numerous papers were published dealing with the drugability of this new class of 
protein-protein interaction modules70,71. Bamborough et al. improved phenyl-
isoxazole sulfonamides72 after analyzing inhibitor binding modes73. 3,5-Dimethyl-
isoxazoles74 and their optimization75 were published by Hewings et al. as potent 
acetyl-lysine-mimetics. While rhodanines and related heterocycles were 
discussed76 to be privileged scaffolds, 2-thiazolidinones were reported77 as 
bromodomain inhibitors already one year later by Zhao et al.. 
 
 
 
1.2.2 The BET family 
 
Subfamily II of the phylogenetic tree of bromodomains (see Figure 11) is the BET 
(bromodomain and extra-terminal) family, with its members bromodomain-
containing protein 2 (BRD2), BRD3, BRD4 and the testis specific species BRDT48. 
They belong to the class of tandem bromodomain proteins, as all of them 
comprising two N-terminal bromodomains and additionally show highly conserved 
areas as well as an extra-terminal domain (Figure 12)52. BRD2, BRD3 and BRD4 
are attributed to be transcriptional regulators78,79 and BRDT is a chromatin 
remodeling factor80. The chance, that BETs can be addressed selectively by drug-
like small molecules, without interfering with other BRDs, raised research efforts 
and led to promising inhibitors81,82. The possibility of using benzotriazepines for 
BET inhibition, we have already published in 201283. One of the most interesting 
facts deals with BRDT, which can only be found in testis and is stringently required 
for spermatogenesis80. Endeavors to produce a contraceptive for male, rely on 
targeting this protein by a potent and selective bromodomain inhibitor84. 
 
 
Figure 12. Sequence overview of mouse BRD4, starting with both N-terminal bromodomains BD1 
and BD2, followed by an extra-terminal domain ET. Suggested helical areas (h) are marked 
greenish, whereas the magenta SEED region is serine-, glutamate- and aspartate-rich. A 
conserved C-terminal motif is denoted by CTM
52
.  
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1.3 BENZODIAZEPINE PHARMACEUTICALS –  
AN IMPORTANT SUBSTANCE CLASS OF DRUGS 
 
The whole benzodiazepine (BzD) success story started in 1960, as Hoffmann-La 
Roche introduced chlordiazepoxide (Librium®, Figure 13A) in clinical treatment, 
which was synthesized by Leo H. Sternbach, one of the leading scientists in this 
research area during that time85. He also was responsible for the development of 
Diazepam, launched under the brand name Valium®, in 1963 by Hoffmann-La 
Roche (Figure 13B), which is certainly the most famous representative of 
benzodiazepines86. In the following decade from 1965 to 1975, benzodiazepines 
became the most widely prescribed drugs in the world87. Driven by this enormous 
therapeutic impact, research on benzodiazepines continued and brought 
worldwide more than 100 pharmaceuticals onto the market over the last 50 
years88. 
 
 
Figure 13. Chemical structure of (A) chlordiazepoxide (Librium
®
), the first clinical benzodiazepine 
drug and (B) diazepam, which was started under the brand name Valium
®
 in 1963. 
 
The mechanism of action of benzodiazepines is described as an allosteric 
modulation of the function of type A of the GABA (-aminobutyric acid) receptor, an 
ionotropic ligand-gated ion channel89,90. Anxiolytic, amnestic, sedative and muscle 
relaxing properties are ascribed to BzDs, which is why they are successfully used 
for seizures, anxiety, muscle spasms and sleeping disorders91,92,93. Despite these 
broad fields of application, drugs for different therapeutic use could be developed, 
as a consequence of unique elimination half-lives and GABAA subtype 
selectivity94.  
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Midazolam, for example, is used as sedative drug and for treatment of insomnia 
and acute seizures95, whereas Verster et al. described alprazolam as potent short 
acting drug for anxiety disorders96. 
 
The "WHO Model List of Essential Medicines"97 includes diazepam and 
midazolam, respectively, which proves the importance of this class of 
pharmaceuticals. 
 
As a reason of the success of benzotriazepines over decades, the structural 
closely related benzotriazepines attracted attention for further development of 
drugs. Research efforts of McDonald et al.98 and Fernandez et al.99 showed new 
biological activities with benzotriazepines and basic approaches for the future. 
 
15 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER  II   –  
Project &  
Strategy of Synthesis 
 
2.1 AIM OF THIS WORK 
 
A cooperation between the group of Prof. Dr. F. Bracher and the group of Prof. Dr. 
S. Knapp of the University of Oxford led to numerous selective and highly potent 
kinase inhibitors100. A productive chemical synthesis of compounds at the Ludwig-
Maximilians University of Munich and a well-organized team for biological assays 
at the Structural Genomics Consortium (SGC) in Oxford established an efficient 
collaboration. After years of successful research, the focus – first concentrated 
exclusively on kinases – became extended by an upcoming class of interesting 
targets: bromodomains. 
 
 
Figure 14. Chemical structures of potent inhibitors of bromodomains. 
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Positive screening results of thienodiazepines against BRD4 by Mitsubishi 
Pharmaceuticals101 and the development of potent bromodomain inhibitors like 
JQ1102 and iBET762103 (Figure 14) raised the interest for this class of drug-like 
small molecules. High-throughput screening (HTS) with commercially available 
compounds against several diverse bromodomains revealed clinical 
benzodiazepines (BzDs), e.g. alprazolam and midazolam (Figure 15) as active 
protein-protein interaction inhibitors selective for BET family members. 
 
 
Figure 15. Chemical structures of two clinical BzDs. 
 
These results gave the initiation for further investigations towards the development 
of potent and selective inhibitors targeting bromodomains of the BET family, which 
was the core issue of this PhD thesis. 
 
To gain better insight of groups relevant or even mandatory for activity of 
benzodiazepines against BETs, typical structure motifs should be varied. 
Therefore, molecular modeling based on the benzodiazepine core scaffold was 
done by the SGC. The resulting target structure (Figure 16) showed significant 
structural changes. 
 
 
Figure 16. Proposed target structure for triazolobenzodiazepine compounds. 
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Clinical triazolobenzodiazepines (TBzDs) commonly contain a 6-aryl substituent 
which was, in our first approach, replaced by an ethyl chain. Furthermore, aliphatic 
chains or (hetero-)aromatic ring systems instead of a simple methyl group in 
position 1 were proposed to reach good interactions with the preferred target 
proteins. These significant changes were supposed to result in either yielding 
already an active compound or forming the basis for further improvement of 
inhibitors by meaningful structure-activity releationships (SAR). 
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2.2 STRATEGY OF SYNTHESIS 
 
2.2.1 Synthesis development for 6-ethyltriazolobenzodiazepines 
 
Preparation of benzodiazepinone 1 was planned to be achieved according to 
established procedures104,105 via a four step synthesis. The following conversion of 
lactam 1 into thiolactam 2 should be carried out under standard conditions106 using 
phosphorus pentasulfide in pyridine. Condensation of carboxylic acid hydrazides 
with benzodiazepine-thione 2 should give the desired 6-ethyl-triazolo-
benzodiazepine compounds (Scheme 1). 
 
 
 
 
Scheme 1. Proposed synthesis for 6-ethyl-triazolobenzodiazepines. 
 
Further modifications were planned to be performed by alkylation or acylation of 
the triazolobenzodiazepines in position 4. Hester et al.107 synthesized a range of 
C-4-substituted triazolobenzodiazepines this way. After deprotonation of the 
slightly acidic methylene group (C-4) by a strong base (e.g. sodium hydride) the 
addition of an electrophile would lead to a substituted derivative (Scheme 2), 
considering that both enantiomers would be generated. For first tests in biological 
assays the racemate would be sufficient. 
 
19 
 
CHAPTER II   –   Project & strategy of synthesis 
 
 
 
 
Scheme 2. 4-substituted triazolobenzodiazepines. 
 
 
 
2.2.2 Synthesis of triazolobenzotriazepines 
 
In consequence of screening results of previously described benzodiazepine 
compounds the class of target molecules was changed to 1,2,4-benzotriazepines, 
in the course of our investigations. 
 
 
Figure 17. Chemical structure of a simple substituted triazolobenzotriazepine. 
 
The additional nitrogen atom at position 4 required a totally different plan for 
synthesis in contrast to the one already established for triazolobenzodiazepines. 
Moreover, the results by differential scanning fluorimetry showed the necessity of 
the annulated 1-methyltriazole ring as well as the preference of a 6-phenyl instead 
of a 6-ethyl residue (Figure 17). 
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2.2.2.1 4-(2-Hydroxyethyl)triazolobenzotriazepine and derivatives 
 
With regard to further functionalization, synthesis of the triazolobenzotriazepine 
scaffold was designed already containing a 2-hydroxyethyl chain. Starting from a 
commercially available 2-aminobenzophenone derivative, known benzotriazepine-
thione 3 was synthesized in three steps as described in literature108,109. 
Preparation of the 1-methyl-1,2,4-triazole ring110 should be realized by treating 
compound 3 first with hydrazine to generate a hydrazone intermediate. Ring 
closure should occur by reaction with triethyl orthoacetate and a catalytic amount 
of para-toluenesulfonic acid (Scheme 3). 
 
 
 
 
Scheme 3. Planned synthesis for 4-(2-hydroxyethyl)triazolobenzotriazepines. 
 
The hydroxyl group in compound 5 makes derivatives easily accessible. The 
missing steric hindrance of the primary alcohol allows the reaction with a broad 
variety of electrophiles under basic conditions. Anhydrides or carboxylic acid 
chlorides, for example, can be used to prepare esters. Isocyanates or 
isothiocyanates present good building blocks to yield carbamates and 
thiocarbamates, respectively. Also carbonate esters (e.g. diethyl carbonate) can 
be used to gain diversity of the attached residues (Scheme 4). 
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Scheme 4. General procedure for derivatization of 4-(2-hydroxyethyl)triazolobenzotriazepines. 
 
 
 
2.2.2.2 4-Benzyltriazolobenzotriazepine 
 
According to the previously described procedure yielding a 2-hydroxyethyl 
substituent in 4 position, commercially available benzylhydrazine 7 should be used 
as starting material to realize a 4-benzyltriazolobenzotriazepine 10. 
 
 
 
 
Scheme 5. Proposed synthesis of 4-benzyltriazolobenzotriazepine. 
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After nucleophilic addition of benzylhydrazine 7 to the isothiocyanate group of 
known108 benzophenone derivative 6 the triazepine ring was planned to be formed 
by treating compound 8 with para-toluenesulfonic acid. The triazole ring of taget 
compound 10 should be built up in the same manner110 as explained above by 
using hydrazine followed by triethyl orthoacetate and a catalytic amount of para-
toluenesulfonic acid (Scheme 5). 
 
 
 
2.2.2.3 4-Substituted 8-chloro-6-phenyl-4H-triazolobenzotriazepine 
 
To avoid a permanently repeating synthesis with at least five steps and the poor 
commercial availability of benzylhydrazines showed the requirement for a central 
precursor which can be functionalized in a fast and simple way. 
 
Nakamura et al. described a synthesis110 of 8-chloro-1-methyl-6-phenyl-4H-
triazolobenzotriazepine 11 in a convergent synthesis with overall nine steps. This 
intermediate can be subjected to N-alkylation by adding a base and various 
substituted benzyl chlorides or benzyl bromides to generate a series of different  
4-benzyltriazolobenzotriazepine derivatives (Scheme 6). 
 
 
Scheme 6. N-Alkylation of compound 11 using various substituted benzyl chlorides or bromides. 
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The alkylation of compound 11 with propargyl bromide 12 enables another 
possibility to gain diversity of target compounds. The terminal alkyne 13 offers the 
option for copper(I)-catalyzed azide-alkyne cycloaddition111, which is tolerating a 
broad variety of functional groups. Primary, secondary and even tertiary aliphatic 
azides as well as aromatic ones can be used111. With additional reagents  
L-ascorbate, in stoichiometric, and copper(II) sulfate pentahydrate in catalytic 
amounts the 1,2,3-triazole containing compounds should be obtained (Scheme 7). 
 
 
 
 
Scheme 7. Synthesis of 1,2,3-triazoles via 1,3-dipolar cycloaddition of terminal alkyne 13 and 
azides. 
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2.2.2.4 4H-Triazolobenzotriazepines with modified core scaffold 
 
All triazolobenzotriazepines planned to be synthesized above share a common 
skeletal structure as well as the same substitution pattern: a 1-methyl group, a  
6-phenyl residue and chlorine in position 8. For this reason they can be clustered 
to a group named “chloro series”. As already mentioned the annulated  
1-methyltriazole ring revealed as an important structural element, position 8 and 
the 6-phenyl ring were focused for further variation of substituents to gain a better 
insight of structure-activity relationship. Again Nakamura et al. described the 
synthesis110 of two additional 4H-triazolobenzotriazepines 14 and 15 (Figure 18). 
 
 
Figure 18. Chemical structures of the 8-nitro-6-phenyl-4H-triazolobenzotriazepine 14 and the  
8-chloro-6-(2-chlorophenyl)-4H-triazolobenzotriazepine 15. 
 
Starting from the corresponding commercially available 2-aminobenzophenone 
derivatives, target molecules 14 and 15, respectively, can be built up in a 
synthesis of 6 steps. With a similar reaction as shown in Scheme 6, N-alkylation of 
compounds 14 and 15 with substituted benzyl chlorides or benzyl bromides should 
be carried out (Scheme 8). 
 
Referring to the term “chloro series” used before and to obtain a better overview of 
screening results, tables and in discussions the compounds planned to be 
synthesized were clustered again. All target molecules yielded after alkylation of 
TBzT 14 were grouped into the “nitro series”, all molecules with the substitution 
pattern 8-chloro and 6-(2-chlorophenyl) according to intermediate 15 were 
summed up as “dichloro series”. 
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Scheme 8. Planned synthesis for generating the “nitro series” and the “dichloro series”. 
 
 
 
2.2.2.5 Further optimization of the annulated benzo ring system 
 
Based on new results further refinement of the bromodomain inhibitors had to be 
done. Having a 6-(2-chlorophenyl) and a 4-(3-methoxybenzyl) moiety attached to 
the triazolobenzotriazepine turned out to be the most favorable combination. 
Therefore, both residues were kept constant during optimization of the benzo ring. 
 
Considering the review112 of David A. Walsh, the substitution pattern of the  
2-aminobenzophenone starting material can almost be chosen freely. The 
following formation of the 2-isothiocyanatobenzophenones should be done 
according to Richter et al.108 using thiophosgene 16. The remaining four steps to 
obtain the novel substituted triazolobenzotriazepines should be carried out as 
already described110 above. Addition of (3-methoxybenzyl)hydrazine 17 and 
subsequent cyclization – catalyzed with para-toluenesulfonic acid – might yield the 
corresponding 5-(2-chlorophenyl)-3-(3-methoxybenzyl)benzotriazepinethione 
derivatives. After treating the benzotriazepinethione derivatives with hydrazine in 
the first step and with triethyl orthoacetate and para-toluenesulfonic acid in the 
second step the formation of the annulated 1-methyltriazole ring should be 
completed (Scheme 9). 
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Scheme 9. Synthesis outline for structural variations of the annulated benzo ring. 
 
In addition to the described synthesis above using multi substituted 2-aminobenzo-
phenones as starting materials, also compounds containing a further annulated 
ring system can be chosen. Figure 19 illustrates a possible structure comprised of 
the triazolobenzotriazepine core scaffold with the preferred substitution pattern 
and an annulated five- or six-membered carbocycle. However also aromatic and / 
or heteroatom containing ring systems would be conceivable. 
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Figure 19. Additional ring annulated to the triazolobenzotriazepine core scaffold to gain diversity 
within synthesized structures. 
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CHAPTER  III   –  
Methods for Structure 
Optimization 
 
A broad variety of different substituted compounds has been synthesized during 
this work. However, we have left nothing to chance. The decision to change the 
scaffold from benzodiazepines to benzotriazepines, using electron withdrawing 
groups or electron donating ones as well as adding or removing ring systems and 
substituents, respectively, was not random. For structure optimization we used 
three different methods, which are discussed in the following chapters: 
 
A) Differential scanning fluorimetry, DSF (Chapter 3.1) 
 
B) Isothermal titration calorimetry, ITC (Chapter 3.2) 
 
C) Co-crystallization of proteins with ligands (Chapter 3.3) 
 
 
These experiments were carried out predominantly by Dr. Sarah Picaud under the 
supervision of Dr. Panagis Filippakopoulos at the Structural Genomics Consortium 
of the University of Oxford. During two research stays I gained valuable insights 
into the different techniques and carried out differential scanning fluorimetry of 
several compounds by myself. 
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3.1 DIFFERENTIAL SCANNING FLUORIMETRY 
 
The general technique we used for determination of binding interactions between 
compounds and proteins was differential scanning fluorimetry (DSF). This kind of 
method, a thermal shift assay, combines two key advantages for broad 
screenings: it is fast and inexpensive. Both aspects allowed us to screen almost all 
synthesized target compounds, against up to 13 bromodomains, in a short space 
of time. 
 
 
 
3.1.1 The principle of measurement 
 
The measurement principle of DSF is based on monitoring the melting 
temperature (Tm) of proteins, which is considered as the point of equal 
concentrations of folded and unfolded protein. 
 
 
Figure 20. (A) Reversible two-state manner of folded (left) and unfolded (right) protein with ligand 
binding. (B) Graphical interpretation of the stability of proteins, related to Gu. A protein stabilized 
by a ligand (blue curve) has a higher stability at room temperature (r.t.) and consequently a higher 
Tm as the native protein (red curve). 
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The stability of proteins has its maximum typically close to room temperature and 
decreases by cooling or heating113. If a protein unfolds in a reversible two-state 
manner, the equilibrium thermodynamics model will apply (Figure 20A)114. This 
thermodynamic interpretation of the stability is given by the temperature 
dependent Gibbs free energy of unfolding (Gu), which becomes zero at the 
melting temperature Tm (Figure 20B)
115. 
 
In case of compound interaction with the protein, Gu usually increases by the free 
energy value of ligand binding (Gb). This stabilization effect leads to a higher Tm 
value of the protein-ligand complex. Exactly this shift in melting temperature (Tm) 
is our desired measurement parameter, because it correlates116 with Gb and 
consequently with the dissociation constant Kd of the ligand, what leads to the 
simplified statement: the higher the Tm shift, the better the affinity of a ligand 
towards a protein (for a more detailed discussion see Chapter 3.1.3). 
 
 
 
3.1.2 Measurement and analysis 
 
The sample preparation was done in a standard 96 well microtiter plate by adding 
the respective compound to each required BRD, mainly represented by the eight 
domains of our target proteins, the BET family (see Chapter 1.2.2), as well as five 
more BRDs (PCAF, CREBBP, LOC93349, PB1(5), BAZ2B), to cover the whole 
phylogenetic tree. The measurements were performed using a real-time PCR 
instrument by heating the plates from room temperature to about 100 °C. For 
visualization of protein unfolding, the mixture was treated with a fluorescent dye, 
named SYPRO® orange. 
 
Analysis of DSF is done with a plot of the fluorescence intensity as a function of 
temperature (Figure 21). Almost no signal is obtained as long as the protein is 
present in the native state, because of the quenched fluorescence of the dye in 
aqueous solution. At higher temperatures, the protein starts to denature and 
exposes its hydrophobic sites. 
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Figure 21. Example graph (blue curve) of a DSF measurement of a protein in presence of 
SYPRO
®
 orange (symbolized by an aromatic molecule), shows the change in fluorescence during 
the different states of the protein. After fitting (purple curve) the graph by processing software the 
Tm value can be determined
117
. 
 
In this unpolar environment, the intensity of the fluorescence of SYPRO® orange 
increases to about 500% (Figure 22), leading to an enormous gain of the 
measured signal. This two-state transition of folded and unfolded protein results in 
a sigmoidal curve, which can be analyzed using, for example, the Boltzmann 
equation to calculate the inflection point Tm. Although SYPRO
® orange has a lower 
gain of fluorescence upon denaturation of the protein, in contrast to e.g. 1-anilino-
8-naphthalene sulfonate (1,8-ANS), the advantage is the excitation wavelength of 
492 nm. Practically, there is no interference of any small molecule with the optical 
properties of the dye, which can produce incorrect results117. 
 
 
Figure 22. Comparison of the 
fluorescence intensities of different 
dyes in the presence of lysozyme. 
The intensities were measured before 
and after incubation for five minutes 
at 100 °C
117
. 
N = native state (folded protein) 
U = unfolded state 
A = agglomeration of proteins 
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3.1.3 Thermodynamic view on DSF: entropy vs. enthalpy  
 
The statement mentioned above, "the higher the Tm shift, the better the affinity of a 
ligand towards a protein", has to be discussed a little bit more in detail. In general, 
it is right with due regard to two restrictions: one the one hand, you can only 
compare results of the same BRD and on the other hand, the compounds 
screened against a certain BRD should share a similar chemical structure to be 
comparable. 
 
But why these limitations? During our research project, we collected plenty of Tm 
shifts of diverse compounds with several bromodomains. ITC (see Chapter 3.2) 
was used subsequently for measuring Kd values of high accuracy. However, we 
discovered a huge difference of Kd values of compounds with similar Tm. 
Obviously, all second domains of BDR2, BRD3, BRD4 and BRDT showed higher 
Tm shifts as the corresponding first domains, but lower affinity of compounds was 
determined by ITC. The answer to this problem was to factor thermodynamic 
aspects, more precisely enthalpy and entropy. 
 
As already shown above (Figure 20B), Tm is related to Gu, the Gibbs free energy 
of unfolding, and in the event of ligand binding, the Gibbs free energy of the 
system G is given by: 
 
                                           
 
where Gb is the additional free energy of binding, H the enthalpy change, T the 
absolute temperature, S the change in entropy, R the gas constant and Ka the 
association constant. 
 
As a consequence that G is a function of T with Tm being the point of intersection 
with the x-axis, Tm is also correlated with H and S. Hence, with our Tm shifts, 
obtained by DSF, it is not possible to decide, whether the major contribution is 
given by entropy or enthalpy. 
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The calculation of Ka and Kd values, respectively, is possible only by referring to 
standard conditions according to equation (ii).  
 
                                             
 
where G°, H° and S° are the corresponding terms under standard conditions. 
Otherwise, to compare diverse Tm values to affinities of different compounds, long 
extrapolations to a defined set of relevant standard conditions has to be done, 
which can produce large errors. 
 
The bond-dissociation energy in chemistry, is defined118 – with limitations – as the 
standard enthalpy change H°. Despite reversible binding events of protein-ligand 
complexes are subjected to different conditions and restrictions, the most 
important parameters for strong ligand binding are hydrogen and/or halogen bonds 
as well as electrostatic interactions119,120. All these factors are enthalpic, whereas 
conformational restrictions and the release of water molecules of the binding 
pocket and the solvated ligand, are associated to entropy121,122.  
 
These matters of fact led to the assumption, that Tm (and also Tm) is dependent 
on both, enthalpy and entropy, but Kd is primarily dependent on enthalpy. Holdgate 
et al. published123, in 2005, a highly interesting paper, dealing with exactly those 
thermodynamic facts in drug discovery. Our hypothesis is supported by the 
equation123 formed by Holdgate et al., which describes the affinity of a ligand at the 
melting temperature (  
  ): 
 
  
    
   
    
    
   
 
  
  
 
  
   
     
     
  
  
   
  
  
        
                
 
where [L] is the free ligand concentration at Tm and Tm is the melting temperature 
for the protein-ligand complex. Hu is the enthalpy of unfolding, Cp u is the heat 
capacity of unfolding at constant pressure and T0 is the melting temperature with 
all three terms referring to the uncomplexed protein. 
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Holdgate et al. also showed123 theoretical calculations, that entropically driven 
ligand bindings can result in the same Tm shift by a fifty fold difference in Kd. This 
is the case in all of the second domains of the BET family, showing high 
temperature shifts in DSF, but low Kd values by ITC, what correlates to the 
entropically driven assumption. Tm shifts of first domains, which are more 
enthalpically driven, resemble very well to results gained e.g. in kinase screenings. 
 
To conclude, DSF can be used as a powerful high-throughput method for 
screening plenty of compounds against many proteins in a rapid and cost-efficient 
way. The obtained Tm shifts give a general survey, if compounds show affinity 
towards any of the proteins or not. For a more detailed consideration of the results, 
care has to be taken, that Tm can only be compared in between compounds 
measured with the same protein. 
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3.2 ISOTHERMAL TITRATION CALORIMETRY 
 
For a very accurate determination of Kd values, isothermal titration calorimetry 
(ITC) was used. This method combines advantages like direct measurements of 
binding stoichiometry (n) between ligand and protein, binding affinity (Ka) of the 
ligand and change in enthalpy (H)124. These parameters allow a further 
calculation of important values like the entropy change (S) and the change in 
Gibbs free energy (G) by simple thermodynamic laws (see equation (i) and (ii), 
Chapter 3.1.3)123. However, ITC is not a high-throughput technique, due to the 
need of relatively large amounts of protein and long duration of measurement up 
to two hours for each sample. 
 
The apparatus (Figure 23A) consists of two cells, located in an adiabatic jacket, 
and a stirring syringe. The reference cell is connected to a constant power supply 
and typically heated with <1mW124. A feedback power is applied to the sample cell 
and responsible to maintain the equivalent temperature of the reference cell. The 
experiment is either be carried out filling the sample cell with the protein and 
adding the ligand by the syringe or the other way around. 
 
 
Figure 23. (A) ITC measuring instrument in a schematic representation. (B) Exemplary exothermic 
ITC diagram with feedback power of the reference cell plotted as a function of time (top) and the 
integrals of the obtained spikes plotted against the molar ratio and fitted by a sigmoidal curve 
(bottom)
123
. 
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The inverse experiment is usually favored, because of the lower concentration of 
the protein in contrast to the ligand. Dilutions always lead to a change in enthalpy, 
which would be also measured and falsify the results125. This effect can be 
minimized by adding the higher diluted component (protein) by syringe into the 
sample cell, filled with the more concentrated component (ligand).  
 
As far as the ligand shows affinity towards the protein, ligand binding occurs after 
every injection, which leads to an exothermic (Figure 23B) or an endothermic 
reaction. An exothermic binding event, releasing heat, decreases the feedback 
power to keep the level of the reference cell and thus, generating the negative 
spikes (peaks in an ITC diagram). In the case of an endothermic reaction, the 
opposite response would take place. The declining availability of free binding sites 
for the ligand, resulting in lower heat release and consequently in smaller spikes, 
which disappear after complete saturation of the binding pockets. The integrals of 
these spikes can be plotted against the molar ratio between protein and ligand for 
further analysis, done by processing software, to yield the requested parameters. 
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3.3 CO-CRYSTALLIZATION OF PROTEINS WITH LIGANDS 
 
DSF and ITC are important tools for measuring affinity and selectivity of ligands for 
certain proteins, determination of binding constants and magnitudes of 
thermodynamic parameters, but neither the binding site nor the binding mode can 
be identified. Therefore, the use of crystallization studies is absolutely essential. 
Co-crystallization structures of protein and ligand with high resolution (better than 
2 Å), give detailed information for further structure refinement (Figure 24). 
 
The question, which part of the protein gets addressed by the ligand and how the 
ligand co-ordinates into the pocket can unerringly be confirmed. The amino acid 
sequence of the binding pocket as well as the orientation of their side chains can 
be ascertained. Moreover, it allows the study of hydrogen bonds, either directly 
from the ligand to the protein or mediated by water molecules. 
 
 
Figure 24. (A) Chemical structure of a 3,5-dimethylisoxazol used as ligand for co-crystallization. 
(B) Crystal structure (PDB ID = 4J0R) of 3,5-dimethylisoxazol with domain one of human BRD4 in 
high resolution of 1.72 Å. Water molecules are shown as red spheres
75
. 
 
For structure optimization, distances and angles can be calculated by appropriate 
software (e.g. WinCoot) to estimate chemical modifications of the ligand. The 
introduction of new (functional) groups might enable the ligand to form further 
interactions and result in better affinities. Even theoretical molecules can be 
superimposed with the crystallized ligand to get more illustrative presentations. 
A                                  B 
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These advantages of co-crystallization structures speak for themselves, however, 
preparation is more characterized by trial and error. Various molar ratios of protein 
and ligand as well as different concentrations of buffer and cryoprotective agents, 
to which further reference will not be made here, have to be tested. 
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CHAPTER  IV   – 
Synthesis, RESULTS & 
DISCUSSION 
 
The following chapter guides through the whole laboratory work in a chronological 
way. First, detailed syntheses – from commercially available starting materials to 
target molecules – of each group of compounds are described and specifics get 
explained. Subsequent to the synthesis part, DSF screening results of the 
corresponding series are discussed. The analysis of temperature shift results was 
used for planning further series and whenever available also ITC measurements 
and X-Ray data (co-crystallizations) were used for their optimization. This cycle 
(Figure 25) of synthesis, screening and analysis was passed through several times 
to yield potent and selective target molecules. 
 
 
 
Figure 25. Illustrative model for continuous improvement of compounds.  
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4.1 TRIAZOLOBENZODIAZEPINES: 
THE FIRST CLASS OF TARGET COMPOUNDS 
 
The first project was the development of a synthesis for triazolobenzodiazepines. 
As already mentioned and described in Chapter 2.1 molecular modeling, done by 
the group of Prof. Knapp at the SGC at the University of Oxford, led to the  
8-chloro-6-ethyl-triazolobenzotriazepine target compound with different 
substitution patterns on the triazole ring in position 1 (Figure 16). 
 
 
 
4.1.1 Synthesis of the benzodiazepinone core scaffold 
 
Synthesis of the 2-aminopropiophenone derivative 20 was done according to 
Mayer et al.104 starting with nitration of commercially available 3-chloro-
propiophenone 18 in position 6 using a mixture of fuming nitric acid and 
concentrated sulfuric acid followed by reduction of the nitro group to an aromatic 
amine with iron powder and ammonium chloride in an overall yield of 55%. The 
next steps were planned to follow the U.S. patent procedure of Bell et al.105 
published in 1973. The acylation of the prepared amine 20 with chloroacetyl 
chloride 21 was realized in sufficient yield after stirring for one hour at room 
temperature. The cyclization of compound 22 into benzodiazepinone 1, however, 
was divided into two steps. The described one-pot procedure of Bell et al.105 led to 
irreproducible and bad to moderate yields. Furthermore a long reaction time was 
needed of at least two, usually three days. The separation of the Finkelstein 
reaction126 – to convert the chloroacetanilide 22 into the iodoacetanilide 23 – from 
the cyclization step led to a quantitative conversion while stirring at room 
temperature for one day. The subsequent cyclization in an ammonia saturated 
ethanol solution offered a practicable way to obtain the desired benzodiazepinone 
1 in high yield (86%) over both steps (Scheme 10). 
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Scheme 10. Preparation of benzodiazepinone core scaffold 1 in a five step synthesis. 
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4.1.2 Preparation of 6-ethyltriazolobenzodiazepines 
 
Conversion of benzodiazepinone 1 into thiolactam 2 could not be accomplished 
under standard conditions106 using phosphorus pentasulfide in pyridine or other 
high boiling solvents, but was successfully realized using Lawesson's reagent 24 
in anhydrous tetrahydrofuran under nitrogen atmosphere (Scheme 11). 
 
 
Scheme 11. Conversion of benzodiazepinone 1 into thiolactam 2 using Lawesson's reagent. 
 
The advantage of Lawesson's reagent 24 are the 4-methoxyphenyl substituents, 
which allow good solubility in organic solvents in contrast to inorganic reagents like 
phosphorus pentasulfide. However, the dithiophosphine ylide 25 as well as the 
metathiophosphonate 26 form various oligomeric byproducts127 in the course of 
the reaction, which pose a challenge to separate by column chromatography. 
 
 
Scheme 12. Dissociation of Lawesson's reagent 24 into the active dithiophosphine ylide 25 
followed by the conversion into the final metathiophosphonate 26. 
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For preparation of different 6-ethyl-triazolobenzotriazepines a choice of carboxylic 
acid hydrazides was needed. Therefore, the commercially available building 
blocks acethydrazide 27a, propanoic acid hydrazide 27c, benzhydrazide 27c, 
isonicotinic acid hydrazide 27e, and 3-methoxybenzoic hydrazide 27f were 
purchased (Scheme 13A). Starting with ethyl glycolate 28, 2-hydroxyacethydrazide 
27b was prepared according to literature known procedure128 (Scheme 13B). 
 
 
Scheme 13. (A) Used carboxylic acid hydrazides 27a-f for triazole preparation and (B) conversion 
of ethyl glycolate 28 into 2-hydroxyacethydrazide 27b. 
 
The target molecules 29a-f were obtained by condensation of thiolactam 2 with 
corresponding carboxylic acid hydrazides 27a-f (Scheme 14). The reactions took 
place in a sealed vial under nitrogen atmosphere over one day and gave the 
desired products in 17% to 67% yields. However an excess of hydrazides were 
needed for obtaining adequate yields, the residual ones were poorly separable 
from the product by column chromatography. This problem was solved by 
converting the hydrazides into water-soluble condensation products upon stirring 
with glucose solution prior to extraction with a lipophilic organic solvent 
(dichloromethane). 
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Scheme 14. Condensation of thiolactam 2 with hydrazides 27a-f yields triazolobenzotriazepine 
derivatives 29a-f. 
 
 
 
4.1.3 Benzotriazepines provided by the University of Greifswald 
 
 
Figure 26. Chemical structures of benzotriazepines 30 – 39 provided by the University of 
Greifswald. 
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During the work on triazolobenzodiazepines a lot of literature search had to be 
done for synthesis development. Numerous papers and patents found, were 
published by Richter et al. – a former research group of the University of 
Greifswald. Their research area deals predominantly with benzotriazepines, a 
class of compounds structurally closely related to our benzodiazepines. For this 
reason we asked Dr. O. Morgenstern who kindly sent us a selection of ten diverse 
compounds 30 – 39 (Figure 26). Those molecules were sent with our synthesized 
triazolobenzodiazepines 29a-f as well as their precursors 1 and 2 for screening on 
bromodomains to the SGC at the University of Oxford. 
 
 
 
4.1.4 Screening of the benzodiazepines and -triazepines 
 
The first DSF screening was carried out at a high compound concentration (cc) of 
100 µM (except compound 29b which was screened later at 10 µM cc). 
Synthesized triazolobenzodiazepines 29a-f, the precursor benzodiazepinone 1, 
thiolactam 2 as well as the benzotriazepines 30 – 39 from the University of 
Greifswald were screened against seven members of the BET family (BRD2(1/2), 
BRD3(1/2), BRD4(1/2), BRDT1). Five more domains (BAZ2B, CREBBP, 
LOC93349, PB1(5), PCAF) of different families were also used in the screening to 
check against affinity across the phylogenetic tree of bromodomains and 
selectivity towards the desired BETs.  
 
The analysis of the obtained temperature shift results (Figure 27) was clear. 
Obviously no compound prepared in our first series, neither the precursors 1 and 2 
nor the triazolobenzodiazepines 29a-f, showed significant (more than 4 °C) shifts. 
The same effect was monitored with the compounds from Greifswald. Again there 
was no significant temperature shift detected with the exception of compounds 36 
and 37, which share both a 6-phenyltriazolobenzotriazepine core structure. 
Especially 36 reached impressive high Tm values, with regard to the high 
compound concentration of 100 µM. Therefore it had to be re-evaluated at the 
standard compound concentration of 10 µM. 
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Figure 27. DSF results of 
triazolobenzodiazepines 29a-f and 
their precursors 1 and 2 as well as 
benzotriazepines 30 – 39 (from the 
University of Greifswald) screened at 
100 µM compound concentration  
(* screened at 10 µM cc). 
 
 
 
 
 
 
 
 
 
 
 
For re-evaluation of compounds 36 and 37, the same bromodomains were used. 
Additionally, four clinical BzDs (alprazolam, estazolam, midazolam, triazolam) and 
a structural related compound GW841819X129 (Figure 30) were screened. These 
results showed, that alprazolam is the only clinical BzD with significant affinity 
against the BET family. Tm shifts of both triazolobenzotriazepines 36 and 37 
decreased, as expected with a ten-fold lower compound concentration, but still 
gave remarkable values. Also compound GW841819X showed high temperature 
shifts within the BET family but no cross affinity towards any other bromodomain. 
 
 
Figure 28. Tm shift results of 
clinical BzDs (alprazolam, 
estazolam, midazolam, 
triazolam), a structural related 
BzD GW841819X and re-
evaluation of triazolobenzo-
triazepines 36 and 37 
screened at 10 µM cc. 
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These unexpected results initiated the preparation of co-crystallizations of 
BRD4(1) with the three most promising compounds – alprazolam (Figure 29B), 
midazolam (Figure 29C) and compound 36 (Figure 29D) by Dr. Filippakopoulos at 
the SGC (Oxford). Molecule GW841819X (Figure 29A) was already available as 
co-crystallization with BRD4(1) at the protein data bank. 
 
 
Figure 29. Detailed co-crystallization structures of BRD4(1) with (A) GW841819X, (B) alprazolam, 
(C) midazolam and (D) compound 36. Conserved water molecules are shown as red spheres
83
. 
 
These four crystal structures gave a clear insight into the binding mode of this 
class of compounds with first domain of BRD4 (cf. Figure 30). Every molecule 
showed the same orientation into the binding pocket with the five-membered ring 
ahead which also is responsible for important hydrogen bonds. One nitrogen of 
this ring always forms a hydrogen bond mediated by a conserved water molecule 
to the tyrosine 97 side chain. 
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In case of an annulated imidazole (cf. midazolam) in contrast to an triazole ring the 
second important hydrogen bond to asparagine 140 is missing. This might explain 
why midazolam showed much weaker interactions (lower Tm) than alprazolam.  
 
A third interaction is displayed in the structure of GW841819X, again with the 
asparagine 140, which can be a hint for the high Tm value against BRD4(1) in the 
DSF screening. This time the oxygen of the terminal amide of the amino acid side 
chain interacts with the NH group of the carbamate residue in position 4. 
 
Structural elements of the molecules can also be explained very well with regard 
to the crystal structures. The 6-phenyl ring fits to a hydrophobic pocket and 
consequently shows better interactions than a 6-ethyl group. Furthermore the 
annulated 1-methyltriazole ring appears to be preferred in contrast to the bulkier 
substituents as long as all compounds use the same orientation mode. 
 
Due to a long production time for co-crystallizations the outcome was not awaited 
for development of a new lead structure and are consequently not considered in 
the following discussion in Chapter 4.1.5. However, the assumption which 
structural variations and modifications has to be done in the following step turned 
out to be appropriate. 
 
 
 
4.1.5 Discussion of the benzodiazepine screening results 
 
To summarize the first screening results on benzodiazepines, it is obvious that the 
proposed 8-chloro-6-ethyl-triazolobenzodiazepines have poor effects on 
bromodomains. Irrespective of which residue is attached to the triazole ring in 
position 1. Neither short aliphatic moieties like methyl or ethyl nor aromatic or 
heteroaromatic residues could achieve significant temperature shifts. Hence, no 
further efforts should be made with this specific class of compounds. Planned 
derivatizations in position 4 were not longer pressed ahead. 
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However, other compounds gave unexpected response. With compound 36 and 
GW841819X (Figure 30), two highly interesting molecules could be identified. Both 
have mainly moderate to high Tm shifts (between 4 and 7 °C) against BETs and 
good selectivity towards this family. 
 
 
Figure 30. Chemical structures of to co-crystallized compounds and important interactions with the 
protein using the example of GW841819X. 
 
Consequently these two molecules were used as leads for modification of 
structures. Both compounds share a very similar core scaffold. A seven-
membered ring, containing at least two nitrogens, with an annulated benzo-ring 
system and a 1-methyltriazole ring. In contrast to our synthesized 
triazolobenzodiazepines both have a 6-phenyl instead of a 6-ethyl residue which is 
presumably essential for affinity to bromodomains. This leads to the assumption 
that it occupies a hydrophobic pocket and / or is responsible for pi stacking. 
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The logical outcome was to adapt the common scaffold and to add unique 
components of both molecules to assemble a new lead structure (Figure 31): 
 
 With regard to the functionalized position 4 of GW841819X the decision for 
triazepines was made. On the one hand the core structure of triazepines 
requests a different synthesis strategy but on the other hand the 
functionalization of a NH group is much easier feasible than of a methylene 
group. Moreover, the attachment of only one group in position 4 in case of 
benzodiazepines would lead to a stereocenter which could be avoided by 
using triazepines. 
 
 The annulated (generally chloro substituted) benzo ring – ubiquitous in 
tested compounds – will be maintained. 
 
 Variations with diverse ring systems, annulated to different sides of the 
seven-membered ring, as well as open structures reveal the annulated 
1,2,4-triazole ring as preferred structural element. 
 
 The methyl group in position 1 seems to be the best choice in comparison 
of all screened compounds. Even between compound 36 and 37 as well as 
between alprazolam and estazolam a loss of affinity can be seen with the 
only difference in the chemical structure is the exchange of the 1-methyl 
group (in compound 36 and alprazolam) by an 1-amino group (compound 
37) and a hydrogen (estazolam), respectively. Furthermore the broad 
variations in position 1 of synthesized target compounds 29a-f also had no 
effect on temperature shifts of the bromodomain screening. 
 
 However in case of compounds 29a-f also the 1-methyl substituted 
compound 29a showed no effect on target proteins. Because of this reason 
the ethyl residue in position 6 will be replaced by a phenyl moiety which is 
the common structural element in this position. 
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Figure 31. New lead structure development with triazolobenzotriazepine core scaffold. 
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4.2 FIRST OPTIMIZATION OF TRIAZOLOBENZOTRIAZEPINES 
 
4.2.1 Synthesis and derivatization of 4-(2-hydroxyethyl)triazolobenzo-
triazepine 
 
Having generated a new lead structure the synthetic approach had to be changed. 
On the one hand an additional nitrogen is planned at position 4 in the seven-
membered ring, on the other hand hydrogen bond donors and / or acceptors 
should be attached at this position. Therefore 4-(2-hydroxyethyl)triazolobenzo-
triazepine 5 was chosen as a central intermediate containing a primary alcohol 
which can easily be modified in various reactions. 
 
(2-Amino-5-chlorophenyl)(phenyl)methanone 40 was used as starting material for 
the synthesis of 4-(2-hydroxyethyl)triazolobenzotriazepine 5. In a similar manner to 
literature known procedure108 compound 40 was converted into the isothiocyanate 
derivative 6 using thiophosgene 16 and calcium carbonate. The highly reactive 
isothiocyanate derivative 6 was treated subsequently with the commercially 
available 2-hydroxyethylhydrazine 41. The obtained thiosemicarbazide derivative 
42 was generated by the addition of the alkylated and consequently more 
nucleophilic hydrazine nitrogen and not by the addition of the less sterical hindered 
hydrazine nitrogen. As a result of this type of addition the following cyclization step 
between the free NH2 group and the keto group can easily occur by heating to 
reflux in ethanol for one hour with a catalytic amount of para-toluenesulfonic acid 
(PTSA). The preparation of the annulated 1,2,4-triazole ring was divided into two 
steps. First a hydrazone like intermediate was generated by treating 
benzotriazepine-2-thione 3 with hydrazine hydrate. After work-up the crude 
product of compound 4 was stirred with triethyl orthoacetate 43 and a catalytic 
amount of PTSA in toluene to obtain compound 5 with the 1-methyltriazole ring in 
moderate yield of 38% over two steps (Scheme 15). 
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Scheme 15. Preparation of 4-(2-hydroxyethyl)triazolobenzotriazepine 5 in a five step synthesis 
starting with commercially available 2-aminobenzophenone derivative 40. 
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Derivatization of compound 5 was done with a broad variety of reactants to gain 
diversity in the resulting target molecules 44a-j (Scheme 16). To list some 
examples: anhydrides, carboxylic acid chlorides or iso(thio)cyanates were used. 
Typical functional groups with hydrogen bond donors and / or acceptors like esters 
(44a – 44d), a carbonate (44e) and (thio)carbamates (44f – 44j) were prepared. 
 
According to the standard protocol130 to prepare acetylsalicylic acid, acetic acid 
anhydride with a catalytic amount of sulfuric acid was used to prepare the 
acetylated compound 44a in 78% yield. The second ester with an aliphatic moiety 
was synthesized using cyclopropanecarbonyl chloride after deprotonation of the 
alcohol with sodium hydride giving compound 44b in moderate yield (51%). Two 
additional esters were prepared with an aromatic residue. For the benzoyl 
derivative again an anhydride (benzoic acid anhydride) was used and treated with 
a catalytic amount of sulfuric acid to obtain the preferred product 44c in 37% yield. 
2-Thiopheneacetic acid was coupled with the primary alcohol of compound 5 
under typical conditions of a Steglich esterification131 using DCC and a catalytic 
amount of DMAP to afford product 44d in 61% yield. The addition of sodium 
hydride to a solution of molecule 5 in diethyl carbonate gave the carbonate 
derivative 44e in high yield (91%). Also carbamates and a thiocarbamate were 
prepared to offer a broader range of interaction possibilities of the binding pocket 
with the target molecules. Therefore N,N-dimethylcarbamoyl chloride was used to 
prepare compound 44f in 69% yield. Identical reaction conditions led to the 
following four compounds 44g-j. After deprotonation of starting material 5 with 
sodium hydride, the corresponding iso(thio)cyanate was added to the solution in 
tetrahydrofuran, followed by stirring for three hours at room temperature. Reaction 
with tert-butyl isocyanate gave compound 44g in 66% yield, with ethyl 
isothiocyanate 85% of 44h and the two aromatic compounds 4-chlorophenyl 
isocyanate and 4-nitrophenyl isocyanate gave their corresponding target 
molecules in 64% (44i) and 36% (44j) yield, respectively. 
 
 
 
 
57 
 
CHAPTER IV   –   Synthesis, results & discussion 
 
 
 
 
 
 
 
 
Scheme 16. Derivatization of 4-(2-
hydroxyethyl)triazolobenzotriazepine 5 to 
target compounds 44a-j using various 
methods. Reagents and conditions: (i) acetic 
acid anhydride, catalytic conc. H2SO4, 80 °C, 
1 h; (ii) cyclopropanecarbonyl chloride 
(2 equiv), sodium hydride (1.2 equiv), THF, r.t., 
3 h; (iii) benzoic acid anhydride (3.0 equiv), 
catalytic conc. H2SO4, THF, reflux, 1 h; (iv) 2-
thiopheneacetic acid (2.0 equiv), DCC 
(2.2 equiv), catalytic DMAP, DCM, r.t., 1 d; (v) 
diethyl carbonate, sodium hydride (1.2 equiv), reflux, 3 h; (vi) N,N-dimethylcarbamoyl chloride 
(3.0 equiv), sodium hydride (1.2 equiv), THF, r.t., 1 d; (vii) tert-butyl isocyanate (2.0 equiv), sodium 
hydride (1.2 equiv), THF, r.t., 3 h; (viii) ethyl isothiocyanate (2.0 equiv), sodium hydride (1.2 equiv), 
THF, r.t., 3 h; (ix) 4-chlorophenyl isocyanate (2.0 equiv), sodium hydride (1.2 equiv), THF, r.t., 3 h; 
(x) 4-nitrophenyl isocyanate (2.0 equiv), sodium hydride (1.2 equiv), THF, r.t., 3 h. 
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4.2.2 Interesting aspects of NMR analysis of special carbamates 
 
Previously (Chapter 4.2.1) described compounds derived from molecule 5, with 
esters and carbonates (44a-e) as new functional groups gave standard signals in 
their NMR spectra. Even the NMR spectra of carbamates 44f and 44g with simple 
aliphatic residues were not out of common. However thiocarbamate 44h as well as 
both aromatic substituted carbamates 44i and 44j showed a remarkable number of 
signals in the proton NMR spectra in relation to their molecular formula. 
 
This observation can be explained with the partial double-bond character (Figure 
32) in the C-N amide bond, which was extensively analyzed by NMR 
techniques132,133,134,135. Whenever this rotational barrier is high enough, the 
rotation at room temperature is slower than the NMR time-scale and consequently 
produces individual NMR signal sets for each of the rotamers (one for the (E) and 
one for the (Z) isomer). Despite various groups studied136,137,138,139 the amide 
resonance in carbamates in detail it has to be proven that both sets of NMR 
signals arise from the same compound. Therefore NMR spectra of the 
corresponding probe were performed at five different temperatures with the aim 
that higher temperatures allow faster interconversion of both rotamers. Thus, the 
separated signals of the same group of both rotamers should overlap at high 
temperatures. 
 
 
Figure 32. Free rotation around the C-N amide bond can be restricted by a rotational barrier, what 
leads to a (E) and a (Z) rotamere. 
 
The NMR spectra of thiocarbamate 44h are illustrated in Figure 33. The 
measurements were performed in deuterated tetrachloroethane at five different 
temperatures. Arrows indicate the example signals which are clearly separated at 
17 °C but show one defined signal at 100 °C. Also the triplet signals of the  
2'''-methyl group (0.89 and 1.11 ppm) converge at higher temperature. 
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Another interesting fact is given by the difference in the chemical shift. The closer 
the protons are to the amide bond, the larger the differences of the chemical shifts 
of the corresponding rotamer signals are. In CD2Cl2 at 17 °C the amide proton, for 
example, shows a difference of 0.23 ppm (peaks at 6.58 and 6.81 ppm), whereas 
the 1-methyl group has only a shift of 0.01 ppm (peaks at 2.54 and 2.55 ppm). No 
shift, however, could be detected within the aromatic protons anymore. 
 
The ratio between the isomers can be calculated by correlation of the integrals of 
the matching rotamer signals. In case of compound 44h a ratio of 37:63 was 
obtained. Steric hindrance might prefer the (E)-isomer which should consequently 
refer to the 63% value in contrast to the (Z)-isomer with 37%. The little disparity 
between the isomers can be accounted for by the small ethyl group. With regard to 
the large aromatic substituents in compound 44i and 44j the ratio changes 
enormously to 7:93 (44i) and 8:92 (44j), respectively, what obviously supports the 
assumption that (E) and (Z) is controlled by steric hindrance. 
 
Figure 33. Temperature dependent NMR spectroscopy of thiocarbamate derivative 44h. Arrows 
indicate example signals which are clearly separated at 17 °C but become one signal at higher 
temperature. Measured in tetrachloroethane-d2 at temperatures as indicated in the corresponding 
spectra (17 °C, 30 °C, 50 °C, 80 °C, 100 °C). 
NH 2'''-H 1''-H 2''-H 
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4.2.3 Synthesis of 4-benzyltriazolobenzotriazepine 
 
The developed synthesis of 4-(2-hydroxyethyl)triazolobenzotriazepine 5 facilitates 
a good access to triazolobenzotriazepines bearing other substituents in 4 position 
by only varying the alkylated hydrazine derivative. For this reason the 
commercially available benzylhydrazine dihydrochloride 7 was chosen instead of 
the 2-hydroxy-ethylhydrazine 41 to prepare a target compound with a completely 
different substitution. 
 
 
 
 
Scheme 17. Synthesis of 4-benzyltriazolobenzotriazepine 10. 
 
Deprotonation of benzylhydrazine dihydrochloride 7 with DIPEA was done prior to 
the stepwise addition of (5-chloro-2-isothiocyanatophenyl)(phenyl)methanone 6 to 
the cooled solution and the reaction mixture was allowed to warm to room 
temperature while stirring for one hour. The mixture was heated to reflux for one 
hour after para-toluenesulfonic acid monohydrate was added to the mixture to 
complete the cyclization to the benzotriazepine-2-thione 9 in an overall yield of 
86%. Preparation of the triazole ring started again with treating compound 9 with 
hydrazine hydrate in followed by the addition of triethyl orthoacetate 43 and a 
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catalytic amount of para-toluenesulfonic acid monohydrate. Target compound 10 
was thereby prepared with a yield of 52% over the last two steps. 
 
 
 
4.2.4 Screening of 4-(2-hydroxyethyl)triazolobenzotriazepine, its 
derivatives and the 4-benzyl analogon 
 
The prepared compounds with the new triazolobenzotriazepine scaffold were sent 
to the SGC for DSF screening. This time an additional BET – BRDT2 – was 
screened to complete the whole family. The temperature shifts were determined at 
a compound concentration of 10 µM. 
 
Again unexpected results were obtained for the twelve compounds. The not further 
functionalized 4-(2-hydroxyethyl)triazolobenzotriazepine 5 showed no significant 
Tm except a low value against the second domain of BRD3. Also the derivatives 
44a-j behaved the same way with tiny Tm shifts between 4 °C and 6 °C against the 
second domain of BRD4 (44a, 44d, 44f) and insignificant values against all the 
other tested bromodomains. However, compound 10 with its unpolar benzyl 
substituent in position 4 gave significant Tm values against all second domains of 
the BETs and remarkable signals for BRD2(2) and BRD4(2). 
 
 
 
 
 
Figure 34. DSF screening results 
of 4-(2-hydroxyethyl)triazolo-
benzotriazepine 5, its derivatives 
44a-j and the 4-benzyl analogon 
10 at a compound concentration 
of 10 µM. For comparison the 
values obtained for 4-methyl 
derivative 36 are presented again. 
 
 B
R
D
2
(1
) 
 B
R
D
2
(2
) 
 B
R
D
3
(1
) 
 B
R
D
3
(2
) 
 B
R
D
4
(1
) 
 B
R
D
4
(2
) 
 B
R
D
T
1
 
 B
R
D
T
2
 
 B
A
Z
2
B
 
 C
R
E
B
B
P
 
 L
O
C
9
3
3
4
9
 
 P
B
1
(5
) 
 P
C
A
F
    
5 
             
   
10 
             
   
44a 
             
   
44b 
             
   
44c 
             
   
44d 
             
  
44e 
             
 Tm(°C) 
44f 
             
  <0 
44g 
             
  0-2 
44h 
             
  2-4 
44i 
             
  4-6 
44j 
             
  6-8 
36 
             
  >8 
62 
 
CHAPTER IV   –   Synthesis, results & discussion 
 
 
 
4.2.5 Discussion of temperature shift results of the first 
triazolobenzotriazepine series 
 
Having generated a new lead structure (Figure 31) according to the obtained 
results of the benzodiazepine screening, twelve new compounds were synthesized 
with a benzotriazepine scaffold. All of them shared a common 8-chloro-1-methyl-6-
phenyltriazolobenzotriazepine structure with different substitutions in 4 position. 
Compound 5 was used as starting material to yield derivatives 44a-j. Surprisingly, 
those compounds with a variety of hydrogen bond donors and / or acceptors were 
not able to interact with the screened bromodomains and – as a consequence – to 
produce high Tm shifts.  
 
The decision to insert these polar groups was mainly driven by good screening 
results of GW841819X, and the published molecules JQ1 and iBET762 (Figure 
35). Nevertheless, our molecules did not show the same effects, what has to be 
discussed. 
 
 
Figure 35. Chemical structures of GW841819X, (+)-JQ1 and iBET762. 
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The 6-phenyl ring shows a para substitution in JQ1 and iBET762, however 
GW841819X contains the unsubstituted phenyl ring alike our molecules. The 
annulated benzo ring system is again unsubstituted in GW841819X , contains a 8-
methoxy group in iBET762, and in JQ1 this ring is entirely replaced by a dimethyl-
thiophene what led to the assumption that a broad range of groups are tolerated in 
this position and the 8-chloro substituent is not responsible for the strong loss of 
affinity. 
 
The most obvious similarity of the three active compounds in contrast to the our 
synthesized ones is on the one hand their benzodiazepine structure and on the 
other hand their comparable moiety in position 4. The carbonyl group of the ester 
(JQ1), the amide (iBET762) and the carbamate (GW841819X) is linked by only 
one atom to the seven-membered ring whereas in compounds 44a-j the carbonyl 
group is separated by three atoms. This distinction might be a hint for the poor 
results in the DSF screening for the polar substituted compounds. The crystal 
structure of GW841819X with BRD4(1) (Figure 29A) also gave another evidence 
for the need of hydrogen bond donors closer attached to the seven-membered 
ring. The additional hydrogen bond between the NH group of the carbamate and 
asparagine 140 definitely increased the interaction strength. However – as already 
mentioned in Chapter 4.1.4 – the results of the crystal structures had no influence 
on the optimization of triazolobenzotriazepines from Greifswald to generate a new 
lead structure. 
 
The most interesting result was reached with compound 10, a 4-benzyl-
triazolobenzotriazepine. Contrary to the other screened molecules the 4-benzyl 
derivative showed noticeable Tm shifts of 6.2 °C against BRD2(2) and 6.9 °C 
against BRD4(2). Also the temperature shift values of the second domains of 
BRD3 (5.2 °C) and BRDT (5.8 °C) implied that good interactions with the 
corresponding bromodomains occurred. 
  
64 
 
CHAPTER IV   –   Synthesis, results & discussion 
 
 
 
As a consequence of this results, no longer efforts were made to improve the polar 
side chains in position 4 but to concentrate on further variations within the benzyl 
moiety. This decision led to a novel lead structure (Figure 36), containing the well 
known substitution pattern 1-methyl, 6-phenyl and 8-chloro as well as the new  
4-benzyl moiety which had to be optimized. Therefore a broad range of molecules 
with diverse ortho, meta and para substituents on the 4-benzyl moiety should be 
prepared to study their effects. 
 
 
Figure 36. Optimized lead structure for next series of triazolobenzotriazepines. 
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4.3 8-CHLORO-6-PHENYLTRIAZOLOBENZOTRIAZEPINES WITH AROMATIC 
SIDE CHAINS IN POSITION 4 
 
4.3.1 Preparation of 4H-triazolobenzotriazepine 11 
 
The previously obtained DSF screening results of the second series of 
triazolobenzotriazepines led to a new lead structure containing a 4-benzyl moiety. 
Further efforts should be made to improve this scaffold by attaching different 
substituents to the benzyl residue. Differences should be made within electronic 
properties by using electron withdrawing or electron donating groups as well as 
within the size of attached substituents (e.g. small atoms like chlorine or bulky 
aliphatic groups). To gain a better insight into sterically hindered positions, 
substituents should be switched between ortho, meta and para and also a chance 
should be given to multi-substitutions. 
 
To meet the requirements for generating a series of different 4-benzyl substituted 
triazolobenzotriazepines, a key step was to prepare the 4H-triazolobenzo-
triazepine (Figure 37), which could easily be further functionalized by N-alkylation. 
In the syntheses of 4-(2-hydroxyethyl)triazolobenzotriazepine 5 and 4-benzyl-
triazolobenzotriazepine 10 the moiety in position 4 of the target compounds was 
already introduced by using different alkylated hydrazine derivatives. However this 
synthesis requires each time the preparation of the corresponding hydrazines – 
whenever they are not commercially available – as well as the following 
construction of the triazolobenzotriazepine scaffold. 
 
 
Figure 37. Chemical structure of the 8-chloro-1-methyl-6-phenyl-4H-triazolobenzotriazepine 11 key 
compound which can easily be modified by N-alkylation. 
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4.3.1.1 Approach starting from synthesized 4-benzyltriazolobenzotriazepine 10 
 
The already synthesized compound 10 represented an appropriate starting 
material to obtain the desired 4H-triazolobenzotriazepine 11. The cleavage of the 
benzyl group was tried using 10% palladium on activated charcoal and formic 
acid140 (Scheme 18). Despite several variations of temperature (room temperature 
to reflux) and time (up to three days) as well as the use of ascending equivalents 
of formic acid up to an high excess, no conversion could be detected by TLC. As 
parallel efforts (see the following Chapter 4.3.1.2) yielded in much better 
perspectives to obtain the target compound 11 this route was no longer pursued. 
 
 
Scheme 18. Attempted cleavage of the benzyl residue in position 4 of molecule 10 to yield the 
unfunctionalized 4H-triazolobenzotriazepine 11. 
 
 
 
4.3.1.2 Synthesis of compound 11 using 4-methoxybenzyl as protecting group 
 
For the preparation of compound 11, first the alkylated hydrazine derivative 48 has 
to be synthesized according to single141 or multi-step110,142 procedures found in 
literature. However, product 48 could either not be obtained or only in poor yield 
and without reproducibility. In 1981, Ghali et al. published143 an interesting way to 
obtain the hydrochloric salts of related alkylated hydrazines. This way turned out to 
be the most effective and fastest one and was only slightly modified by using a 
different borane complex. Starting with 4-methoxybenzaldehyde 45 the hydrazone 
derivative 47 was obtained by condensation with tert-butyl carbazate 46 after 
heating to reflux in ethanol for one hour. The reduction of compound 47 to the 
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corresponding hydrazine could not be accomplished using standard reagents like 
sodium cyanoborohydride144 or sodium borohydride145, but was successfully 
performed with a 2 M dimethylsulfide complex of borane in tetrahydrofuran. The 
following addition of concentrated hydrochloric acid removed the boc-protecting 
group selectively with regard to the also acid-cleavable PMB group. Stirring for 
10 min at 60 °C gave the colorless solid of (4-methoxybenzyl)hydrazine 
hydrochloride 48 in 98% yield over three steps. 
 
 
 
 
 
Scheme 19. Synthesis of the para-methoxybenzyl (PMB) protected hydrazine derivative 48. 
 
The following synthesis of target compound 11 was already described by 
Nakamura et al.110 but was mainly modified in isolation and purifications steps as 
well as in reaction conditions. After the preparation of compound 48 was 
successfully realized it was subsequently used in the next step. First the 
deprotonation of the hydrochloric salt 48 was done by stirring in methanol with 
DIPEA, then the previously synthesized isothiocyanate 6 was added. The 
generated thiosemicarbazide derivative 49 was not isolated but directly treated 
with a catalytic amount of para-toluenesulfonic acid monohydrate to build up the 
seven-membered triazepine ring system of compound 50. 
  
68 
 
CHAPTER IV   –   Synthesis, results & discussion 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 20. Synthesis of 4H-triazolobenzotriazepine 11, starting from previously synthesized 
isothiocyanate derivative 6. 
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The conversion of compound 50 in molecule 51 with hydrazine hydrate followed by 
the treatment with triethyl orthoacetate 43 and para-toluenesulfonic acid 
monohydrate was carried out in analogous way as already described in the 
synthesis of 4-(2-hydroxyethyl)triazolobenzotriazepine 5 and 4-benzyltriazolo-
benzotriazepine 10. The last step was the removal of the acid-cleavable para-
methoxybenzyl (PMB) protecting group. For this purpose compound 51 was 
dissolved in a solution of strong hydrogen bromide in acetic acid and was stirred 
over night. The required 4H-triazolobenzotriazepine 11 could be obtained in high 
yield of 88%. 
 
 
 
4.3.2 Derivatization of 4H-triazolobenzotriazepine 11 with various 
substituted 4-benzyl residues 
 
4.3.2.1 Benzylation via Mitsunobu reaction 
 
With regard to the fact that benzyl bromide is known as strong lachrymator the 
original plan (Chapter 2.2.2.3) to synthesize the target compounds by N-alkylation 
with benzyl bromides was tried to be avoided. As alternative route the reaction of 
8-chloro-1-methyl-6-phenyl-TBzT 11 with 4-(tert-butyl)benzyl alcohol 52 was 
attempted under Mitsunobu conditions (Scheme 21). 
 
 
Scheme 21. Attempted Mitsunobu reaction to attach benzyl residues. 
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According to a method worked out by Mayer et al.146 for the N-alkylation of imides 
triphenylphosphine (PPh3) and diisopropyl azodicarboxylate (DIAD) were used in 
tetrahydrofuran as reagents under microwave conditions. However no conversion 
to product 53 could be detected by TLC and GC/MS. Also another attempt by 
heating the reaction mixture in the oil bath to reflux for three days did not result in 
any conversion. 
 
 
 
4.3.2.2 Benzylation via N-alkylation of compound 11 using benzyl bromides or 
chlorides 
 
 
Scheme 22. Successful reaction to convert compound 11 into a 4-benzyl substituted derivative 53. 
 
With having no success using the Mitsunobu reaction to yield benzylated target 
compounds, the initial strategy was revisited. In contrast to the 4-(tert-butyl)benzyl 
alcohol 52, used in the Mitsunobu reaction, the reagent was the closely related  
4-(tert-butyl)benzyl bromide 54. Starting with the deprotonation of 4H-triazolo-
benzotriazepine 11 with sodium hydride the yellowish solution in tetrahydrofuran 
immediately turned into purple. The benzyl bromide derivative 54 was added and 
the reaction mixture was stirred for one hour at room temperature. During this time 
the solution changed its color back again to yellow and the desired product  
4-(4-[tert-butyl]benzyl)-8-chloro-1-methyl-6-phenyltriazolobenzotriazepine 53 was 
obtained in moderate yield of 42% (Scheme 22). 
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Scheme 23. N-Alkylation of starting molecule 11 with different benzyl bromides 55a-e. 
 
With the goal to generate a series of compounds with substituted 4-benzyl 
moieties, the synthesis treating starting compound 11 with sodium hydride 
followed by benzyl bromides was continued. Three additional para substituted 
reagents – 4-iodobenzyl (55a), 4-nitrobenzyl (55b) and 4-(trifluoromethyl)benzyl 
(55c) bromide – were used to prepare the corresponding target molecules 56a-c in 
the same manner as compound 53. Furthermore 3-chlorobenzyl bromide (55d) 
and 2-bromobenzyl bromide (55e), respectively, were chosen as representatives 
of meta and ortho substituted derivatives (Scheme 23). 
 
 
Scheme 24. N-Alkylation of compound 11 carried out with benzyl chlorides 57a-c. 
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In addition to the benzyl bromides also benzyl chlorides were converted with 
compound 11 to benzylated target molecules. However, reaction conditions had to 
be changed as no or only poor conversion was detected by trying the same 
conditions used with benzyl bromides. After heating the reaction mixtures to reflux 
for four hours good yields of target compounds 58a-c were obtained (Scheme 24). 
Next to another ortho substituted reagent (57a), one disubstituted (3,4-dichloro-
benzyl chloride, 57b) and one trisubstituted (3,4,5-trimethoxybenzyl chloride, 57c) 
was used to gain diversity and a more extensive correlation between substitution 
patterns and activity against bromodomains. 
 
All synthesized compounds were obtained in good to high yields of 61 – 89% (56a, 
56c-e and 58a-c) with the exception of the 4-nitrobenzyl bromide 55b which gave 
product 56b only in moderate yield of 43%. 
 
 
 
4.3.3 Preparation of 1,4-substituted 1,2,3-triazole compounds 
 
After a broad variety of 4-benzyl substituted compounds were prepared it was 
considered to replace the phenyl ring by a five-membered aromatic substituent. 
Therefore 1,2,3-triazoles were chosen as they are not very complex to synthesize. 
With regard to keep the methylene linker in between the seven-membered 
triazepine scaffold and the connected aromatic ring, the first step was to attach a 
propynyl group to starting compound 11. This was realized by using again sodium 
hydride to obtain the deprotonated species of 4H-triazolobenzotriazepine 11 which 
was thereupon treated with propargyl bromide 12. After stirring for one hour in 
tetrahydrofuran at room temperature the propargyl compound 13 could be isolated 
in good yield of 69% (Scheme 25). Alkyne 13 complies the requirements to 
proceed with a 1,3-dipolar cycloaddition, more precisely with the copper(I)-
catalyzed azide-alkyne cycloaddition111. Only adequate azides had to be chosen to 
convert the precursor 13 into substituted 1,2,3-triazole containing target 
compounds. 
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Scheme 25. Alkylation of compound 11 with propargyl bromide 12 followed by microwave-assisted 
click chemistry to give compound 59, containing a 1,2,3-triazole. 
 
On the basis of the work of Prof. Dr. Rolf Huisgen on 1,3-dipolar cycloadditions147 
this type of reaction was constantly further developed. A highly interesting 
modification of this triazole synthesis was published148 by Castagnolo et al. in 
2007. They described a microwave-assisted click chemistry with an in-situ 
generation of benzyl azide by using sodium azide and benzyl chloride. This one-
pot synthesis offers a great economy of time due to a lower number of reaction 
and purification steps. For the first run, a microwave vial was charged with alkyne 
derivative 13 and sodium azide as well as copper(II) sulfate pentahydrate in 
catalytic and L-ascorbate in stoichiometric amounts dissolved in a mixture of water 
and tert-butanol. With the intention to yield a very small substituted triazole ring, 
iodomethane was added instead of the described benzyl chloride. Using reaction 
conditions similar to those published by Castagnolo et al., after a short reaction 
time of 10 min at 125 °C and a maximum power of 100 W the desired product 59 
with a 4-(1-methyltriazol-4-yl)methyl residue could be obtained in 49% yield 
(Scheme 25). 
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This type of reaction – the copper-catalyzed azide-alkyne cycloaddition (CuAAC) – 
is the most commonly used 1,3-dipolar cycloaddition in organic chemistry149. 
Despite neither the origin of the selectivity of the cycloaddition nor the 
complexation of the Cu(I)-species is proven yet, an illustration of a proposed111 
catalytic cycle is shown in Scheme 26. 
 
 
Scheme 26. Azide-alkyne [3+2] cylcoaddition with copper(I)-catalyst illustrated in an proposed 
catalytic cycle
111
. 
 
The catalytic cycle starts with the formation of the copper(I) acetylide I out of the 
copper-catalyst and the terminal alkyne. This first intermediate already explains 
why only terminal alkynes can be used in CuAACs in contrast to ruthenium 
catalyzed reactions which also tolerates internal alkynes. Evidence for a non 
concerted [3+2] cycloaddition directly to IV was given by DFT calculations of Himo 
et. al.150. Instead, over an annealing sequence of Cu(I)-acetylide I with the terminal 
azide a six-membered intermediate III is generated which rearranges to the five-
membered triazole ring IV. Regaining of the copper(I)-catalyst by elimination 
results in the 1,4-disubstituted 1,2,3-triazole ring (Scheme 26). However, recent 
publications show new suggestions for catalytic cycles including dinuclear151 or 
polynuclear152,153,154 copper(I) intermediates. 
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To obtain more informative results within the group of 1,2,3-triazole residues two 
additional derivatives were prepared. This time the corresponding alkyl bromides, 
1-bromopropane 60a and benzyl bromide 60b, were added to the reaction 
mixtures to obtain the propylated (61a) and the benzylated (61b) target 
compounds, respectively. The reactions were carried out in the same manner as 
described above (preparation of compound 59, Scheme 25) using sodium azide, 
copper(II) sulfate pentahydrate and sodium L-ascorbate in a mixture of water and 
tert-butanol. The microwave-assisted synthesis gave 4-([1-propyltriazol-4-
yl]methyl)triazolobenzotriazepine 61a in moderate yield (41%) and 4-([1-benzyl-
triazol-4-yl]methyl)triazolobenzotriazepine 61b in good yield of 80%. 
 
 
Scheme 27. Two additional target compounds 61a and 61b prepared by click chemistry. 
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4.3.4 Screening and co-crystallization results of synthesized triazolo-
benzotriazepines with 4-benzyl and 4-(triazol-4-yl)methyl moieties 
 
Differential scanning fluorimetry was carried out with 15 compounds again at a 
concentration of 10 µM against 13 bromodomains, with the exception of compound 
58c which was not screened against LOC93349. The missing data presented not 
a problem as LOC93349 is not a member of the BET family but only screened to 
check against any cross interaction with domains of other subfamilies. 
 
The screening (Figure 38) obtained four remarkable compounds (13, 51, 58c, 61b) 
with Tm shifts of more than 6 °C. Especially 51 and 58c showed high impact on the 
desired target domains of the BET family without any indication of interactions with 
other subfamilies. Only three compounds (53, 56e, 58a) did not show significant 
Tm values of more than 4 °C. This observation implies that either their 
substitution is in an unfavorable position or electronic properties are disfavored. In 
combination with the rest of the screened molecules which cover the not only 
ortho, meta and para substituted benzyl moieties but also 1,2,3-triazole containing 
residues first interesting structure-activity relationships could be gained, which are 
discussed in the following Chapter 4.3.5. 
 
Figure 38. DSF screening results 
of 4H-triazolobenzotriazepine 11, 
4-benzyl substituted compounds 
51, 53, 56a-e and 58a-c as well as 
propynyl derivative 13 and the 
1,2,3-triazolyl moiety containing 
compounds 59, 61a and 61b. 
Compound concentration 10 µM. 
Combination of LOC93349 and 
58c was not screened (grey 
colored cell). 
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Figure 39. Co-crystallization structure 
of 4-(4-methoxybenzyl)triazolobenzo-
triazepine 51 with first domain of 
BRD4 shown in two different 
perspectives (A / B). The amino acids 
of the bromodomain are colored 
marine blue and their surface is 
colored grey. The ligand coloring was 
done by atom: carbon (yellow), 
oxygen (red), nitrogen (blue) and 
chlorine (green). 
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition to the useful screening outcome we tried to receive even more 
illustrating results by x-ray structures. Molecule 51, containing the para-
methoxybenzyl residue in 4 position, could be successfully co-crystallized with first 
domain of BRD4 (A/B). This structure displayed the proper fitting of compound 51 
into the KAc binding pocket of BRD4(1). The molecule orientates with the  
1-methyltriazole ring towards the inside of the bromodomain pocket while the other 
ring systems cover groves towards the surface of the binding pocket. 
  
A 
 
 
 
 
 
 
B 
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4.3.5 Explanation and discussion of recently screened 
triazolobenzotriazepines 
 
Temperature shift screening of new synthesized compounds produced positive 
and interesting results. A progress in research efforts was clearly noticeable as 
most of the compounds gave significant Tm values. Another important success 
was the fact that despite of increased affinity to members of the BET family, Tm 
shifts yielded with bromodomains of other families still were kept quite low. 
Furthermore incipient stages were made to get information about structure-activity 
relationships. To get a more expressive information about the obtained Tm shifts, 
they had to be analyzed more in detail. 
 
Next to both precursors 11 (4H-triazolobenzotriazepine) and 13 (4-proynyl-
triazolobenzotriazepine) the rest of the screened molecules can be clustered into a 
small group of 1,2,3-triazolyl containing triazolobenzotriazepines (59, 61a-b) and 
into the main group of benzylated triazolobenzotriazepines (51, 53, 56a-e, 58a-c). 
 
The 4H-TBzT precursor 11 was screened for the sake of completeness and 
showed results as expected with 2.8 °C maximum Tm shift. This insignificant 
values, however, confirm the assumption that substituents in position 4 are 
responsible for important interactions to the targeted BETs. 
 
The "click reaction" products 59 and 61a-b as well as their precursor 13 already 
gave remarkable Tm shifts. The methyl (59) and propyl (61a) substituted 1,2,3-
triazoles showed similar Tm values, approximately 5 °C for all of the second 
domains and a lower to nearly no signal for all of the first domains of the BETs. 
The same trend could be seen with compounds 13 and 61b. Despite their great 
diversity of the attached residue, both compounds showed interesting high Tm 
values (6.3 – 7.0 °C) against second domains but unfortunately also increased 
affinity towards first domains of the BET family. This effect should be avoided as 
far as possible to optimize the molecules to site selective BET inhibitors, what 
means that they only target first domains or second domains of the BETs. 
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The series of benzylated triazolobenzotriazepines – composed of ten compounds 
– allowed a much more reasonable discussion about SAR and consequent 
optimization options. Obviously, ortho substitution decreased affinity for any of the 
measured domains compared with the unsubstituted benzyl compound 10. The  
2-bromobenzyl (56e) and 2-methylbenzyl (58a) compound did not show any 
significant Tm value. A similar observation was made with compound 53. The 
very bulky tert-butyl moiety in para position destroyed every affinity in comparison 
with the 4-iodo (56a), 4-nitro (56b) and 4-trifluoromethyl (56c) substituted 
compounds which showed Tm values of at least 4.5 °C against two bromodomains. 
The only meta substituted compound 56d, having a 3-chlorobenzyl residue, also 
showed a trend to a higher affinity to second domains alike the already discussed 
compounds of the 4-(triazolo-4-yl)methyl series. The closely related 3,4-dichloro-
benzyl substituted compound (58b), however, hardly gave significant Tm shifts. 
Consequently, the additional 4-chloro substitution must be responsible for the 
decrease in temperature shift values. Outstanding results were obtained with 
target molecules containing a methoxy substituted residue. Both, the  
4-(4-methoxybenzyl)triazolobenzotriazepine (51) and the 4-(3,4,5-trimethoxy-
benzyl)triazolobenzotriazepine (58c) reached generally high Tm shifts (6 – 8 °C) 
against BETs and very high Tm values against BRD4(2) of 8.3 °C and 8.0 °C, 
respectively. Even 9.0 °C were achieved against BRDT2 by compound 58c. 
Furthermore, these compounds were highly selective for the BET family with no 
detectable cross activity towards other subfamilies of bromodomains as far as they 
were screened. 
 
The co-crystallization structure which was obtained of compound 51 with the first 
domain of BRD4, displayed that the 6-phenyl moiety as well as the annulated 
benzo ring occupy a groove of the binding pocket. Although the position of the 
benzyl residue is located more towards the surface of the pocket meaningful SAR 
studies, resulted from various substitutions of the 4-benzyl moiety, could be 
obtained. Consequently, modifications of the 6-phenyl and / or of the annulated 
benzo ring could produce additional interesting SAR results. 
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To sum up the obtained results, the first goal to synthesize a potent and highly 
selective compound for bromodomains of the BET family was already achieved, 
but directly opened a more refined and even more interesting question:  
Is it possible to optimize the synthesized molecules to site selective inhibitors? 
Can we address molecules selectively to first OR to second domains of 
bromodomains of the BET family? 
 
This question gave enormous limitations to the already developed molecules and 
the direction of the following synthesis sequences. A general view on the last 
screening results showed that we were able to synthesize molecules which 
produce good to high shifts in the screening assay. Now the task was to filter out 
compounds comprising the potential to be optimized to site selectivity or maybe 
already having a trend to it. 
 
With regard to an improvement of the molecules to a site selective compound and 
the fact that no clear SAR could be made of the obtained results no further  
4-(triazolo-4-yl)methyl) substituted compounds were prepared. The focus was 
concentrated now towards new benzylated series with different substituted core 
scaffolds. These efforts should lead to a more informative SAR. 
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4.4 4-BENZYL SERIES WITH DIFFERENT SUBSTITUTED SCAFFOLDS 
 
4.4.1 Synthesis of a "nitro" and a "dichloro" substituted  
4H-triazolobenzotriazepine 
 
The first step to improve site selectivity was to get better insight into SAR. 
Therefore the successfully prepared 4-benzyl series, which already gave good 
structure to activity relations, should be expanded. The core structure of the 
hitherto synthesized series contained a 8-chloro and a 6-phenyl substituent. In the 
patent of Nakamura et al. two further 4H-triazolobenzotriazepines 14 and 15 as 
well as their synthesis are described110 (Scheme 28). 
 
In the same way as described in Chapter 4.3.1.2 for the synthesis of 4H-triazolo-
benzotriazepine 11, preparation of the isothiocyanates 64 and 65 as well as the 
rest of the reaction sequence to the target building blocks 14 and 15 was modified. 
Mainly work-up and purification steps were improved, e.g. to use flash column 
chromatography on flash silica gel instead of long crystallization steps. 
 
Conversion of the commercially available 2-aminobenzophenones 62 and 63 into 
isothiocyanates 64 and 65 followed the same procedure as described for 
compound 6 using thiophosgene 16 and calcium carbonate to obtain the products 
in moderate (69%, 64) to high (96%, 65) yields. Preparation of the triazepine ring 
was realized using 4-methoxybenzylhydrazine hydrochloride 48 and DIPEA in the 
first step, followed by para-toluenesulfonic acid monohydrate in the second step. 
Both compounds were obtained in similar yields of 63% (66) and 64% (67) over 
two steps. The 1-methyltriazole ring was accomplished again by treating the 
starting materials 66 and 67, respectively, first with hydrazine hydrate then with 
triethyl orthoacetate 43 and para-toluenesulfonic acid monohydrate. The  
4-methoxybenzyl substituted triazolobenzotriazepines 68 and 69 were obtained in 
78% and 76%, respectively. Deprotection of the PMB group to yield the 
corresponding 4H-triazolobenzotriazepines in 93% (14) and 79% (15) was done in 
a 45% solution of hydrogen bromide in acetic acid (Scheme 28). 
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Scheme 28. Synthesis of 4H-triazolobenzotriazepines 14 and 15 according to Nakamura et al.
110
. 
 
With regard to a more clear and easier discussion of results and comparison of 
closely related molecules, the synthesized compounds were grouped into series. 
Comprising the same scaffold with only small variations of the precursors 11, 14 
and 15 (Figure 40), the series were named by their substitution pattern of the 
corresponding core structure: "chloro series" (11), "nitro series" (14) and "dichloro 
series" (15). 
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Figure 40. The substitution pattern of the core scaffold named the corresponding series generated 
by derivatization in position 4: "chloro series" (11), "nitro series" (14) and "dichloro series" (15). 
 
 
 
4.4.2 The nitro series: Derivatization of 1-methyl-8-nitro-6-phenyl-4H-
triazolobenzotriazepine 14 
 
 
Benzyl halide derivative Substitution Product 
Yield 
No. X = R = No. 
54 Br 4-tert-butyl 71a 72% 
55a Br 4-iodo 71b 68% 
55b Br 4-nitro 71c 60% 
55d Br 3-chloro 71d 70% 
55e Br 2-bromo 71e 63% 
57b Cl 3,4-dichloro 71f 48% 
57c Cl 3,4,5-trimethoxy 71g 38% 
70 Br 3-methoxy 71h 62% 
 
Scheme 29. Derivatization of 4H-triazolobenzotriazepine 14 by N-alkylation produced eight target 
molecules of the nitro series. Reagents and conditions: (i) benzyl bromide derivative (3.0 equiv), 
sodium hydride (1.1 equiv), THF, r.t., 1 h; (ii) benzyl chloride derivative (3.0 equiv), sodium hydride 
(1.1 equiv), THF, reflux, 4 h. 
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The nitro series was planned to see what effect a change of the substituent in 
position 8 can have. To be able to compare both series with each other, the 
replacement of the chloro by a nitro group should be the only modification. The 
benzyl bromides and benzyl chlorides converted with 4H-triazolobenzotriazepine 
14 were nearly the same as used in the chloro series. The group of para 
substituted compounds was reduced by 4-(trifluoromethyl)benzyl compound and 
one ortho substituted compound (2-methylbenzyl) was also leaved out. 3-Methoxy-
benzyl bromide 70 was added to the set of benzyl halides as a consequence of the 
combination of two aspects. One the one hand the meta substituted  
3-chlorobenzyl bromide 55d gave interesting temperature shift results which 
showed a trend to site selectivity and on the other hand high Tm values of methoxy 
substituted compounds (51, 58c) were obtained before. 
 
The synthesis of the target compounds 71a-h followed the established procedure 
as already used within the chloro series in Chapter 4.3.2.2. After deprotonation of 
the 4H-triazolobenzotriazepine 14 using 1.1 equivalents of sodium hydride, the 
corresponding benzyl halide was added. The reaction was carried out in 
anhydrous tetrahydrofuran for one hour at room temperature when using benzyl 
bromides. The conversion with benzyl chlorides was done in anhydrous 
tetrahydrofuran by heating to reflux for four hours. The target molecules 71a-h 
could be synthesized in moderate to good yields (38 – 72%) throughout (Scheme 
29). 
 
 
 
4.4.3 Preparation of the dichloro series by N-alkylation of 8-chloro-6-(2-
chlorophenyl)-1-methyl-4H-triazolobenzotriazepine 15 
 
The preparation of the "dichloro series" followed the same intention as the 
development of the nitro series. However, this time the 8-chloro substituent was 
maintained while an additional chlorine was introduced in ortho position of the  
6-phenyl ring. The study of the effect of this labeling in combination with the other 
two series should allow us to get a comprehensive SAR. 
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Benzyl halide derivative Substitution Product 
Yield 
No. X = R = No. 
54 Br 4-tert-butyl 72a 97% 
55a Br 4-iodo 72b 67% 
55b Br 4-nitro 72c 66% 
55d Br 3-chloro 72d 77% 
55e Br 2-bromo 72e 76% 
57b Cl 3,4-dichloro 72f 59% 
57c Cl 3,4,5-trimethoxy 72g 68% 
70 Br 3-methoxy 72h 81% 
 
Scheme 30: Conversion of 8-chloro-6-(2-chlorophenyl)triazolobenzotriazepine 15 with a variety of 
benzyl chlorides and bromides to target compounds 72a-h. Reagents and conditions: (i) benzyl 
bromide derivative (3.0 equiv), sodium hydride (1.1 equiv), THF, r.t., 1 h; (ii) benzyl chloride 
derivative (3.0 equiv), sodium hydride (1.1 equiv), THF, reflux, 4 h. 
 
Under identical reaction conditions as used preparing the nitro series, the target 
compounds of the dichloro series 72a-h were synthesized. The starting material 
15 was treated with sodium hydride and the corresponding benzyl halide derivative 
in anhydrous tetrahydrofuran. Reactions using benzyl bromide derivatives were 
stirred for one hour at room temperature whereas reactions with benzyl chlorides 
were heated to reflux for four hours. A good comparability was guaranteed by 
converting the 4H-triazolobenzotriazepine 15 with exactly the same benzyl 
bromides and benzyl chlorides as used before in the nitro series. Consistently 
good yields from 59 – 81% were achieved. Even an almost quantitative yield of 
97% was reached with 4-(tert-butyl)benzyl bromide 54 to target compound 72a. 
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4.4.4 Isotope effects in mass spectra obtained from multi-halide 
substituted compounds 
 
The distribution of isotopes is an important factor in the analysis of mass 
spectrometry. In 1922, Francis William Aston was awarded the Nobel Prize in 
chemistry for his outstanding research of discovering isotopes by mass 
spectrometry155. His research became an area of high interest and his efforts 
paved the way for numerous scientists who improved his studies especially by 
more precise mass spectrometers. Despite carbon, hydrogen, oxygen and 
nitrogen are the main components of organic molecules, their contribution to the 
isotope peaks is very low. The explanation is their isotope distribution with a very 
high natural abundance of the main isotope 12C (98.93%), 1H (99.9885%), 16O 
(99.757%) and 14N (99.632%)156. In contrast both chlorine and bromine have a 
considerable abundance of a second natural isotope, in case of chlorine 35Cl 
(75.77%) and 37Cl (24.23%) and in case of bromine 79Br (50.69%) and 81Br 
(49.31%)157. Halide substituted compounds consequently show a very obvious and 
characteristic distribution of their molecule peak (and potential fragments) which 
increases in complexity with a rising number of halogen atoms. Neglecting the 
minor isotope effects, in the following discussion only halogens are considered. 
 
Interesting examples for more complex isotope distributions in mass spectrometry 
are compounds 72e and 72f. The synthesized compound of the dichloro series 
contain three and four halogen atoms, respectively, and thus showed a complex 
composition of molecule mass peaks in the corresponding mass spectra. 
 
 
Figure 41. Compound 72e is substituted by three halogen atoms and compound 72f even contains 
four chloro substituents. 
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For compound 72e three halogen atoms are present with two abundant isotopes 
each. Consequently there are 23 = 8 feasible combinations of isotopes, resulting in 
four molecule peaks in the MS spectra (Figure 42). The relative intensities of the 
molecule peaks can be calculated by the following example. 
 
1) The probability P for each isotope pattern over all isotopes n has to be 
calculated by 
                                   
 
 
In case of the first isotope combination 
 
                                                        
 
means that with a probability of 29% molecule 72e comprises the isotope 
pattern (35Cl, 35Cl, 79Br). 
 
2) In case of multiple combinations for the same mass peak (cf. M + 2, M + 4) 
the probabilities of each isotope combination have to be summed up. The 
isotope combinations (35Cl, 37Cl, 79Br) and (37Cl, 35Cl, 79Br) as well as (35Cl, 
37Cl, 81Br) and (37Cl, 35Cl, 81Br) are not distinguishable by mass 
spectrometry and they have the same probabilities. Nevertheless, both 
possibilities have to be considered by summing up the single probabilities 
for the corresponding molecule peak. Either they are listed twice and for 
each combination P is calculated or (like in the next example) they are 
weighted by their number of variations (in this case: two). 
 
3) Now, the peak with the highest probability (in this case: M + 2) will be set to 
100%. The other relative intensities are obtained by 
 
                        
    
      
 
 
                          
    
      
 
         
         
             
 
The calculated values match literature158 as well as practical data very well. 
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Molecule 
peak 
Isotope 
combinations 
Probability P Relative 
intensity 
 
single summation 
M 
35
Cl, 
35
Cl, 
79
Br 0.2910 62% 
M + 2 
35
Cl, 
37
Cl, 
79
Br 0.0931 
0.4693 100% 
37
Cl, 
35
Cl, 
79
Br 0.0931 
35
Cl, 
35
Cl, 
81
Br 0.2831 
M + 4 
37
Cl, 
37
Cl, 
79
Br 0.0297 
0.2107 45% 
35
Cl, 
37
Cl, 
81
Br 0.0905 
37
Cl, 
35
Cl, 
81
Br 0.0905 
M + 6 
37
Cl, 
37
Cl, 
81
Br 0.0290 6% 
 
Figure 42. Eight combinations of halogen isotopes are possible for compound 72e. They produce 
four molecules peaks in the MS spectra with different intensities
158
. 
 
The same method as before can be used calculating the isotope peaks in the 
mass spectra of compound 72f. In this case with two different isotopes of four 
chloro substituents 24 = 16 different combinations are possible. However, with only 
chloro atoms are present in this compound, which are not distinguishable by mass 
spectroscopy, there are only five different combinations but (M + 2) and (M + 6) 
can occur in four different variations and (M + 4) can even occur in six different 
variations. Therefore the single probability of each combination has to be weighted 
by its number of variations (V) to obtain the probability P of each molecule peak 
(Figure 43). The complete calculation led to a distribution of the molecule peak into 
five isotope peaks of M, (M + 2), (M + 4), (M + 6) and (M + 8) with the 
corresponding intensities of 78%, 100%, 48%, 10% and 0.8%. 
 
Molecule 
peak 
Isotope 
combination 
V 
Probability 
P 
Relative 
intensity 
 
M 
35
Cl, 
35
Cl, 
35
Cl,
 35
Cl 1 0.3296 78% 
M + 2 
37
Cl, 
35
Cl, 
35
Cl,
 35
Cl 4 0.4216 100% 
M + 4 
37
Cl, 
37
Cl, 
35
Cl,
 35
Cl 6 0.2022 48% 
M + 6 
37
Cl, 
37
Cl, 
37
Cl,
 35
Cl 4 0.0431 10% 
M + 8 
37
Cl, 
37
Cl, 
37
Cl,
 37
Cl 1 0.0035 0.8% 
 
Figure 43. Example for calculation of the molecule peak of compound 72f which split up into five 
peaks as a consequence of different isotope combinations
158
. 
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4.4.5 Temperature shift results and discussion of the nitro and the 
dichloro series 
 
In total 20 compounds, ten of each series, were screened against the standard 
eight family members of the BETs and the five representatives of other subfamilies 
of bromodomains. A compound concentration of 10 µM was used again and 
LOC92249 was left out of both 3,4,5-trimethoxybenzyl substituted compounds 71g 
and 72g. 
 
At a first glance, the compounds of the nitro series looked much more active than 
those of the dichloro series. On the average the 8-nitro substituted compounds 
indeed gave higher temperature shift signals, but hardly trends are readable from 
the chart of results. A much more interesting tendency – a trend to site selectivity – 
is given by the dichloro series, however most signals are too weak to consider 
them as significant results (Figure 44). 
 
Figure 44. Temperature shift 
screening results of the nitro 
series and of the dichloro 
series. 4H-Triazolobenzo-
triazepines 14 and 15 were 
also screened as well as the 
4-methoxybenzyl substituted 
compounds 68 and 69.  
Both 3,4,5-trimethoxybenzyl 
substituted compounds 71g 
and 72g were not screened 
against LOC93349 (grey 
colored cells). A compound 
concentration of 10 µM was 
used. 
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 Tm(°C) 
72c 
             
  <0 
72d 
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72h 
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The unsubstituted compounds in 4 position 14 and 15, both gave poor Tm values 
as expected (cf. chloro series). Compounds 71a and 72a, containing the bulky tert-
butyl group in para position of the N-benzyl moiety, again showed no significant Tm 
shift, probably as a consequence of steric interference. The same observation was 
made with both 2-bromobenzyl substituted compounds 71e and 72e. As already 
observed within the chloro series of compound 56e and 58a, the ortho substituent 
obviously is responsible for steric interactions which mismatch the space given by 
the binding pocket. 
 
The 4-methoxybenzyl substituted compounds 68 and 69 as well as 71g and 72g 
with an attached 3,4,5-trimethoxybenzyl residue showed a enormous decrease in 
their temperature shifts compared to the analogous compounds of the chloro 
series 51 and 58c, respectively. This implies that both modifications, the exchange 
of the 8-chloro by a 8-nitro group as well as the additional chloro substituent in 
ortho position of the 6-phenyl rings is responsible for a decrease in affinity towards 
the targeted domains. 
 
The simple para substituted compounds (71a, 71b, 72a, 72b, containing iodo and 
tert-butyl residues) as well as the disubstituted 4-(3,4-dichlorobenzyl)triazolo-
benzotriazepines (71f, 72f) either gave only poor response in the DSF screening 
or showed also no trend to a compound which could be improved to a site specific 
one. 
 
A very interesting results however was obtained with the newly introduced residue. 
Compounds 71h and 72h containing the 3-methoxybenzyl moiety showed on the 
one hand the highest Tm shift against the second domain of BRD(4) within the nitro 
series (71h) and on the other hand a distinctive trend towards site selectivity 
against the second domains of BRD(2), BRD(3) and BRD(4) within the dichloro 
series (72h). Thus, this compound is an evidence of progress and a good example 
which presents the improvement that can be made by stepwise analysis of 
structure-activity relationships obtained by DSF. 
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4.4.6 Lead structure optimization by comparison of the three benzyl series 
 
The complete screening of triazolobenzotriazepines covers 47 compounds 
clustered into the three series "chloro", "nitro" and dichloro". A lot of information 
was gained out of the DSF screenings and structural variations could be 
connected to an increase or a decrease of the corresponding temperature shifts 
what led to a good prediction of structure-activity relationships. 
 
For the upcoming lead structure optimization the previous screenings results of all 
three series were used. The screening charts of the series as depicted in Figure 
34, Figure 38 and Figure 44 gave first illustrations by their contrast levels starting 
from colorless for low Tm shifts and turning over five steps into dark red what 
indicates high Tm shifts. With regard to the development of a site selective 
compound a second analysis was used. Therefore the difference of the Tm 
values of both domains (Tm domain 2 – Tm domain 1; Tm(D2-D1)) of each BRD 
was plotted on the ordinate against the residue in position 4 of the corresponding 
compound on the abscissa (see two examples in Figure 45 and Figure 46). 
 
The chloro series, which was screened in two parts, has to be considered 
separately. The 4-(2-hydroxyethyl)triazolobenzotriazepine 5 and its derivatives 
44a-j showed weak response in the DSF screening (Figure 34) and consequently 
no tendency to site selectivity but only spread and low values in the plot of Figure 
45. The subsequently prepared compounds, analogs of the screening hit 
compound 10, containing substituted 4-benzyl residues or a 4-(triazol-4-yl)methyl 
moiety showed exceptionally improved Tm values (Figure 38). Even more, a trend 
to site selectivity against BRD2 and BRDT (Figure 45) is given by several 
compounds especially of those which contain the 4-(triazol-4-yl)methyl residue 
(59, 61a, 61b) as well as their precursor 13 containing a 4-propynyl substituent. 
 
However, both additional series, the nitro and the dichloro one, gave the decisive 
factor for the next generation of compounds. The greater number of comparable 
values and the repeating results of SAR confirmed predictions of the chloro series 
and enabled a further development with profound knowledge. 
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Figure 45. Plot of the whole chloro series with regard to site selectivity. 
 
 
Figure 46. Plot of the benzyl residues of all three series to filter out the moiety in position 4 with the 
highest site selectivity. 
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The nitro series as well as the dichloro series showed impressively, by their DSF 
results in comparison with the chloro series, how a small change of the core 
scaffold can affect the strength of interaction with the targeted bromodomains. 
 
The replacement of the 8-chloro by a 8-nitro group decreased the Tm values of the 
best compounds of the chloro series 51 and 58c but showed an slight increase in 
Tm shifts of BRD2(2), BRD3(1) and BRD3(2) of the para substituted molecules 71a 
and 71b. For this reason position 8 offered a good starting point for further 
optimization of the triazolobenzotriazepines. Furthermore, the crystal structure of 
compound 51 with BRD4(1) (Figure 39) showed a distinctive groove which might 
also be occupied by an additional substituent in position 9. Thus to both positions 
a residue should be attached in the next generation of TBzTs (Figure 47). 
 
The great benefit of the dichloro series is the fact that almost exclusively second 
domains are targeted as illustrated in the chart of results (Figure 44). Despite most 
of the obtained results are not significant as they gave only poor response in the 
temperature shift screening the trend is obvious and 3-methoxybenzyl compound 
72h gave an evidence that it is possible to increase affinity towards the second 
domains. With this observation the new lead structure (Figure 47) was planned to 
have this 6-(2-chlorophenyl) residue as a constant element of the core structure. 
 
The choice of the residue in position 4 was again tried to filter out by a plot 
comparing the site selectivity of the corresponding 4-benzyl residues of all three 
series (Figure 46). Non convincing results were obtained of the three moieties 
benzyl, (4-trifluoromethyl)benzyl and 2-methylbenzyl as they were only used in the 
chloro series. The 4H-triazolobenzotriazepines as well as those with an ortho 
substituted benzyl residue in position 4 gave poor site selectivity results in the plot. 
Similarly weak results were obtained with the (4-tert-butyl)benzyl and the  
3,4-dichlorobenzyl moieties. The 4-methoxybenzyl and especially the  
3,4,5-trimethoxybenzyl residue showed strongly spread results of site selectivity. 
Consequently both meta substituted benzyl residues and the 4-iodobenzyl as well 
as the 4-nitrobenzyl were the most interesting ones. 
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By a more detailed examination, however, the 3-methoxybenzyl residue turned out 
to be the most promising one. With the lowest distribution and the highest 
accumulation of data points (five of eight points) at a remarkable Tm(D2-D1) of 
approximately 4 °C second domains seem to be the preferred target of  
3-methoxybenzyl substituted compounds. Hence this 3-methoxybenzyl residue 
should also be introduced as an invariable structural element of the new lead 
structure (Figure 47). 
 
 
Figure 47. New developed lead structure for the next generation of potentially site selective BET 
inhibitors. 
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4.5 MODIFICATION OF 6-(2-CHLOROPHENYL)-4-(3-METHOXYBENZYL)-
TRIAZOLOBENZOTRIAZEPINE IN POSITIONS 8 AND 9 
 
4.5.1 Preparation of 2-aminobenzophenones 
 
For the desired modifications in positions 8 and 9 of the triazolobenzotriazepines 
according to the designed lead structure in Chapter 4.4.6 (Figure 47) different  
2-aminobenzophenones had to be synthesized as starting materials. Therefore 
two different approaches were used as described in the following Chapters 4.5.1.1 
and 4.5.1.2. 
 
 
 
4.5.1.1 Two step synthesis using photochemistry 
 
According to previous optimization steps methoxy groups showed distinct 
improvement of activity. For this reason, the first approach was to replace the  
8-chloro substituent by a 8-methoxy group. 
 
 
 
 
Scheme 31. Photochemical synthesis of 2-aminobenzophenone derivative 76. 
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The synthesis of (2-amino-5-methoxyphenyl)(2-chlorophenyl)methanone 76 was 
successfully accomplished in two steps. Using commercially available 4-methoxy-
aniline 73 and 2-chlorobenzoyl chloride 74 known159 amide 75 was obtained in 
almost quantitative yield of 98% after stirring for just about 15 min at room 
temperature in anhydrous tetrahydrofuran. A photo-Fries rearrangement of amide 
75, carried out according to Ferrini et al.160 for 24 h at room temperature in 
acetonitrile under irradiation with 254 nm led to published161 product 76 in 12% 
yield. 
 
The radical reaction mechanism caused the low yield of product 76. The homolytic 
cleavage of the amide bond by UV light of 254 nm produced two monoradical 
species: 4-methoxyaniline radical and 2-chlorobenzoyl radical. Figure 48 shows 
the mesomeric structures of the monoradical 4-methoxyaniline species 73 I-III. 
Whenever reaction occurs with the carbonyl radical, 73-I would lead to the starting 
material 75 and both ortho radicals 73-II would lead to the desired product 76. 
Reaction products with 73-III cannot rearomatize and are consequently disfavored. 
However the benzoyl radical also comprises different mesomeric structures of 
radicals next to the carbonyl one what leads to a lot of different other combination 
possibilities. 
 
 
Figure 48. Mesomeric structures of monoradical 4-methoxyaniline species 73 I-III after homolysis. 
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4.5.1.2 Synthesis by "ortho selective acylation" of aniline derivatives 
 
 
 
 
 
Scheme 32. Borane adduct mediated "ortho selective acylation" of 3,4-dimethoxyaniline 77. 
 
In contrast to the symmetric 4-methoxyaniline 73 the unsymmetrically substituted 
3,4-dimethoxyaniline 77 was even less adapted for photo-Fries rearrangement due 
to a higher probability of undesired byproduct generation. A different method was 
found published in 2006 by Liu et al.162. They described an "ortho selective 
acylation" method of aniline derivatives with a variety of substitution pattern in 
position 3 and 4.  
 
The substituted aniline 77 was stirred first with dichlorophenylborane 79 and 
triethylamine to form a borane adduct followed by the addition of  
2-chlorobenzaldehyde 78. This borane adduct coordinates to the carbonyl oxygen 
of the aldehyde and directs the carbonyl carbon into ortho position of the aniline 
derivative. A six-membered transition state provides after basic workup the not 
purified intermediate 80 which was oxidized to final product 81 using manganese 
dioxide. According to this patent synthesis of compound 81 (Scheme 32) could 
successfully be accomplished. 
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The same type of reaction as described above was carried out again using  
3,4-(methylenedioxy)aniline 82 and 2-chlorobenzaldehyde 78 to prepare known162 
compound 83 (Scheme 33). 
 
 
Scheme 33. Preparation of known
162
 compound 83 according to Liu et al. in two steps. 
 
 
 
4.5.2 Preparation of (3-methoxybenzyl)hydrazine hydrochloride 86 
 
For the synthesis of the chloro, nitro and dichloro series a 4-methoxybenzyl 
residue was used because of its property to act as an acid-cleavable protecting 
group. With the goal of producing no longer whole series of triazolobenzo-
triazepines with different residues in position 4, but maintain the 3-methoxybenzyl 
group, the detour via the 4-unsubstituted triazolobenzotriazepine was not 
necessary anymore. 
 
For this reason (3-methoxybenzyl)hydrazine hydrochloride 86 was prepared in the 
same manner as described for compound 48 in Chapter 4.3.1.2. Condensation of 
3-methoxybenzaldehyde 84 and tert-butyl carbazate 46 yielded hydrazone 85. 
Without purification a 2 M dimethylsulfide complex of borane in tetrahydrofuran 
was added and after 15 min at room temperature addition of concentrated 
hydrochloric acid gave product 86 in high yield of 90% (Scheme 34). 
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Scheme 34. Synthesis of (3-methoxybenzyl)hydrazine hydrochloride 86. 
 
 
 
4.5.3 Synthesis of 6-(2-chlorophenyl)-4-(3-methoxybenzyl)triazolobenzo-
triazepines 
 
With the successful preparation of the 2-aminobenzophenones (76, 81, 83) as 
novel starting materials and (3-methoxybenzyl)hydrazine hydrochloride 86, which 
is needed as building block to built up the triazepine ring, the general synthesis of 
the target compounds followed the well known procedures108,110 described several 
times in previous chapters. To obtain the new 6-(2-chlorophenyl)-4-(3-methoxy-
benzyl)triazolobenzotriazepines with modifications in the annulated benzo ring, the 
synthesis started again with conversion of the 2-aminobenzophenones (76, 81, 83) 
into the corresponding isothiocyanate derivatives (87, 88, 89) using thiophosgene 
16 and calcium carbonate. The subsequent addition of compound 86 to the 
isothiocyanates was followed by the para-toluenesulfonic acid catalyzed 
cyclization to the benzotriazepinethione compounds 93, 94 and 95. After treating 
them with hydrazine hydrate in the first step and triethyl orthoacetate 43 as well as 
para-toluenesulfonic acid monohydrate in the second step, target compounds 96 
(51%), 97 (35%) and 98 (40%) could be prepared in moderate to good yields. 
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Scheme 35. Synthesis of modified 6-(2-chlorophenyl)-4-(3-methoxybenzyl)-TBzTs 96, 97 and 98. 
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4.5.4 Screening results and discussion of novel triazolobenzotriazepines 
 
The differential scanning fluorimetry was carried out the common way with the 
three novel triazolobenzotriazepines 96, 97 and 98 (Figure 49A) in a compound 
concentration of 10 µM. The compounds were screened against all eight members 
of the BET family as well as against BAZ2B, CREBBP, PB1(5) and PCAF. 
 
The 8-methoxy-TBzT 96 an the 8,9-dimethoxy-TBzT 97 showed highly improved 
results as they combined high affinity towards specific bromodomains like 
BRD3(2) and BRDT2 as well as a strong selectivity towards second domains of 
the corresponding BRDs – at least according to the Tm values. In contrast the 
8,9-methylenedioxy-TBzT 98 gave poor Tm values and showed no site selectivity. 
 
Figure 49. (A) Screening results of 8-methoxy-
TBzT 96, 8,9-dimethoxy-TBzT 97 and 8,9-
methylenedioxy-TBzT 98 carried out at a 
compound concentration of 10 µM. 
(B) Compound 96 and 97 in a more detailed 
presentation with the measured Tm values. 
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With all three compounds showed the same core structure and even similar 
substitution pattern in position 4 and 6, the question raised why compound 98 led 
to comparatively poor temperature shifts. The rigid methylenedioxy structural 
element obviously is responsible for the decrease of most Tm values and even 
more a deterioration of selectivity in case of BRDT. The freely rotatable methoxy 
groups in compound 96 and 97 are consequently much more flexible and 
adaptable to the given spatial conditions in the binding pocket. 
 
Both compounds 96 and 97 showed highly interesting results (Figure 49). Against 
BRDT they reached a remarkable Tm(D2-D1) of 5.9 °C (96) and 4.9 °C (97). 
Especially the 8,9-dimethoxy substituted triazolobenzotriazepine 97 was able to 
obtain further good selectivity – according to DSF results – against all the other 
BRDs with Tm(D2-D1) of 4.2 °C (BRD2), 2.3 °C (BRD3) and 2.9 °C (BRD4). The 
advantage of the second methoxy group attached to the annulated benzo ring 
system appeared primarily with the important decrease of Tm (2 °C) of the first 
domain of BRD4 but maintaining the Tm shift (4.7 °C) of BRD4(2). 
 
As already discussed in Chapter 3.1 the obtained temperature shift results of DSF 
screenings do not correlate directly with each other. Meaning that a Tm shift of 
4 °C of first and of second domain does not consequently results in the same Kd 
values determined by ITC. Especially second domains mostly result in a higher Tm 
shift as first domains by tendency. 
 
Previous measurements of Kd values by ITC did not yield any binding constant, 
although compound 56a showed a Tm of 4.9 °C against second domain of BRD2 
and compound 69 has a Tm of 5.1 °C against second domain of BRDT. However, 
the measurement was planned to give results in a very low micromolar or even 
nanomolar range which was obviously not reached. 
 
The following four measurements of binding constants of compound 96 yielded 
results with remarkable affinity towards the desired proteins BRD4 and BRDT as 
well as unexpected values. 
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The first ITC measurements of compound 96 were carried out with the domains of 
BRD4 and gave the following results: 
 
 Kd [BRD4(1)] =  481 nM  [Tm = 3.8 °C] 
 Kd [BRD4(2)] =  92 nM  [Tm = 4.6 °C] 
 
 
Figure 50. ITC plots and data analysis of binding measurements of compound 96 with (A) BRD4(1) 
and with (B) BRD4(2). 
 
With a Kd of 481 nM compound 96 showed an expected result for a Tm of 3.8 °C 
of the first domain of BRD4 (Figure 50A). However a remarkable results was 
gained with the second domain of BRD4. A temperature shift of 4.6 °C – more an 
average value than a very high one – obtained a strong binding constant of 92 nM 
(Figure 50). Consequently a more than fivefold lower Kd was measured for the 
second domain of BRD4 representing already a good selectivity. With regard to 
compound 97, which obtained a Tm value of 1.8 °C (2 °C less than compound 96) 
for BRD4(1), the Kd value must be clearly weaker and thus a much higher 
selectivity must be gained. However, no ITC results of compound 97 were 
available until completion of the thesis. 
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The noticeable difference of 5.9 °C (Tm(D2-D1)) between first and second domain of 
BRDT in temperature shift screening with 8-methoxytriazolobenzotriazepine 96 
caused additional measurements by isothermal titration calorimetry. The following 
data were obtained by ITC performance: 
 
 Kd [BRDT1] =  1.54 µM  [Tm = 1.6 °C] 
 Kd [BRDT2] =  145 nM  [Tm = 7.5 °C] 
 
 
Figure 51. Binding constants of compound 96 with (A) BRDT1 and (B) BRDT2 measured by ITC. 
 
The temperature shift of the first domain with only 1.6 °C was very low and 
consequently containing relatively high errors in contrast to higher Tm values. 
Thus the Kd value for the first domain was hard to estimate and with 1.54 µM 
stronger than expected. However the second domain produced a low Kd value of 
145 nM what led to an impressive comparison of the results. 6-(2-Chlorophenyl)-8-
methoxy-4-(3-methoxybenzyl)-1-methyltriazolobenzotriazepine 96 showed more 
than a tenfold difference in Kd against the first and the second domain of BRDT. 
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4.6 ADDITIONAL PERFORMED BIOASSAYS 
 
Both bioassays, the agar diffusion test and the MTT assay, were performed in our 
group at the Ludwig-Maximilians University of Munich by Martina Stadler. 
 
 
 
4.6.1 Agar diffusion test (ADT) 
 
4.6.1.1 Background 
 
All synthesized compounds were routinely screened for antibacterial and 
antifungal activity against eight different model germs. These model germs were 
grown on agar plates and treated with the compound to be examined. Whenever 
growth inhibition (GI) or a total inhibition (TI) of the corresponding germ takes 
place a bacteria-free areola can be observed of which the diameter is measured. 
This zones of inhibition are correlated to the ones obtained with the reference 
substances tetracycline for antibacterial and clotrimazole for antifungal activity 
(Figure 52). Nevertheless this experiment gives only a general overview whether a 
substance is an antimicrobial agent. 
 
The following microorganism were used as model germs: 
 
DSMZ-No. 426 Escherichia coli gram-negative bacterium 
DSMZ-No. 8361 Pseudomonas antimicrobia gram-negative bacterium 
DSMZ-No. 20675 Staphylococcus equorum gram-positive bacterium 
DSMZ-No. 14446 Streptococcus entericus gram-positive bacterium 
DSMZ-No. 1345 Yarrowia lipolytica yeast 
DSMZ-No. 11226 Candida glabrata yeast 
DSMZ-No. 70663 Aspergillus niger dermatophyte 
DSMZ-No. 1988 Hyphopichia burtonii mold fungus 
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Figure 52. Reference compounds for antibacterial (tetracycline) and antifungal (clotrimazole) 
activity. 
 
 
 
4.6.1.2 Screening results and discussion 
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used reference: Tetracycline used reference: Clotrimazole 
1 --- --- 
11 mm 
(40 mm) 
--- --- --- --- --- 
20 --- --- --- --- 
10 mm GI 
(22 mm TI,  
25 mm GI) 
8 mm GI 
(30 mm) 
8 mm GI 
(13 mm TI,  
22 mm GI) 
8 mm GI 
(30 mm) 
23 
10 mm 
(28 mm) 
--- 
12 mm 
(40 mm) 
10 mm 
(20 mm) 
8 mm 
(22 mm TI,  
25 mm GI) 
12 mm 
(30 mm) 
13 mm GI 
(13 mm TI,  
22 mm GI) 
11 mm 
(30 mm) 
64 --- --- 
10 mm 
(40 mm) 
7 mm 
(21 mm) 
7 mm 
(20 mm TI,  
28 mm GI) 
7 mm 
(25 mm) 
--- 
10 mm GI 
(25 mm) 
65 --- --- 
11 mm 
(40 mm) 
7 mm 
(21 mm) 
7 mm 
(20 mm TI,  
28 mm GI) 
7 mm 
(25 mm) 
--- 
11 mm GI 
(25 mm) 
87 --- --- 
10 mm 
(40 mm) 
7 mm 
(22 mm) 
--- --- --- --- 
88 --- --- 
10 mm 
(30 mm) 
8 mm 
(30 mm) 
--- --- --- --- 
89 --- --- 
20 mm 
(30 mm) 
12 mm 
(30 mm) 
--- --- --- --- 
 
Figure 53. ADT results of compounds which showed total inhibition (TI) against the screened 
microorganism. Whenever growth inhibition (GI) is (also) observed the results are marked 
accordingly. The inhibition zone diameters of the corresponding reference substance are given in 
brackets. 
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Figure 53 shows compounds with a total or a growth inhibition against the 
screened model germs. No final target compound, neither a 
triazolobenzodiazepine nor a triazolobenzotriazepine gave any response in the 
antibiotic and antifungal test. Only intermediates of the triazolobenzodiazepine 
reaction sequence showed zones of inhibition. Benzodiazepinone 1 only against 
Staphylococcus equorum as antibiotic agent and 2-aminopropiophenone 20 with 
an antifungal growth inhibition against all four representatives. Iodoacetanilide 23 
showed mainly total inhibition of almost all screened microorganisms except 
Pseudomonas antimicrobia. All isothiocyanates (64, 65, 87, 88, 89) were active 
against both gram-positive bacteria whereas 64 and 65 additionally showed 
activity against yeast and the mold fungus. 
 
 
 
4.6.2 MTT assay 
 
4.6.2.1 The colorimetric assay principle 
 
The MTT assay was used for measuring cytotoxicity of all synthesized 
compounds. Therefore the standard protocol according to Mosmann163 was 
followed, which described the conversion of a water-soluble yellow tetrazolium salt 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) 99 into the 
deep blue formazan product 100 which is insoluble in water (Scheme 36). 
 
 
Scheme 36. Reaction of the yellow tetrazolium salt 101 into the blue formazan product 102. 
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This reaction only occurs in the cytosol of viable cells by mitochondira, 
peroxisomes and special oxidoreductases. As reducing agent either nicotinamide 
adenine dinucleotide (NADH) or nicotinamide adenine dinucleotide phosphate 
(NADPH) is used. The level of produced formazan, detected by photometric 
quantification, consequently gives a direct correlation to the cell viability. For the 
assay human leukemia cell line LH-60 was used and Triton X-100 as positive 
control. 
 
 
 
4.6.2.2 Screening results and discussion 
 
Compound IC50 [µM]  Compound IC50 [µM]  Compound IC50 [µM] 
5 26  51 17  71b 13 
6 40  53 17  71c 15 
9 21  56a 15  71d 21 
10 19  56b 14  71e 17 
11 47  56c 11  71f 15 
15 29  56d 13  71h 32 
22 38  56e 14  72a 12 
23 9  58a 15  72b 14 
29b 40  58b 11  72c 14 
29e 46  58c 28  72d 23 
29f 29  59 21  72e 18 
42 32  61b 4  72f 16 
44b 28  64 34  72h 31 
44c 46  65 14  87 12 
44e 33  66 9  88 10 
44f 31  67 18  89 6 
44h 31  68 32  96 25 
44i 15  69 22  98 29 
44j 16  71a 17    
 
Figure 54. MTT screening results of compounds with a IC50 of 50 µM or lower. 
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The screening results (Figure 54) provide a good insight whether compounds 
show a trend to cytotoxicity, however, the results have to be treated with caution 
as they are not measured in triplicates and are consequently uncorrected. 
Furthermore no statement can be made about the mechanism of action. Below a 
IC50 value of 5 µM a compound is defined as cytotoxic, therefore only compounds 
are listed in Figure 54 with less than the tenfold IC50 value (50 µM). Therefore 
several compounds are not listed in Figure 54 as they showed an IC50 value higher 
than 50 µM and all except 61b are above the critical concentration of 5 µM.  
 
The low IC50 value of 9 µM of iodoacetanilide 23 might be reasoned due to its 
capability to react as strong alkylating reagent. The same reason could cause the 
IC50 value of 6 µM of compound 89 with the strong electrophilic isothiocyanate 
group. In comparison with the other benzotriazepinethiones only compound 66 
with the 8-nitro substituent showed a low IC50 value probably caused by the nitro 
group. The only significantly cytotoxic target compound was the 4-([1-benzyl-
triazol-4-yl]methyl)triazolobenzotriazepine 61b. 
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CHAPTER  V   –  
SUMMARY 
 
Development of new protein-protein interaction inhibitors targeting bromodomains 
of the BET family was the superior goal of this thesis. The importance of these 
epigenetic readers modules, which are selective for -N-acetylated lysine residues, 
is their predominately association to nuclear proteins. For example, deletion of 
BRD2 or BRD4 led to lethality of mice164,165 and deletion of the first domain of the 
testis-specific BRDT induced male sterility in mice166. Moreover the expression 
level is of prime importance as studies with BRD4 showed that upregulated as well 
as downregulated expression caused cell cycle arrest167,168. 
 
During the work demands increased and the aim was specified to obtain a site 
selective compound for second domains of bromodomain and extra-terminal 
domain proteins. To reach this goal, the work in hand combines purposeful organic 
synthetic chemistry – done at the Ludwig-Maximilians University in Munich – with 
powerful techniques for screening, structure refinement and analysis carried out at 
the Structural Genomics Consortium (SGC) of the University of Oxford.  
 
Synthesis efforts yielded 56 target compounds with triazolobenzodiazepine or  
-triazepine core structure and a number of precursor compounds. More than 70 
compounds were screened by differential scanning fluorimetry (DSF) against – at 
least – twelve domains to find potential inhibitors for bromodomains of the BET 
family. Kd values of promising compounds were determined by isothermal titration 
calorimetry (ITC) and even co-crystallization structures of interesting compounds 
with bromodomains were prepared. 
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With the clinical benzodiazepine alprazolam (Figure 55A) was identified as a 
potent inhibitor of bromodomains of the BET family, structure 29c (Figure 55B), 
resulting from molecular modeling studies at the SGC provided the basis for first 
series of compounds. 
 
 
Figure 55. (A) Chemical structure of alprazolam. (B) First TBzD target structure. 
 
Starting with commercially available 3-chloropropiophenone 18 known105 
benzodiazepinone 1 was prepared in a five step synthesis. The conversion into 
thiolactam 2 was carried out using Lawesson's reagent 24, followed by a 
condensation of different carboxylic acid hydrazides 27a-f. According to this 
procedure six different substituted triazolobenzodiazepine (TBzD) target 
compounds 29a-f were synthesized and screened subsequently via DSF. 
 
 
 
 
Scheme 37. Outline for synthesis of TBzD target compounds. Lawesson's reagent 24 was used for 
conversion (i) of compound 1 into thiolactam 2. 
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With the expectation to obtain a convincing SAR already after the first screening 
we sent additional ten compounds provided by researchers from the University of 
Greifswald to the SGC. Those compounds shared a closely related 
benzotriazepine scaffold with a variety of substitutions on the core structure. 
 
Despite screening at a high compound concentration of 100 µM, synthesized 
benzodiazepines gave no response in DSF. Almost the same result was obtained 
within the benzotriazepines with two exceptions 36 and 37. Especially the 1-methyl 
substituted triazolobenzotriazepine (TBzT) 36 (Figure 56A), showed remarkable 
Tm values against the BET family. Two core statements were made after the 
analysis of these screening results. On the one hand the annulated triazole ring 
was essential for activity but no other groups than methyl in position 1 were 
tolerated. On the other hand as compound 29a comprised this structural element 
of the annulated 1-methyltriazole ring but showed no activity obviously also an 
aromatic substituent in position 6, instead of the used 6-ethyl moiety, is essential 
for activity. 
 
 
Figure 56. (A) Chemical structures of JQ1 and new screening hit 36. (B) Lead structure for new 
triazolobenzotriazepines. 
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Consequently the triazolobenzotriazepine scaffold was chosen as new lead 
structure. Furthermore, the knowledge of functional groups like carbamates or 
amides in residues in position 4 of molecules like JQ1 (Figure 56B) and different 
iBETs was one reason to plan to attach also moieties with similar groups in 
position 4 of TBzT screening hit. This led to a modified lead structure with a 
benzotriazepine core scaffold, bearing a phenyl residue instead of the ethyl group 
in position 6, an annulated 1-methyltriazole ring and a variety of polar moieties in 
position 4 (Figure 56B). 
 
 
 
 
 
Scheme 38. Preparation of the first TBzT series starting from a commercially available 2-amino-
benzophenone derivative 40. 
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To improve the first generation of triazolobenzotriazepines from the University of 
Greifswald by the introduction of polar residues in position 4, central intermediate 
5 was synthesized according to Richter et al.108 and Nakamura et al.110 (Scheme 
38). Conversion of commercially available 2-aminobenzophenone 40 with 
thiophosgene gave isothiocyanate 6, which upon reaction with 2-hydroxyethyl-
hydrazine 41 and subsequently para-toluenesulfonic acid gave the triazepine 3. 
Treating compound 3 first with hydrazine hydrate, followed by the addition of 
triethyl orthoacetate 43 led to the desired TBzT bearing a 2-hydroxyethyl residue 
at C-4.  
 
This primary alcohol could easily be functionalized by various methods using 
different starting materials to produce target compounds 44a-j containing esters, a 
carbonate and (thio)carbamates in the side chain (Scheme 38). 
 
With a working synthesis in hands, it was also tried to introduce a completely 
different group in position 4. Therefore only the used hydrazine derivative was 
changed from 2-hydroxyethylhydrazine 41 to benzylhydrazine 7. 
 
 
 
 
Scheme 39. Preparation of 4-benzyltriazolobenzotriazepine 10. 
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In the same manner as used for preparation of compound 5 the 4-benzyl 
substituted compound 10 was generated starting from isothiocyanate derivative 6. 
The addition of the benzylhydrazine 7 to the isothiocyanate group of compound 6 
and the subsequent cyclization obtained compound 9. The triazole ring of 
compound 10 was prepared using hydrazine hydrate followed by triethyl 
orthoacetate 43 (Scheme 39). 
 
The screening using DSF of the obtained twelve target compounds showed 
unexpected results. Low Tm values were detected for compound 5 and its 
derivatives 44a-j. Presumably the ethylene spacer between the tricyclic ring 
system of the core structure and the hydrogen bond donors and / or acceptors of 
the residue is too long and consequently responsible for poor interaction with the 
protein. However, the rather unpolar benzyl compound 10 gained remarkable Tm 
values for second domains of BRD2 and BRD4 as well as significant values for 
BRD3(2) and BRDT2. For that reason no longer efforts were made to improve the 
polar side chain in position 4 but to concentrate on SAR of various substituted  
4-benzyl residues (Figure 57). 
 
 
Figure 57. Lead structure with 4-benzyl residues. 
 
To prepare a series of 4-benzylated TBzTs the reaction sequence used before 
was ineligible. For most of the desired substitution patterns the corresponding 
benzylhydrazines had to be prepared first as they were not commercially available 
and moreover, for each target compound the whole reaction sequence would have 
been to be passed through in a non-convergent manner. 
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The solution of this problem was using the 4H-triazolobenzotriazepine 11, 
published110 by Nakamura et al. in 1996, as a central building block which could 
easily be alkylated at N-4. The 4-(4-methoxybenzyl)triazolobenzotriazepine 51 was 
prepared the same way as described above in a four step synthesis starting from 
isothiocyanate 6. Compound 51 was deprotected by treatment with hydrogen 
bromide in acetic acid to yield intermediate 11. The attempted N-alkylation of 11 
by Mitsunobu reaction using benzyl alcohols failed while the preparation of nine 
benzylated compounds (53, 56a-e, 58a-c) could be accomplished by simple  
N-alkylation using the corresponding benzyl bromides or chlorides after  
N-deprotonation (Scheme 40). 
 
 
 
 
Scheme 40. Reaction scheme for preparation of 4-benzylated TBzTs. 
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Additional three compounds (59, 61a-b) with triazolylmethyl side chains as hetero-
analogues of the N-benzyl series were prepared by N-alkylation of 11 with 
propargyl bromide 12 followed by Huisgen [3+2]-cycloaddition reaction with 
appropriate alkyl azides (Scheme 41). 
 
 
Scheme 41. Synthesis of 1,2,3-triazolylmethyl-TBzTs. 
 
With regard to later discussions all hitherto synthesized compounds containing the  
8-chloro-6-phenyl substitution pattern were clustered into the "chloro" series. The 
screening via DSF showed that considerable progress was made according to the 
previous two screenings with triazolobenzodiazepines and -triazepines.  
 
The comparison of ten different substituted benzyl compounds elucidated first 
meaningful structure-activity relationships and highly active compounds with Tm 
shifts up to 9 °C were obtained. Interestingly, both compounds (51, 58c) including 
methoxybenzyl substituents obtained the highest Tm values but still showed no 
cross activity towards any other bromodomain than the ones of the BET family.  
 
Lower Tm shifts but also interesting information were provided by compounds like 
56d. The 3-chloro substituted benzyl residue, for example, showed weak tendency 
for site selectivity for second domains. Furthermore ortho (56e, 58a) and very 
bulky (53) substituents at the benzyl residue led to a strong decrease of activity.  
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The small series of 1,2,3-triazole containing compounds consequently were less 
expressiveness. Their throughout significant Tm values, however, might still be of 
high interest for further optimizations. In medicinal chemistry, the exchange of a 
phenyl ring by a 1,2,3-triazole is a very common tool to introduce diversity into a 
molecule ("bioisosterism") and the simple chemistry allows a fast and easy way to 
generate them, but in our experience 1,2,3-triazoles are less active than their 
phenyl analogues in most cases. Thus, the introduction of the triazoles was a 
success. These compounds were quite active but their optimization was no longer 
pursued as the benzylated compounds already offered interesting SAR which 
were more promising to be followed. 
 
With the decision to go on with benzyl residues in position 4, two additional 
scaffolds were used to obtain a broader SAR. The known110 compounds, a 8-nitro 
as well as a 8-chloro-6-(2-chlorophenyl) substituted 4H-triazolobenzotriazepine 14 
and 15, were synthesized following the same reaction sequence as used for the  
8-chloro substituted compound 11.  
 
Compounds 14 and 15 were alkylated in the same manner as compound 11 with 
various benzyl bromides or benzyl chlorides to obtain eight target compounds in 
each series which were named "nitro" (71a-h) and "dichloro" (72a-h) series 
according to the "chloro" series introduced above (Scheme 42). 
 
 
Scheme 42. Generation of the "nitro" and the "dichloro" series. 
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DSF results confirmed most of the already obtained trends with regard to the 
benzyl residues. In both new series the bulky tert-butyl substituent knocked out 
activity of the corresponding compounds (71a, 72a) against proteins of the BET 
family. Also the compounds bearing ortho substituted benzyl residues (71e, 72e) 
were inactive. Comparison of the series by their scaffold variations led to clear 
messages: the "nitro" series only improved activity in general, the "dichloro" series 
raised site selectivity for second domains. 
 
The 8-nitro substitution improved most of the compounds and led to higher Tm 
values in contrast to the "chloro" series. However the increase in affinity was 
linked to all of the BETs equally and consequently no trend towards site selectivity 
was obtained. 
 
The "dichloro" series showed lower Tm shifts throughout the chart of results. This 
was expected as the same observation was already made in the first screening of 
clinical benzodiazepines. The only difference of alprazolam and triazolam is this 
chloro substituent in ortho position of the 6-phenyl ring, and triazolam was virtually 
inactive in the screening. The great advantage of the "dichloro" series, however, 
was the evident trend to site selectivity for second domains of the BET family.  
 
Another decisive step was made by the introduction of the new 3-methoxybenzyl 
substituent of compound 72h which was added as a combination of the best 
residues of the "chloro" series. Methoxy substituted benzyl moieties showed 
highest activity and 3-chlorobenzyl showed best trend to site selectivity providing 
in combination with the dichloro scaffold compound 72h which only showed 
significant Tm values for second domains. 
 
The new lead structure (Figure 58) for final triazolobenzotriazepines combined the 
well known structural element of the tricyclic core scaffold with the best 
substitution pattern consisting of a 1-methyl, a 4-(3-methoxybenzyl) and a 6-(2-
chlorophenyl) moiety. The nitro series already showed that variations in position 8 
can lead to improved activities in DSF screening, therefore different substitutions 
on the annulated benzo ring should be tested. 
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Figure 58. Lead structure for next generation of triazolobenzotriazepines. 
 
Three different 2-aminobenzophenones (Figure 59) were synthesized as starting 
materials. Known161 compound 76 was obtained by using a photochemical 
approach according to Ferrini et al.160 whereas both literature known162 
compounds 81 and 83 were generated by an ortho selective acylation method 
using dichlorophenylborane 79. 
 
 
Figure 59. Three 2-aminobenzophenones used as starting materials for new target structures. 
 
The 2-aminobenzophenones (76, 81, 83) were converted according to previously 
described procedures108,110 in a five step synthesis to yield desired target 
compounds 96, 97 and 98 (Scheme 43). This time the preferred 3-methoxybenzyl 
substituent was directly inserted by utilization of the corresponding hydrazine 
derivative. This allowed a shorter reaction sequence to the target compounds as 
the cleavage of the para-methoxybenzyl protecting group and the following  
N-alkylation with the matching benzyl bromide was avoided. 
 
Although the methylenedioxy substituted target triazolobenzotriazepine 98 only 
gave weak Tm values in DSF and showed no trend to site selectivity, remarkable 
selectivity towards second domains was gained by compounds 96 and 97, 
respectively, according to the results of differential scanning fluorimetry. 
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Scheme 43. Preparation of final target compounds. 
 
Kd values of compound 96 determined by isothermal titration calorimetry confirmed 
the results obtained by DSF. More than a fivefold difference in Kd was measured 
for first (481 nM) and second (92 nM) domain of BRD4. An even stronger 
divergence of more than a tenfold value was reached within protein BRDT. First 
domain showed a Kd of 1.54 µM whereas the second domain showed 145 nM. The 
second methoxy group in position 9 of compound 97 obviously reduces activity 
only for first domains and keeps it as high for second domains as yielded of 
compound 96. Consequently the 8,9-dimethoxy derivative 97 must lead to even 
more diverging Kd values and thus represents the most site selective compound 
produced in this thesis, however no ITC data were available until the completion of 
this work. 
 
This dissertation chronologically describes the development of a new inhibitor 
starting from the discovery of a clinical benzodiazepine (alprazolam) as screening 
hit followed by several cycles of lead structure improvement to finally yield a site 
selective compound. While alprazolam only showed weak Tm shifts against both 
domains of BRD3 and BRD4 the optimized compound 97 showed distinctly 
improved Tm values for second domains of BET proteins and consequently 
remarkable selectivity (Figure 60). 
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BRD2(1) 1.9 1.7 
 
  
BRD2(2) 3.3 5.9 
 
Tm(°C) 
BRD3(1) 4.1 3.7 
 
 <0 
BRD3(2) 4.6 6.0 
 
 0-2 
BRD4(1) 4.8 1.8 
 
 2-4 
BRD4(2) 4.1 4.7 
 
 4-6 
BRDT1 0.8 1.4 
 
 6-8 
BRDT2 
 
6.3 
 
 >8 
 
Figure 60. DSF result comparison of screening hit alprazolam and final compounds 97. 
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CHAPTER  VI   – 
EXPERIMENTAL SECTION 
 
6.1 GENERAL INFORMATION AND INSTRUMENTS 
 
NMR, MS and IR measurements were carried out by the analytical division of the 
Department of Pharmacy at the LMU Munich under the direction of Dr. Lars 
Allmendinger. Elemental analysis was done by the analytical division of the 
Department of Chemistry at the LMU Munich. 
 
 
 
6.1.1 Nuclear magnetic resonance spectroscopy 
 
The measurements (1H, 13C, DEPT, COSY, HMQC, HMBC) were performed on 
either a “JNM-Eclipse+400” (1H: 399.8 MHz, 13C: 100.5 MHz) or a “JNM-
Eclipse+500” (1H: 500.2 MHz, 13C: 125.8 MHz), (Jeol, USA). The chemical shifts 
are in -values (ppm) relative to the internal standard TMS. The spectra were 
analyzed by first order and coupling constants J are given in Hertz [Hz]. 
Abbreviations for the characterization of the signals: s = singlet, d = doublet, 
t = triplet, q = quartet, m = multiplet, bs = broad singlet, dd = doublet of doublets, 
td = triplet of doublets, ddd = doublet of doublets of doublets. Integration is 
determined as the relative number of protons. Error of reported values: chemical 
shift 0.01 ppm for 1H NMR, 0.1 ppm for 13C NMR; coupling constant: 0.1 Hz. The 
used solvent for each spectrum is reported. 
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6.1.2 Mass spectrometry 
 
Low resolution mass spectrometry was carried out for EI and CI on a “Hewlett 
Packard 5989A” (Hewlett Packard, USA) and for ESI and APCI on an “AB Sciex 
API 2000” (AB Sciex, USA). High resolution mass spectrometry was measured for 
EI on a “Jeol JMS GCmate II” (Jeol, USA) and for ESI on a “Thermo Finnigan LTQ 
FT” (Thermo Fisher Scientific, USA). 
 
 
6.1.3 Infrared spectroscopy 
 
Liquid or oily substances were measured neat between NaCl plates, for solids KBr 
pallets were prepared. A “Perkin Elmer FT-IR Spectrometer Paragon 1000” 
(PerkinElmer, USA) was used. Abbreviations of the corresponding intensity of the 
signals: s = strong, m = medium, w = weak. 
 
 
6.1.4 Melting points 
 
Measurements were done on a "Büchi B-540" apparatus (Büchi, Switzerland). All 
values are given in °C and are uncorrected. 
 
 
6.1.5 High pressure liquid chromatography 
 
The analytical HPLC purity was performed on either a “Merck Hitachi LaChrom 
Elite” (Hitachi-Merck, Germany) or a “HP Agilent system 1100 series” (Agilent 
Technologies, Germany) with an “Agilent Poroshell 120 EC-C18 3.0 x 100 mm 
2.7-Micron” column. For detection a DAD detector was used. The chromatographic 
separations were monitored at 210 nm or 254 nm using a bandwidth of 4 nm. 
Column temperature: 40 – 45 °C; Injection volume: 5 µL of a dilution of 100 µg / 
mL; Flowrate: 0.5 mL / min; Eluent: MeCN / H2O / THF (400 : 99 : 1). 
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6.1.6 Elemental analysis 
 
Elemental analysis was measured on either a CHN-Rapin (Heraeus, Germany) or 
a Vario EL (Elementar, Germany). 
 
 
6.1.7 Flash column and thin layer chromatography 
 
Flash column chromatography was performed on flash silica gel (60 M, 0.040 – 
0.063 mm) purchased from Merck (Merck, Germany). For each compound the 
eluent is reported in the corresponding experimental part. 
 
Analytical thin layer chromatography (TLC) was performed on unmodified standard 
silica layers “Polygram polyester sheets” (designation: SIL G/UV254; thickness of 
layer: 0.20 mm; plate size: 4 x 8 cm; fluorescent indicator: UV254) purchased from 
Macherey-Nagel (Germany). Visualization was done by UV-light using wavelength 
= 254 or 365 nm. 
 
 
6.1.8 Microwave assisted synthesis 
 
Reactions were done using a single mode cavity microwave reactor “Discover SP 
System” (CEM, USA). 
 
 
6.1.9 Chemicals and solvents 
 
All chemicals were purchased from the Sigma-Aldrich Corporation (Germany), 
Fisher Scientific (Germany) or Th. Geyer GmbH & Co. KG (Germany). All 
chemicals were of analytical grade and no further purification was needed. 
Commercially available solvents were used if not stated otherwise. THF was dried 
under reflux over sodium sticks with benzophenone as indicator. 
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6.2 PROTEIN STABILITY SHIFT ASSAY 
 
Experiments were carried out at the University of Oxford. 
 
Thermal melting experiments were carried out using an Mx3005p Real Time PCR 
machine (Stratagene). Proteins were buffered in 10 mM HEPES pH 7.5, 500 mM 
NaCl and assayed in a 96-well plate at a final concentration of 2 µM in 20 µL 
volume. Compounds were added at a final concentration of 10 µM or 100 µM in 
order to probe weaker interactions. SYPRO® Orange (Molecular Probes) was 
added as a fluorescence probe at a dilution of 1:1000. Excitation and emission 
filters for the SYPRO® Orange dye were set to 465 nm and 590 nm, respectively. 
The temperature was raised with a step of 3 °C per minute from 25 to 96 °C and 
fluorescence readings were taken at each interval. The temperature dependence 
of the fluorescence during the protein denaturation process was approximated by 
the equation: 
 
          
      
           
 
 
where        is the difference in unfolding free energy between the folded and 
unfolded state, R is the gas constant and yF and yU are the fluorescence intensity 
of the probe in the presence of completely folded and unfolded protein, 
respectively. The baselines of the denatured and native states were approximated 
by a linear fit. The observed temperature shifts,    
   , were recorded as the 
difference between the transition midpoints of sample and reference wells 
containing protein without ligand in the same plate and determined by non-linear 
least squares fit. 
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6.3 ISOTHERMAL TITRATION CALORIMETRY 
 
Experiments were carried out at the University of Oxford. 
 
Experiments were carried out on a VP-ITC titration microcalorimeter from 
MicroCal™, LLC (Northampton, MA). All experiments were carried out at 15 °C 
while stirring at 295 rpm, in ITC buffer (50 mM HEPES pH 7.4 at 25 °C, 150 mM 
NaCl). The microsyringe was loaded with a solution of the protein sample (150 µM 
BRD4(1) in ITC buffer). All titrations were conducted using an initial control 
injection of 2 µL followed by 34 identical injections of 8 µL with a duration of 16 s 
(per injection) and a spacing of 250 s between injections. The heat of dilution was 
determined by independent titrations (protein into buffer) and was subtracted from 
the experimental data. The collected data were evaluated using a single binding 
site model and the MicroCal™ Origin software. Thermodynamic parameters were 
calculated (G = H – TS = – RTlnKB, where G, H and S are the changes in 
free energy, enthalpy and entropy of binding, respectively). 
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6.4 CRYSTAL STRUCTURES 
 
Experiments were carried out at the University of Oxford. 
 
6.4.1 Crystallization 
 
Aliquots of the purified proteins were set up for crystallization using a mosquito™ 
crystallization robot (TTP Labtech, Royston, UK). Coarse screens were typically 
setup onto Greiner 3-well plates using three different drop ratios of precipitant to 
protein per condition (100 + 50 nL, 75 + 75 nL and 50 + 100 nL). Initial hits were 
optimized further scaling up the drop sizes. All crystallizations were carried out 
using the sitting drop vapor diffusion method at 4 °C. BRD4(1) crystals with 
alprazolam were grown by mixing 200 nL of the protein (9.5 mg/mL and 5 mM final 
ligand concentration) with 100 nL of reservoir solution containing 0.20 M sodium 
sulfate, 0.1 M BT-Propane pH 6.5, 20% PEG3350 and 10% ethylene glycol. 
BRD4(1) crystals with midazolam were grown by mixing 200 nL of protein (9.36 
mg/mL and 5 mM final ligand concentration) with 100 nL of reservoir solution 
containing 0.1 M magnesium chloride, 0.1 M MES pH 6.5, 15% PEG6000 and 
10% ethylene glycol. BRD4(1) crystals with 36 were grown by mixing 200 nL of 
protein (9 mg/mL and 5 mM final ligand concentration) with 200 nL of reservoir 
solution containing 0.1 M MES pH 6.5, 10% PEG3350 and 10% ethylene glycol. In 
all cases diffraction quality crystals grew within a few days. 
 
 
 
6.4.2 Data collection and structure solution 
 
All crystals were cryo-protected using the well solution supplemented with 
additional ethylene glycol and were flash frozen in liquid nitrogen. Data were 
collected in-house on a Rigaku FRE rotating anode system equipped with a 
RAXIS-IV detector (alprazolam and midazolam complexes) or at the Diamond 
beamline I04.1 (36 complex). Indexing and integration was carried out using 
MOSFLM169 and scaling was performed with SCALA170 or XDS171. Initial phases 
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were calculated by molecular replacement with PHASER172 using the known 
models of BRD4(1) (PDB ID 2OSS). Initial models were built by ARP/wARP173 
followed by manual building in COOT174. Refinement was carried out in 
REFMAC5175. In all cases thermal motions were analyzed using TLSMD176 and 
hydrogen atoms were included in late refinement cycles. Data collection and 
refinement statistics can be compiled in Table 2 of our paper in Bioorg. Med. 
Chem.83 The models and structure factors have been deposited with PDB 
accession codes: 3U5J (BRD4(1)/alprazolam), 3U5K (BRD4(1)/midazolam), 3U5L 
(BRD4(1)/36), respectively. 
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6.5 AGAR DIFFUSION TEST 
 
Bacteria and fungi were purchased from the DSMZ (Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany) and cultivated 
according to supplied procedures. For sterile working conditions the bioassay was 
carried out using a laminar air flow HERAsafe safety cabinets (Heraeus, 
Germany). 
 
AC agar, purchased from the Sigma-Aldrich Corporation (Germany), was used as 
growing medium for Escherichia coli, Pseudomonas antimicrobial, Staphylococcus 
equorum, Streptococcus entericus, Yarrowia lipolytica, Candida glabrata and 
Hyphopichia burtonii. 35.5 g AC agar and 2 g agar were suspended in 1 L of water 
and autoclaved. As long as the suspension was still warm and fluid, each Petri 
dish was filled in sterile conditions with 15 mL and was allowed to stand for 
30 min. For Aspergillus niger potato dextrose agar (Sigma-Aldrich Corporation, 
Germany) was used as growing medium. Preparation procedure followed the one 
of AC agar using 39 g potato dextrose agar and 1 g agar. 
 
A 1% (m/v) DMSO screening solution was prepared of the compounds. 5 µL of the 
corresponding solution were spread at a filter circle plate (Schleicher & Schuell, 
Germany). 2.5 µL (m/v) of a 1% solution in DMSO of the reference compounds 
clotrimazole and tetracycline, respectively, were also spread at a filter circle. A 
blank value was prepared by spreading 5 µL of pure DMSO on a filter circle. The 
solvent was evaporated over night. 
 
In sterile working conditions, a Petri dish was prepared by adding the respective 
germ on a metal insert, four substance filter plates, the corresponding reference 
filter plate and the blank value plate. Incubation was done in a drying cabinet at a 
temperature of 32.1 °C (bacteria) and 28.0 °C (fungi), respectively. After 36 h 
analysis of the screening results was done by manual measuring of the diameter 
of the zones of inhibition. 
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6.6 MTT ASSAY 
 
The MTT assay was performed using human leukemia cell line HL-60 purchased 
from the DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkurlturen 
GmbH, Braunschweig, Germany). A 10 mM stock solution in DMSO was prepared 
of the compounds to be tested. A serial dilution was prepared by a successively 
1:1 dilution with DMSO ten times. 
 
For the blank value DMSO was used. For the positive control a solution of the 
detergent Triton® X-100 in a final concentration of 1 µg/mL was used. Wells 
containing control cells were neither treated with DMSO nor with a compound 
solution or with Triton® X-100. 
 
Each well of a microtiter plate was filled with 99 µL of a HL-60 suspension and 
1 µL of either the compound solution, the pure DMSO (blank) or the Triton® X-100 
(positive control). The plate was incubated for 24 h at 37 °C and 5% CO2. 
Subsequently, each well was treated with 10 µL of a MMT stock solution of 5 mg 
MTT in 1 mL of phosphate buffered saline (PBS) and incubated again for two 
hours under the same conditions. After the following addition of 190 µL of DMSO 
the solution was allowed to stand for another 60 min while shaking occasionally.  
 
Photometric quantification of the yielded dye was performed on an ELISA MRX II 
Microplate reader (Dynex, Germany) at a wavelength of  = 570 nm. The statistical 
analysis and the calculation of the corresponding IC50 values was done using 
Prism 4 software (GraphPad, USA). 
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6.7 GENERAL PROCEDURES 
 
GP 1   – Preparation of triazolobenzodiazepine derivatives 
 
7-Chloro-5-ethyl-1H-benzo[e][1,4]diazepine-2(3H)-thione 2 (1 equiv) and the 
respective carboxyhydrazide (2 equiv) were dissolved in n-butanol (volume as 
stated in procedure) and heated to 130 °C in a sealed vial under nitrogen 
atmosphere for 1 d. The reaction mixture was cooled to room temperature and 
stirred with 25 mL of an aqueous glucose solution (0.1 g/mL) at room temperature 
for 2 h. The mixture was extracted with dichloromethane (3 x 10 mL). The 
combined organic layers were washed with water (25 mL), dried over sodium 
sulfate, filtered and the solvent was evaporated. Purification was done by flash 
column chromatography on flash silica gel (dichloromethane / methanol 9:1), 
yielding triazolobenzodiazepines in 17 – 67% yield. 
 
 
 
GP 2   – Preparation of the isothiocyanate group using thiophosgene 
 
Calcium carbonate (1.5 equiv) was suspended in cooled (0 °C) water 
(50 mL/mmol) and thiophosgene 16 (1.1 equiv) was added to the reaction mixture. 
2-Aminobenzophenone derivative (1.0 equiv) was dissolved in dichloromethane 
(2.5 mL/mmol) and added over a period of 30 min to the vigorously stirred 
suspension. After complete addition, the reaction mixture was stirred for another 
hour with the ice bath in place, followed by additional 4 h at room temperature. 
The precipitate was filtered off prior to separation of the organic and the aqueous 
layer. The organic layer was washed three times with water (1 mL/mmol), dried 
over sodium sulfate, filtered and evaporated. Where required, purification was 
done by flash column chromatography on flash silica gel – unless stated otherwise 
– with dichloromethane, giving the isothiocyanate product in 63 – 98% yield. 
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GP 3   – Two step annulation of the 1-methyl-1,2,4-triazole ring 
 
The respective benzotriazepine-2-thione derivative (1.0 equiv) was dissolved in 
tetrahydrofuran (8 mL/mmol) and treated with hydrazine hydrate (5.0 equiv). After 
stirring at room temperature for 18 h the solvent was evaporated. The residue was 
dissolved in ethyl acetate (8 mL/mmol), washed three times with water 
(4 mL/mmol), dried over sodium sulfate, filtered and concentrated under reduced 
pressure. The residue was dissolved in toluene (5 mL/mmol) and after adding 
triethyl orthoacetate 43 (1.3 equiv) and para-toluenesulfonic acid monohydrate 
(0.2 equiv), the mixture was heated to reflux for 3 h. The solvent was evaporated 
and purification was done by flash column chromatography on flash silica gel 
(dichloromethane / methanol 19:1), yielding the corresponding triazolobenzo-
triazepine compounds in 38 – 78% yield. 
 
 
 
GP 4   – 4-N-alkylation of triazolobenzotriazepines with benzyl bromide 
derivatives 
 
4H-Triazolobenzotriazepine derivative (1.0 equiv) was dissolved in anhydrous 
tetrahydrofuran (9 mL/mmol) and sodium hydride (1.1 equiv) was added 
portionwise as a 60 % dispersion in mineral oil to the vigorously stirred solution. 
Subsequently, the corresponding benzyl bromide (3.0 equiv) was added, and after 
stirring for 1 h at room temperature, the solvent was evaporated and purification 
was done by flash column chromatography on flash silica gel – unless stated 
otherwise – with dichloromethane / methanol (9:1), yielding the 4-N-benzyl 
functionalized triazolobenzotriazepine compounds in 42 – 97% yield. 
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GP 5   – 4-N-alkylation of triazolobenzotriazepines with benzyl chloride 
derivatives 
 
4H-Triazolobenzotriazepine derivative (1.0 equiv) was dissolved in anhydrous 
tetrahydrofuran (9 mL/mmol) and sodium hydride (1.1 equiv) was added 
portionwise as a 60 % dispersion in mineral oil to the vigorously stirred solution. 
Subsequently, the corresponding benzyl chloride (3.0 equiv) was added, and after 
stirring for 4 h at reflux, the solvent was evaporated and purification was done by 
flash column chromatography on flash silica gel – unless stated otherwise – with 
dichloromethane / methanol (9:1), yielding the 4-N-benzyl functionalized 
triazolobenzotriazepine compounds in 48 – 74% yield. 
 
 
 
GP 6   – Microwave assisted synthesis of 1,2,3-triazoles via copper(I)-
catalyzed 1,3-dipolar cycloadition 
 
A 10 mL microwave vial was charged with 8-chloro-1-methyl-6-phenyl-4-(prop-2-
yn-1-yl)-4H-benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine 13 (1.1 equiv), sodium 
azide (1.1 equiv) and the respective halogen compound (1.0 equiv). The starting 
materials were suspended in a 1:1 mixture of tert-butanol / water (10 mL/mmol) 
prior to the addition of sodium L-ascorbate (0.2 equiv) and copper(II) sulfate 
pentahydrate (0.05 equiv). The tightly sealed vial was stirred for 10 min under 
microwave irradiation (max. power: 100 W; ramp time: 1 min; max. temperature: 
125 °C; max. pressure: 8 bar). After cooling to 60 °C, the reaction mixture was 
concentrated under reduced pressure and extracted with dichloromethane (2 x 10 
mL). The combined organic layers were dried over sodium sulfate, filtered and 
evaporated. Purification was done by flash column chromatography on flash silica 
gel – unless stated otherwise – with ethyl acetate / methanol (9:1), yielding the 
1,4-disubstituted 1,2,3-triazoles in 37 – 73% yield. 
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6.8 DESCRIPTION OF COMPOUNDS 
 
 
 
7-Chloro-5-ethyl-1H-benzo[e][1,4]diazepine-2(3H)-one (1) 
(Literature known compound but different procedure
104
) 
 
N-(4-Chloro-2-propionylphenyl)-2-iodoacetamide 23 (6.5 g, 18 mmol, 1.0 equiv) 
was dissolved in 130 mL of ethanol and ammonia was passed through the solution 
three times (each time for 5 min). The ammonia saturated solution was stirred at 
room temperature for 3 h. Purification was done by flash column chromatography 
on flash silica gel (ethyl acetate, Rf = 0.50). Compound 1 (3.6 g, 16 mmol, 87 %) 
was yielded as pale yellow solid. 
 
1H NMR (500 MHz, CD2Cl2):  (ppm) = 1.11 (t, 
3JHH = 7.4 Hz, 3 H, 2’-H), 2.75 (q, 
3JHH = 7.4 Hz, 2 H, 1’-H), 4.08 (s, 2 H, 3-H), 7.06 (d, 
3JHH = 8.6 Hz, 1 H, 9-H), 7.42 
(dd, 4JHH = 2.4 Hz, 
3JHH = 8.6 Hz, 1 H, 8-H), 7.56 (d, 
4JHH = 2.4 Hz, 1 H, 6-H), 9.09 
(bs, 1 H, 1-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 11.5 (C-2’), 32.2 (C-1’), 56.2 (C-3), 123.0 
(C-9), 128.3 (C-6), 129.6 (C-7), 130.1 (C-5a), 131.5 (C-8), 136.4 (C-9a), 172.1 (C-
2), 172.8 (C-5) 
 
MS (CI): m/z (%) = 225 (30), 223 (100) [M + H]+ 
 
MF: C11H11ClN2O 
 
MW: 222.67 g/mol 
138 
 
CHAPTER VI   –   Experimental section 
 
 
 
 
 
7-Chloro-5-ethyl-1H-benzo[e][1,4]diazepine-2(3H)-thione (2) 
 
7-Chloro-5-ethyl-1H-benzo[e][1,4]diazepine-2(3H)-one 1 (2.0 g, 9.1 mmol, 
1.0 equiv) and Lawesson’s reagent 24 (4.0 g, 10 mmol, 1.1 equiv) were 
suspended in 19 mL of anhydrous tetrahydrofuran and stirred over night at room 
temperature under nitrogen atmosphere. Water (250 mL) was added and the 
mixture was extracted three times with dichloromethane (each 40 mL). The 
combined organic layers were washed with water, dried over sodium sulfate, 
filtered and evaporated. Purification was done by flash column chromatography on 
flash silica gel (ethyl acetate / isohexane 1:2, Rf = 0.46), yielding product 2 (1.1 g, 
4.8 mmol, 53 %) as yellow solid. 
 
mp: 168.7 °C 
 
1H NMR (400 MHz, CD2Cl2):  (ppm) = 1.13 (t, 
3JHH = 7.4 Hz, 3 H, 2’-H), 2.75 (q, 
3JHH = 7.3 Hz, 2 H, 1’-H), 4.49 (s, 2 H, 3-H), 7.12 (d, 
3JHH = 8.6 Hz, 1 H, 9-H), 7.45 
(dd, 4JHH = 2.3 Hz, 
3JHH = 8.6 Hz, 1 H, 8-H), 7.58 (d, 
4JHH = 2.3 Hz, 1 H, 6-H), 
10.19 (bs, 1 H, 1-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 11.4 (C-2’), 31.8 (C-1’), 62.9 (C-3), 122.9 
(C-9), 128.7 (C-6), 131.1 (C-7), 131.5 (C-5a), 131.6 (C-8), 136.9 (C-9a), 172.4 (C-
5), 201.6 (C-2) 
 
IR [cm-1]:    = 3113 (w), 3070 (w), 2973 (m), 2899 (m), 2853 (m), 2731 (m), 
2675 (w), 1635 (s), 1576 (m), 1520 (m), 1474 (s), 1358 (s), 1163 (s), 1009 (m), 
838 (m) 
 
MS (CI): m/z (%) = 241 (35), 239 (100) [M + H]+ 
139 
 
CHAPTER VI   –   Experimental section 
 
 
 
 
MS (EI): m/z (%) = 240 (35), 238 (100) [M]+∙, 203 (50) 
 
HR-MS (EI): calcd. for C11H11ClN2S [M]
+∙ 238.0331; found 238.0296 
 
Elemental analysis calcd. (%) for C11H11ClN2S (238.7): C 55.34, H 4.64, N 11.73; 
found C 55.21, H 4.62, N 11.36 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C11H11ClN2S 
 
MW: 238.74 g/mol 
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7-Chloro-3-(2-hydroxyethyl)-5-phenyl-1H-benzo[e][1,2,4]triazepine-2(3H)-
thione (3) 
(Literature known compound but different procedure
109
) 
 
A catalytic amount of para-toluenesulfonic acid monohydrate (3.0 mg, 14 µmol, 
2.5 mol%) and N-(2-benzoyl-4-chlorophenyl)-1-(2-hydroxyethyl)hydrazinecarbo-
thioamide 42 (200 mg, 0.572 mmol, 1.00 equiv) were dissolved in ethanol (20 mL) 
and heated to reflux for 1 h. The solvent was evaporated and purification was 
done by flash column chromatography on flash silica gel (dichloromethane / ethyl 
acetate 9:1, Rf = 0.50), yielding product 3 (175 mg, 0.527 mmol, 92 %) as yellow 
solid. 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 2.91 (s, 1 H, OH), 4.08 – 4.15 (m, 2 H, 2’’-
H), 4.28 – 4.35 (m, 2 H, 1’’-H), 6.92 (d, 3JHH = 8.5 Hz, 1 H, 9-H), 7.04 (d, 
4JHH = 
2.4 Hz, 1 H, 6-H), 7.40 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.6 Hz, 1 H, 8-H), 7.42 – 7.55 (m, 
5 H, 2’-H, 3’-H, 4’-H, 5’-H, 6’-H), 7.78 (s, 1 H, 1-H) 
 
13C NMR (100 MHz, CDCl3):  (ppm) = 58.3 (C-2’’), 61.3 (C-1’’), 122.0 (C-9), 127.3 
(C-5a), 129.0 (C-3’, C-5’), 129.5 (C-2’, C-6’), 130.0 (C-7), 130.6 (C-6), 131.5 (C-
4’), 133.2 (C-8), 135.6 (C-1’), 143.0 (C-9a), 167.0 (C-5), 192.6 (C-2) 
 
MS (CI): m/z (%) = 334 (35), 332 (100) [M + H]+ 
 
MF: C16H14ClN3OS 
 
MW: 331.82 g/mol 
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8-Chloro-4-(2-hydroxyethyl)-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo-
[3,4-c][1,2,4]triazepine (5) 
 
Synthesis of the triazole-ring followed GP3. 7-Chloro-3-(2-hydroxyethyl)-5-phenyl-
1H-benzo[e][1,2,4]triazepine-2(3H)-thione 3 (1.7 g, 5.3 mmol, 1.0 equiv) was 
treated first with hydrazine hydrate (1.3 mL, 26 mmol, 5.0 equiv). Triethyl 
orthoacetate 43 (1.3 mL, 6.9 mmol, 1.3 equiv) and para-toluenesulfonic acid 
monohydrate (200 mg, 1.06 mmol, 0.20 equiv) were used in the second step. 
Product 5 (710 mg, 3.16 mmol, 38 %) was obtained after purification (Rf = 0.27) as 
colorless solid. 
 
mp: 226.3 °C 
 
1H NMR (500 MHz, CD2Cl2):  (ppm) = 2.55 (s, 3 H, 1-CH3), 3.49 (bs, 1 H, OH), 
3.83 – 4.07 (m, 4 H, 1’’-H, 2’’-H), 7.26 (d, 4JHH = 2.4 Hz, 1 H, 7-H), 7.32 (d, 
3JHH = 
8.7 Hz, 1 H, 10-H), 7.39 – 7.44 (m, 2 H, 3’-H, 5’-H), 7.46 – 7.50 (m, 1 H, 4’-H), 
7.52 – 7.55 (m, 2 H, 2’-H, 6’-H), 7.61 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 57.2 (C-2’’), 60.3 (C-1’’), 
124.4 (C-10), 128.9 (C-3’, C-5’), 129.5 (C-2’, C-6’), 130.7 (C-6a), 130.9 (C-4’), 
131.7 (C-7), 132.2 (C-9), 133.1 (C-8), 133.8 (C-10a), 136.4 (C-1’), 148.7 (C-1), 
160.4 (C-3a), 161.5 (C-6) 
 
IR [cm-1]:    = 3058 (w), 2924 (w), 1630 (w), 1520 (s), 1489 (m), 1431 (m), 
1319 (m), 1074 (m), 825 (m), 696 (m), 536 (m) 
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MS (CI): m/z (%) = 356 (30), 354 (100) [M + H]+ 
 
MS (EI): m/z (%) = 353 (5) [M]+∙, 295 (100) 
 
HR-MS (EI): calcd. for C18H16ClN5O [M]
+∙ 353.1043; found 353.1046 
 
Elemental analysis calcd. (%) for C18H16ClN5O (353.8): C 61.10, H 4.56, N 19.79; 
found C 60.98, H 4.49, N 19.74 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C18H16ClN5O 
 
MW: 353.81 g/mol 
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(5-Chloro-2-isothiocyanatophenyl)(phenyl)methanone (6) 
(Literature known compound but different procedure
108
) 
 
Compound 6 was prepared according to GP2 using 2-amino-5-chloro-
benzophenone 40 (5.0 g, 22 mmol, 1.0 equiv) as starting material, calcium 
carbonate (3.3 g, 33 mmol, 1.5 equiv) and thiophosgene 16 (1.8 mL, 24 mmol, 
1.1 equiv). No purification was needed after workup procedure, yielding product 6 
(5.8 g, 21 mmol, 98 %) as cream-colored solid. 
 
1H NMR (500 MHz, CDCl3):  (ppm) = 7.29 (d, 
3JHH = 8.4 Hz, 1 H, 3-H), 7.46 (d, 
4JHH = 2.4 Hz, 1 H, 6-H), 7.48 (dd, 
4JHH = 2.4 Hz, 
3JHH = 8.4 Hz, 1 H, 4-H), 7.50 – 
7.54 (m, 2 H, 3’-H, 5’-H), 7.62 – 7.67 (m, 1 H, 4’-H), 7.78 – 7.83 (m, 2 H, 2’-H, 6’-
H) 
 
13C NMR (100 MHz, CDCl3):  (ppm) = 128.5 (C-2), 128.7 (C-3), 129.1 (C-3’, C-5’), 
130.1 (C-6), 130.3 (C-2’, C-6’), 132.1 (C-4), 132.9 (C-5), 134.3 (C-4’), 136.2 (C-1’), 
136.5 (C-1), 138.3 (NCS), 193.2 (CO) 
 
MS (CI): m/z (%) = 276 (40), 274 (100) [M + H]+ 
 
MF: C14H8ClNOS 
 
MW: 273.74 g/mol 
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3-Benzyl-7-chloro-5-phenyl-1H-benzo[e][1,2,4]triazepine-2(3H)-thione (9) 
 
To a well stirred and cooled (0 °C) solution of benzylhydrazine dihydrochloride 7 
(374 mg, 1.92 mmol, 1.05 equiv) in 3 mL of methanol, N,N-diisopropylethylamine 
(668 µL, 3.84 mmol, 2.10 equiv) was added dropwise. After stirring for 30 min at 
room temperature, a solution of (5-chloro-2-isothiocyanatophenyl)(phenyl)-
methanone 6 (500 mg, 1.83 mmol, 1.00 equiv) in 10 mL of tetrahydrofuran was 
added and stirring was continued for 16 h. The mixture was concentrated under 
reduced pressure, dissolved in ethanol (15 mL), treated with a catalytic amount of 
para-toluenesulfonic acid monohydrate (9.0 mg, 46 µmol, 2.5 mol%) and heated to 
reflux for 1 h. The solvent was evaporated and purification was done by flash 
column chromatography on flash silica gel (dichloromethane, Rf = 0.55), giving 
compound 9 (593 mg, 1.57 mmol, 86 %) as pale yellow solid. 
 
mp: 195.5 °C 
 
1H NMR (500 MHz, DMSO-d6):  (ppm) = 5.18 (s, 2 H, 1’’-H), 6.91 (d, 
4JHH = 
2.4 Hz, 1 H, 6-H), 7.18 – 7.22 (m, 2 H, 2’-H, 6’-H), 7.23 – 7.27 (m, 2 H, 9-H, 4’’’-H), 
7.27 – 7.34 (m, 4 H, 2’’’-H, 3’’’-H, 5’’’-H, 6’’’-H), 7.41 (t, 3JHH = 7.7 Hz, 2 H, 3’-H, 5’-
H), 7.48 – 7.53 (m, 1 H, 4’-H), 7.62 (dd, 4JHH = 2.5 Hz, 
3JHH = 8.7 Hz, 1 H, 8-H), 
10.62 (s, 1 H, 1-H) 
 
13C NMR (125 MHz, DMSO-d6):  (ppm) = 58.6 (C-1’’), 123.1 (C-9), 127.2 (C-4’’’), 
127.6 (C-5a), 127.9 (C-7), 128.3 (C-2’’’, C-6’’’), 128.3 (C-3’’’, C-5’’’), 128.7 (C-3’, C-
5’), 129.0 (C-2’, C-6’), 129.1 (C-6), 131.0 (C-4’), 132.7 (C-8), 135.2 (C-1’), 137.0 
(C-1’’’), 143.2 (C-9a), 166.5 (C-5), 193.1 (C-2) 
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IR [cm-1]:    = 3217 (m), 3062 (w), 2994 (w), 1605 (m), 1512 (m), 1482 (s), 
1371 (m), 1324 (m), 1237 (m), 1191 (s), 1169 (s), 1003 (m), 832 (m), 740 (s), 
697 (s) 
 
MS (CI): m/z (%) = 380 (40), 378 (100) [M + H]+, 344 (20), 290 (60), 274 (10), 145 
(20), 108 (45) 
 
MS (EI): m/z (%) = 377 (5) [M]+∙, 344 (100), 273 (40), 241 (30), 91 (55), 77 (40) 
 
HR-MS (EI): calcd. for C21H16ClN3S [M]
+∙ 377.0753; found 377.0750 
 
HPLC purity: 91 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C21H16ClN3S 
 
MW: 377.89 g/mol 
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4-Benzyl-8-chloro-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo[3,4-c][1,2,4]-
triazepine (10) 
 
Synthesis of the triazole-ring followed GP3. 3-Benzyl-7-chloro-5-phenyl-1H-
benzo[e][1,2,4]triazepine-2(3H)-thione 9 (320 mg, 0.847 mmol, 1.00 equiv) was 
treated first with hydrazine hydrate (206 µL, 4.23 mmol, 5.00 equiv). Triethyl 
orthoacetate 43 (201 µL, 1.10 mmol, 1.30 equiv) and para-toluenesulfonic acid 
monohydrate (32 mg, 0.17 mmol, 0.2 equiv) were used in the second step. 
Product 10 (176 mg, 0.440 mmol, 52 %) was obtained after purification (Rf = 0.31) 
as pale yellow solid. 
 
mp: 105.8 – 108.2 °C 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.55 (s, 3 H, 1-CH3), 4.88 (d, 
2JHH = 
13.7 Hz, 1 H, 1’’-HH), 5.11 (d, 2JHH = 13.6 Hz, 1 H, 1’’-HH), 7.22 (d, 
4JHH = 2.4 Hz, 
1 H, 7-H), 7.24 – 7.28 (m, 1 H, 4’’’-H), 7.29 – 7.34 (m, 3 H, 10-H, 3’’’-H, 5’’’-H), 
7.34 – 7.38 (m, 2 H, 3’-H, 5’-H), 7.39 – 7.42 (m, 4 H, 2’-H, 6’-H, 2’’’-H, 6’’’-H), 7.42 
– 7.46 (m, 1 H, 4’-H), 7.60 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 58.1 (C-1’’), 124.3 (C-10), 
128.6 (C-3’’’, C-5’’’), 128.8 (C-3’, C-5’), 129.5 (C-2’, C-6’), 129.6 (C-2’’’, C-6’’’), 
127.7 (C-4’’’), 130.8 (C-6a), 130.8 (C-4’), 131.5 (C-7), 132.1 (C-9), 132.9 (C-8), 
133.9 (C-10a), 136.6 (C-1’), 137.8 (C-1’’’), 148.6 (C-1), 160.3 (C-3a), 161.2 (C-6) 
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IR [cm-1]:    = 3060 (w), 3029 (w), 2922 (w), 2857 (w), 2363 (w), 2344 (w), 
1535 (m), 1518 (s), 1489 (m), 1445 (m), 11430 (m), 1319 (m), 1271 (w), 1171 (w), 
1029 (w), 826 (w), 736 (m), 695 (m) 
 
MS (CI): m/z (%) = 402 (100), 400 (85) [M + H]+, 149 (30) 
 
MS (EI): m/z (%) = 401 (8), 399 (25) [M]+∙, 371 (40), 295 (35), 280 (40), 91 (100), 
77 (75) 
 
HR-MS (EI): calcd. for C23H18ClN5 [M]
+∙ 399.1251; found 399.1252 
 
HPLC purity: 94 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H18ClN5 
 
MW: 399.88 g/mol 
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8-Chloro-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine 
(11) 
(Literature known compound but different procedure
110
) 
 
8-Chloro-4-(4-methoxybenzyl)-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo[3,4-c]-
c[1,2,4]triazepine 51 (1.04 g, 2.42 mmol, 1.0 equiv) was dissolved in a 45 % 
solution of hydrogen bromide in acetic acid (15 mL) and treated with anisole 
(526 µL, 4.84 mmol, 2.00 equiv). The mixture was stirred over night at room 
temperature and further for 30 min at 60 °C yielding the hydrobromic salt of target 
compound 11. The mixture was taken to dryness under reduced pressure and re-
dissolved in tetrahydrofuran (30 mL). A saturated aqueous sodium hydrogen 
carbonate solution (35 mL) was added and after stirring for 20 min at room 
temperature the reaction mixture was concentrated under reduced pressure. 
Extraction was done with ethyl acetate (3 x 30 mL) and the combined organic 
layers were washed with water (50 mL). The organic layer was dried over sodium 
sulfate, filtered and evaporated. Purification was done by flash column 
chromatography on flash silica gel (dichloromethane / methanol 9:1, Rf = 0.66), 
yielding compound 11 (635 mg, 2.05 mmol, 88 %) as colorless solid. 
 
mp: 139.8 °C (lit. 140 – 142 °C)110 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.57 (s, 3 H, 1-CH3), 7.25 (d, 
4JHH = 2.4 Hz, 
1 H, 7-H), 7.33 (d, 3JHH = 8.7 Hz, 1 H, 10-H), 7.39 – 7.44 (m, 2 H, 3’-H, 5’-H), 7.44 
– 7.49 (m, 1 H, 4’-H), 7.52 – 7.55 (m, 2 H, 2’-H, 6’-H), 7.60 (dd, 4JHH = 2.4 Hz, 
3JHH 
= 8.7 Hz, 1 H, 9-H), 8.38 (s, 1 H, 4-H) 
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13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.9 (1-CH3), 124.3 (C-10), 128.9 (C-3’, C-
5’), 129.4 (C-2’, C-6’), 130.6 (C-4’), 130.7 (C-6a), 131.9 (C-7), 132.1 (C-9), 133.0 
(C-8), 133.8 (C-10a), 136.8 (C-1’), 148.5 (C-1), 158.6 (C-3a), 161.0 (C-6) 
 
IR [cm-1]:    = 3346 (w), 3242 (m), 3208 (m), 3178 (m), 3065 (m), 3029 (m), 
2360 (w), 1713 (w), 1615 (m), 1578 (m), 1548 (s), 1527 (s), 1495 (s), 1489 (s), 
1446 (s), 1425 (s), 1376 (m), 1350 (m), 1309 (s), 1270 (m), 1172 (m), 1136 (w), 
1105 (m), 1076 (m), 1033 (w), 987 (w), 916 (m), 889 (m), 825 (s), 775 (s), 744 (s), 
698 (s) 
 
MS (CI): m/z (%) = 312 (50), 310 (100) [M + H]+ 
 
MS (EI): m/z (%) = 311 (35), 309 (100) [M]+∙, 253 (60), 219 (70), 77 (60) 
 
HR-MS (EI): calcd. for C16H12ClN5 [M]
+∙ 309.0781; found 309.0781 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C16H12ClN5 
 
MW: 309.75 g/mol 
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8-Chloro-1-methyl-6-phenyl-4-(prop-2-yn-1-yl)-4H-benzo[e][1,2,4]triazolo- 
[3,4-c][1,2,4]triazepine (13) 
 
8-Chloro-1-methyl-6-phenyl-4H-benzo[e][1,2,4]-triazolo[3,4-c][1,2,4]triazepine 11 
(0.65 g, 2.1 mmol, 1.0 equiv) was dissolved in anhydrous tetrahydrofuran (12 mL) 
and sodium hydride (92 mg, 2.31 mmol, 1.10 equiv) was added portionwise as a 
60 % dispersion in mineral oil to the vigorously stirred solution. Subsequently, 
propargyl bromide 12 (584 µL, 5.25 mmol, 2.50 equiv) was added as 80wt% 
solution in toluene and after stirring for 1 h at room temperature the solvent was 
evaporated. Purification was done by flash column chromatography on flash silica 
gel (dichloromethane / methanol 9:1, Rf = 0.63), yielding product 13 (504 mg, 
1.45 mmol, 69 %) as pale yellow solid. 
 
mp: 231.8 – 232.4 °C 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.37 (t, 
4JHH = 2.5 Hz, 1 H, 3’’-H), 2.56 (s, 
3 H, 1-CH3), 4.46 – 4.64 (m, 2 H, 1’’-H), 7.29 (d, 
4JHH = 2.4 Hz, 1 H, 7-H), 7.34 (d, 
3JHH = 8.7 Hz, 1 H, 10-H), 7.40 – 7.44 (m, 2 H, 3’-H, 5’-H), 7.46 – 7.51 (m, 1 H, 4’-
H), 7.54 – 7.58 (m, 2 H, 2’-H, 6’-H), 7.62 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-
H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 44.3 (C-1’’), 72.8 (C-3’’), 
79.5 (C-2’’), 124.4 (C-10), 128.9 (C-3’, C-5’), 129.6 (C-2’, C-6’), 130.5 (C-6a), 
131.0 (C-4’), 131.7 (C-7), 132.3 (C-9), 133.1 (C-8), 133.6 (C-10a), 136.3 (C-1’), 
148.9 (C-1), 159.4 (C-3a), 161.6 (C-6) 
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IR [cm-1]:    = 3308 (s), 3074 (w), 2949 (w), 2922 (w), 2361 (m), 2342 (w), 
1636 (m), 1560 (m), 1541 (s), 1522 (s), 1487 (m), 1444 (m), 1422 (m), 1381 (w), 
1348 (w), 1319 (m), 1308 (m), 1272 (m), 1170 (m), 1104 (w), 1064 (w), 1036 (w), 
829 (m), 692 (m) 
 
MS (CI): m/z (%) = 350 (35), 348 (100) [M + H]+, 255 (10), 210 (20) 
 
MS (EI): m/z (%) = 349 (7), 347 (25) [M]+∙, 332 (95), 305 (15), 295 (25), 280 (10), 
270 (25), 253 (25), 243 (40), 229 (5), 219 (20), 204 (20), 181 (10), 177 (25), 163 
(10), 151 (15), 136 (10), 110 (15), 77 (100), 51 (35) 
 
HR-MS (EI): calcd. for C19H14ClN5 [M]
+∙ 347.0938; found 347.0937 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C19H14ClN5 
 
MW: 347.80 g/mol 
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1-Methyl-8-nitro-6-phenyl-4H-benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine  
(14) 
(Literature known compound but different procedure
110
) 
 
4-(4-Methoxybenzyl)-1-methyl-8-nitro-6-phenyl-4H-benzo[e][1,2,4]triazolo[3,4-c]-
[1,2,4]triazepine 68 (2.2 g, 5.0 mmol, 1.0 equiv) was dissolved in a 45 % solution 
of hydrogen bromide in acetic acid (20 mL) and treated with anisole (1.1 mL, 
10 mmol, 2.0 equiv). The mixture was stirred over night at room temperature and 
further for 30 min at 60 °C yielding the hydrobromic salt of target compound 14. 
The mixture was taken to dryness under reduced pressure and re-dissolved in 
tetrahydrofuran (40 mL). A saturated sodium hydrogen carbonate solution (40 mL) 
was added and after stirring for 20 min at room temperature the reaction mixture 
was concentrated under reduced pressure. Extraction was done with ethyl acetate 
(3 x 35 mL) and the combined organic layers were washed with water (35 mL). 
The organic layer was dried over sodium sulfate, filtered and evaporated. 
Purification was done by flash column chromatography on flash silica gel 
(dichloromethane / methanol 19:1, Rf = 0.32), yielding compound 14 (1.49 g, 
4.65 mmol, 93 %) as yellow solid. 
 
mp: 259.4 °C (lit. 258 – 260 °C)110 
 
1H NMR (400 MHz, CD2Cl2)  (ppm) = 2.62 (s, 3 H, 1-CH3), 7.40 – 7.46 (m, 2 H, 
3’-H, 5’-H), 7.48 – 7.52 (m, 1 H, 4’-H), 7.53 – 7.56 (m, 2 H, 2’-H, 6’-H), 7.56 (d, 
3JHH = 8.9 Hz, 1 H, 10-H), 8.09 (d, 
4JHH = 2.5 Hz, 1 H, 7-H), 8.44 (dd, 
4JHH = 
2.6 Hz, 3JHH = 8.9 Hz, 1 H, 9-H), 8.83 (s, 1 H, 4-H) 
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13C NMR (100 MHz, CD2Cl2):  (ppm) = 13.1 (1-CH3), 124.1 (C-10), 126.9 (C-9), 
127.4 (C-7), 129.1 (C-3’, C-5’), 129.3 (C-2’, C-6’), 130.4 (C-6a), 131.0 (C-4’), 136.3 
(C-1’), 140.3 (C-10a), 145.9 (C-8), 148.6 (C-1), 158.8 (C-3a), 160.5 (C-6) 
 
IR [cm-1]:    = 3232 (m), 3172 (m), 3083 (m), 2361 (w), 1616 (m), 1578 (m), 
1551 (m), 1523 (s), 1489 (m), 1445 (m), 1427 (m), 1345 (s), 1322 (s), 1280 (m), 
1253 (m), 1101 (w), 1078 (w), 1034 (w), 989 (w), 911 (w), 881 (w), 778 (m), 
749 (m), 737 (m), 698 (m) 
 
MS (CI): m/z (%) = 321 (100) [M + H]+ 
 
MS (EI): m/z (%) = 320 (100) [M]+∙, 290 (10), 273 (25), 248 (30), 218 (80), 205 
(25), 178 (20), 151 (25), 75 (75) 
 
HR-MS (EI): calcd. for C16H12N6O2 [M]
+∙ 320.1022; found 320.1029 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C16H12N6O2 
 
MW: 320.31 g/mol 
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8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-benzo[e][1,2,4]triazolo[3,4-c][1,2,4]-
triazepine (15) 
(Literature known compound but different procedure
110
) 
 
8-Chloro-6-(2-chlorophenyl)-4-(4-methoxybenzyl)-1-methyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 69 (2.9 g, 6.3 mmol, 1.0 equiv) was dissolved in a 
45 % solution of hydrogen bromide in acetic acid (25 mL) and treated with anisole 
(1.4 mL, 13 mmol, 2.0 equiv). The mixture was stirred over night at room 
temperature and further for 30 min at 60 °C yielding the hydrobromic salt of target 
compound 15. The mixture was taken to dryness under reduced pressure and re-
dissolved in tetrahydrofuran (40 mL). A saturated sodium hydrogen carbonate 
solution (40 mL) was added and after stirring for 20 min at room temperature the 
reaction mixture was concentrated under reduced pressure. After addition of ethyl 
acetate (50 mL) precipitation of a colorless solid occurred. The precipitate was 
filtered off and dried under reduced pressure yielding compound 15 (1.69 g, 
4.91 mmol, 79 %) as colorless solid. 
 
mp: 279.9 °C (lit. 282 – 284 °C)110 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.55 (s, 3 H, 1-CH3), 6.99 (d, 
4JHH = 2.4 Hz, 
1 H, 7-H), 7.31 (d, 3JHH = 8.7 Hz, 1 H, 10-H), 7.38 – 7.46 (m, 3 H, 3’-H, 5’-H, 6’-H), 
7.56 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H), 7.57 – 7.60 (m, 1 H, 4’-H), 8.56 
(s, 1 H, 4-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.9 (1-CH3), 124.2 (C-10), 127.7 (C-5’), 
130.0 (C-7), 130.1 (C-3’), 131.4 (C-6a), 131.5 (C-6’), 131.9 (C-4’), 132.0 (C-9), 
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132.9 (C-10a), 133.2 (C-2’), 133.4 (C-8), 135.9 (C-1’), 148.6 (C-1), 158.5 (C-3a), 
159.3 (C-6) 
 
IR [cm-1]:    = 3239 (m), 3177 (m), 3131 (m), 3094 (m), 3067 (m), 3030 (m), 
2362 (w), 1935 (w), 1817 (w), 1618 (m), 1553 (s), 1529 (m), 1494 (s), 1424 (s), 
1350 (m), 1315 (s), 1281 (m), 1178 (m), 1106 (m), 1068 (m), 1014 (m), 917 (m), 
892 (m), 847 (m), 828 (m), 762 (s), 711 (m), 579 (s) 
 
MS (CI): m/z (%) = 348 (10), 346 (70), 344 (100) [M + H]+ 
 
MS (EI): m/z (%) = 347 (5), 345 (30), 343 (55) [M]+∙, 287 (30), 253 (100), 239 (30), 
177 (30), 151 (20), 111 (30), 100 (20), 75 (90) 
 
HR-MS (EI): calcd. for C16H11Cl2N5 [M]
+∙ 343.0392; found 343.0387 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C16H11Cl2N5 
 
MW: 344.20 g/mol 
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N-(4-Chloro-2-propionylphenyl)-2-iodoacetamide (23) 
(Literature known compound but different procedure
177
) 
 
2-Chloro-N-(4-chloro-2-propionylphenyl)acetamide177 22 (5.5 g, 21 mmol, 
1.0 equiv) and sodium iodide (6.3 g, 42 mmol, 2.0 equiv) were dissolved in 140 mL 
of acetone. The solution was stirred over night at room temperature. The produced 
sodium chloride precipitated and was filtered off. Acetone was evaporated and the 
residue was dissolved in dichloromethane and washed with water in a separating 
funnel. The organic phase was dried over sodium sulfate, filtered and evaporated, 
yielding product 23 (7.4 g, 21 mmol, 99 %) as colorless solid. 
 
1H NMR (500 MHz, CD2Cl2):  (ppm) = 1.20 (t, 
3JHH = 7.2 Hz, 3 H, 3’’-H), 3.06 (q, 
3JHH = 7.1 Hz, 2 H, 2’’-H), 3.88 (s, 2 H, 2-H), 7.52 (d, 
3JHH = 8.9 Hz, 1 H, 5’-H), 7.93 
(s, 1 H, 3’-H), 8.54 (d, 3JHH = 9.0 Hz, 1 H, 6’-H), 12.00 (bs, 1 H, NH) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 0.9 (C-2), 8.4 (C-3’’), 33.7 (C-2’’), 122.4 
(C-6’), 123.4 (C-2’), 128.2 (C-4’), 130.7 (C-3’), 134.7 (C-5’), 139.4 (C-1’), 167.1 (C-
1), 204.8 (C-1’’) 
 
MS (CI): m/z (%) = 354 (25), 352 (80) [M + H]+, 288 (20), 264 (30), 226 (80), 208 
(20), 186 (15), 184 (100), 154 (15), 146 (20), 121 (60) 
 
MF: C11H11ClINO2 
 
MW: 351.57 g/mol 
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8-Chloro-6-ethyl-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine (29a) 
 
According to GP1, compound 29a was synthesized, using 7-chloro-5-ethyl-1H-
benzo[e][1,4]diazepine-2(3H)-thione 2 (66 mg, 0.28 mmol, 1.0 equiv) and 
acethydrazide 27a (41 mg, 0.55 mmol, 2.0 equiv) dissolved in 5 mL of n-butanol. 
After purification (Rf = 0.61), product 29a (29 mg, 4.8 mmol, 53 %) was obtained 
as yellow solid. 
 
mp: 173.5 – 174.9 °C 
 
1H NMR (500 MHz, CDCl3):  (ppm) = 1.09 (t, 
3JHH = 7.3 Hz, 3 H, 2’-H), 2.60 (s, 
3 H, 1-CH3), 2.56 – 2.65 (m, 1 H, 1’-HH), 2.80 – 2.89 (m, 1 H, 1’-HH), 3.93 (d, 
2JHH 
= 13.0 Hz, 1 H, 4-HH), 5.28 (d, 2JHH = 13.0 Hz, 1 H, 4-HH), 7.35 (d, 
3JHH = 8.6 Hz, 
1 H, 10-H), 7.60 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.6 Hz, 1 H, 9-H), 7.68 (d, 
4JHH = 
2.3 Hz, 1 H, 7-H) 
 
13C NMR (125 MHz, CDCl3):  (ppm) = 11.0 (C-2’), 12.4 (1-CH3), 32.3 (C-1’), 45.7 
(C-4), 124.6 (C-10), 128.9 (C-7), 130.7 (C-10a), 131.1 (C-9), 131.9 (C-6a), 133.9 
(C-8), 150.2 (C-1), 154.9 (C-3a), 170.9 (C-6) 
 
IR [cm-1]:    = 3066 (w), 2971 (m), 2933 (m), 2852 (w), 2360 (w), 1635 (s), 
1542 (s), 1485 (s), 1426 (s), 1378 (m), 1111 (m), 831 (m) 
 
MS (CI): m/z (%) = 263 (30), 261 (100) [M + H]+ 
 
MS (EI): m/z (%) = 262 (10), 260 (25) [M]+∙, 231 (30), 225 (100), 197 (25) 
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HR-MS (EI): calcd. for C13H13ClN4 [M]
+∙ 260.0829; found 260.0813 
 
HPLC purity: 95 % [ = 210 nm], 94 % [ = 254 nm] 
 
MF: C13H13ClN4 
 
MW: 260.72 g/mol 
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8-Chloro-6-ethyl-1-hydroxymethyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]-
diazepine (29b) 
 
According to GP1, compound 29b was synthesized, using 7-chloro-5-ethyl-1H-
benzo[e][1,4]diazepine-2(3H)-thione 2 (300 mg, 1.26 mmol, 1.00 equiv) and 2-
hydroxyacethydrazide 27b (226 mg, 2.51 mmol, 2.00 equiv) dissolved in 7 mL of 
n-butanol. After purification (Rf = 0.47), product 29b (98 mg, 0.35 mmol, 28 %) 
was obtained as pale yellow solid. 
 
mp: 198.0 – 199.6 °C 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 1.08 (t, 
3JHH = 7.3 Hz, 3 H, 2’’-H), 2.58 – 
2.72 (m, 1 H, 1’’-HH), 2.80 – 2.92 (m, 1 H, 1’’-HH), 3.00 (s, 1 H, OH), 3.99 (d, 2JHH 
= 13.1 Hz, 1 H, 4-HH), 4.47 (d, 2JHH = 13.7 Hz, 1 H, 1’-HH), 4.99 (d, 
2JHH = 
13.7 Hz, 1 H, 1’-HH), 5.24 (d, 2JHH = 13.1 Hz, 1 H, 4-HH), 7.66 (dd, 
4JHH = 2.4 Hz, 
3JHH = 8.6 Hz, 1 H, 9-H), 7.68 (d, 
4JHH = 2.4 Hz, 1 H, 7-H), 8.15 (d, 
3JHH = 8.6 Hz, 
1 H, 10-H) 
 
13C NMR (100 MHz, CDCl3):  (ppm) = 11.1 (C-2’’), 32.4 (C-1’’), 45.4 (C-4), 53.6 
(C-1’), 126.2 (C-10), 128.6 (C-7), 130.5 (C-10a), 131.2 (C-6a), 132.0 (C-9), 134.4 
(C-8), 153.7 (C-1), 154.9 (C-3a), 172.0 (C-6) 
 
IR [cm-1]:    = 2935 (w), 1633 (s), 1538 (m), 1487 (s), 1443 (s), 1290 (w), 1113 (m), 
1055 (m), 1024 (m), 827 (m) 
 
MS (CI): m/z (%) = 279 (25), 277 (100) [M + H]+ 
 
160 
 
CHAPTER VI   –   Experimental section 
 
 
 
MS (EI): m/z (%) = 278 (5), 276 (20) [M]+∙, 241 (100) 
 
HR-MS (EI): calcd. for C13H13ClN4O [M]
+∙ 276.0778; found 276.0778 
 
Elemental analysis calcd. (%) for C13H13ClN4O (276.7): C 56.42, H 4.74, N 20.25; 
found C 56.03, H 4.84, N 19.89 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C13H13ClN4O 
 
MW: 276.72 g/mol 
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8-Chloro-1,6-diethyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine (29c) 
 
According to GP1, compound 29c was synthesized, using 7-chloro-5-ethyl-1H-
benzo[e][1,4]diazepine-2(3H)-thione 2 (900 mg, 3.77 mmol, 1.00 equiv) and 
propanoic acid hydrazide 27c (664 mg, 7.54 mmol, 2.00 equiv) dissolved in 15 mL 
of n-butanol. After purification (Rf = 0.47), product 29c (464 mg, 1.69 mmol, 45 %) 
was obtained as yellow solid. 
 
mp: 203.6 – 205.9 °C 
 
1H NMR (500 MHz, CDCl3):  (ppm) = 1.07 (t, 
3JHH = 7.4 Hz, 3 H, 2’’-H), 1.34 (t, 
3JHH = 7.5 Hz, 3 H, 2’-H), 2.60 – 2.70 (m, 1 H, 1’’-HH), 2.77 – 2.89 (m, 2 H, 1’-HH, 
1’’-HH), 3.00 – 3.11 (m, 1 H, 1’-HH), 3.92 (d, 2JHH = 13.0 Hz, 1 H, 4-HH), 5.28 (d, 
2JHH = 13.0 Hz, 1 H, 4-HH), 7.37 (d, 
3JHH = 8.6 Hz, 1 H, 10-H), 7.59 (dd, 
4JHH = 
2.4 Hz, 3JHH = 8.6 Hz, 1 H, 9-H), 7.67 (d, 
4JHH = 2.3 Hz, 1 H, 7-H) 
 
13C NMR (125 MHz, CDCl3):  (ppm) = 11.1 (C-2’’), 11.5 (C-2’), 19.8 (C-1’), 32.4 
(C-1’’), 45.7 (C-4), 124.6 (C-10), 128.8 (C-7), 130.9 (C-10a), 131.1 (C-9), 131.8 
(C-6a), 133.8 (C-8), 154.8 (C-1), 155.1 (C-3a), 171.0 (C-6) 
 
IR [cm-1]:    = 3060 (w), 2986 (m), 2934 (m), 2873 (m), 2362 (w), 2343 (w), 
1630 (m), 1540 (m), 1485 (s), 1430 (s), 1261 (s), 1108 (s), 1027 (s), 818 (s), 
799 (s) 
 
MS (CI): m/z (%) = 277 (30), 275 (100) [M + H]+ 
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MS (EI): m/z (%) = 276 (10), 274 (30) [M]+∙, 245 (40), 239 (100) 
 
HR-MS (EI): calcd. for C14H15ClN4 [M]
+∙ 274.0985; found 274.0987 
 
HPLC purity: 91 % [ = 210 nm], 93 % [ = 254 nm] 
 
MF: C14H15ClN4 
 
MW: 274.75 g/mol 
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8-Chloro-6-ethyl-1-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine (29d) 
 
According to GP1, compound 29d was synthesized, using 7-chloro-5-ethyl-1H-
benzo[e][1,4]diazepine-2(3H)-thione 2 (515 mg, 2.16 mmol, 1.00 equiv) and 
benzhydrazide 27d (587 mg, 4.31 mmol, 2.00 equiv) dissolved in 10 mL of n-
butanol. After purification (Rf = 0.49), product 29d (422 mg, 1.31 mmol, 61 %) was 
obtained as yellow solid. 
 
mp: 176.8 °C 
 
1H NMR (400 MHz, CD2Cl2):  (ppm) = 1.13 (t, 
3JHH = 7.3 Hz, 3 H, 2’’-H), 2.67 – 
2.80 (m, 1 H, 1’’-HH), 2.82 – 2.96 (m, 1 H, 1’’-HH), 4.00 (d, 2JHH = 13.0 Hz, 1 H, 4-
HH), 5.21 (d, 2JHH = 13.1 Hz, 1 H, 4-HH), 6.87 (d, 
3JHH = 8.7 Hz, 1 H, 10-H), 7.30 
(dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H), 7.37 – 7.52 (m, 5 H, 2’-H, 3’-H, 4’-H, 
5’-H, 6’-H), 7.69 (d, 4JHH = 2.4 Hz, 1 H, 7-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 11.2 (C-2’’), 32.8 (C-1’’), 46.2 (C-4), 126.8 
(C-10), 127.2 (C-1’), 128.8 (C-2’, C-6’), 128.9 (C-7), 129.3 (C-3’, C-5’), 130.7 (C-
4’), 131.1 (C-9), 132.0 (C-10a), 132.2 (C-6a), 133.9 (C-8), 153.6 (C-1), 157.3 (C-
3a), 171.9 (C-6) 
 
IR [cm-1]:    = 3057 (w), 2970 (m), 2930 (m), 2854 (m), 2365 (w), 2345 (w), 
1631 (m), 1534 (m), 1485 (s), 1472 (s), 1422 (s), 1287 (s), 1107 (s), 977 (m), 
821 (m), 768 (m), 696 (m) 
 
MS (CI): m/z (%) = 325 (35), 323 (100) [M + H]+ 
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MS (EI): m/z (%) = 324 (15), 322 (50) [M]+∙, 293 (50), 287 (100) 
 
HR-MS (EI): calcd. for C18H15ClN4 [M]
+∙ 322.0985; found 322.0963 
 
Elemental analysis calcd. (%) for C18H15ClN4 (322.8): C 66.98, H 4.68, N 17.36; 
found C 65.57, H 4.78, N 17.01 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C18H15ClN4 
 
MW: 322.79 g/mol 
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8-Chloro-6-ethyl-1-(pyridin-4-yl)-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]-
diazepine (29e) 
 
According to GP1, compound 29e was synthesized, using 7-chloro-5-ethyl-1H-
benzo[e][1,4]diazepine-2(3H)-thione 2 (55 mg, 0.23 mmol, 1.0 equiv) and 
isonicotinic acid hydrazide 27e (63 mg, 0.46 mmol, 2.0 equiv) dissolved in 4 mL of 
n-butanol. After purification (Rf = 0.49), product 29e (13 mg, 0.04 mmol, 17 %) was 
obtained as yellow solid. 
 
mp: 157.3 – 159.9 °C 
 
1H NMR (500 MHz, CDCl3):  (ppm) = 1.16 (t, 
3JHH = 7.4 Hz, 3 H, 2’’-H), 2.72 – 
2.82 (m, 1 H, 1’’-HH), 2.88 – 2.98 (m, 1 H, 1’’-HH), 4.01 (d, 2JHH = 13.3 Hz, 1 H, 4-
HH), 5.36 (d, 2JHH = 13.3 Hz, 1 H, 4-HH), 6.90 (d, 
3JHH = 8.7 Hz, 1 H, 10-H), 7.39 
(dd, 4JHH = 2.3 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H), 7.41 (dd, 
3JHH = 6.2 Hz, 2 H, 2’-H, 6’-
H), 7.72 (d, 4JHH = 2.3 Hz, 1 H, 7-H), 8.72 (d, 
3JHH = 5.7 Hz, 2 H, 3’-H, 5’-H) 
 
13C NMR (125 MHz, CDCl3):  (ppm) = 11.3 (C-2’’), 32.7 (C-1’’), 45.9 (C-4), 122.3 
(C-2’, C-6’), 126.4 (C-10), 129.0 (C-7), 131.1 (C-10a), 131.3 (C-9), 131.9 (C-6a), 
134.3 (C-1’), 134.7 (C-8), 150.9 (C-3’, C-5’), 151.2 (C-1), 158.0 (C-3a), 171.7 (C-6) 
 
IR [cm-1]:    = 3036 (m), 2971 (m), 2927 (m), 2853 (m), 2366 (w), 2344 (w), 
2225 (w), 1633 (m), 1604 (m), 1531 (m), 1484 (s), 1467 (s), 1434 (s), 1290 (m), 
1110 (m), 985 (m), 827 (s), 728 (m), 576 (m) 
 
MS (CI): m/z (%) = 326 (35), 324 (100) [M + H]+ 
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MS (EI): m/z (%) = 325 (10), 323 (25) [M]+∙, 294 (50), 288 (100), 78 (40) 
 
HR-MS (EI): calcd. for C17H14ClN5 [M]
+∙ 323.0938; found 323.0934 
 
HPLC purity: 80 % [ = 210 nm], 80 % [ = 254 nm] 
 
MF: C17H14ClN5 
 
MW: 323.78 g/mol 
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8-Chloro-6-ethyl-1-(3-methoxyphenyl)-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]-
diazepine (29f) 
 
According to GP1, compound 29f was synthesized, using 7-chloro-5-ethyl-1H-
benzo[e][1,4]diazepine-2(3H)-thione 2 (66 mg, 0.28 mmol, 1.0 equiv) and 3-
methoxybenzoic acid hydrazide 27f (92 mg, 0.55 mmol, 2.0 equiv) dissolved in 
3 mL of n-butanol. After purification (Rf = 0.50), product 29f (65 mg, 0.18 mmol, 
67 %) was obtained as yellow solid. 
 
mp: 132.6 – 133.7 °C 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 1.14 (t, 
3JHH = 7.4 Hz, 3 H, 2’’-H), 2.70 – 
2.82 (m, 1 H, 1’’-HH), 2.83 – 2.96 (m, 1 H, 1’’-HH), 3.81 (s, 3 H, OCH3), 4.00 (d, 
2JHH = 13.4 Hz, 1 H, 4-HH), 5.33 (d, 
2JHH = 13.2 Hz, 1 H, 4-HH), 6.88 (ddd, 
4JHH = 
1.0 Hz, 4JHH = 1.5 Hz, 
3JHH = 7.7 Hz, 1 H, 6’-H), 6.91 (d, 
3JHH = 8.7 Hz, 1 H, 10-H), 
7.00 (ddd, 4JHH = 1.0 Hz, 
4JHH = 2.5 Hz, 
3JHH = 8.4 Hz, 1 H, 4’-H), 7.14 (dd, 
4JHH = 
1.5 Hz, 4JHH = 2.4 Hz, 1 H, 2’-H), 7.30 (dd, 
3JHH = 7.7 Hz, 
3JHH = 8.4 Hz, 1 H, 5’-H), 
7.32 (dd, 1 H, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 9-H), 7.66 (d, 
4JHH = 2.4 Hz, 1 H, 7-H) 
 
13C NMR (100 MHz, CDCl3):  (ppm) = 11.2 (C-2’’), 32.6 (C-1’’), 45.9 (C-4), 55.4 
(OCH3), 113.7 (C-2’), 116.4 (C-4’), 120.6 (C-6’), 126.4 (C-10), 127.6 (C-1’), 128.4 
(C-7), 130.0 (C-5’), 130.8 (C-9), 131.4 (C-10a), 131.5 (C-6a), 133.7 (C-8), 153.2 
(C-1), 156.9 (C-3a), 159.9 (C-3’), 171.7 (C-6) 
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IR [cm-1]:    = 3072 (w), 2970 (w), 2935 (w), 1632 (m), 1583 (m), 1535 (m), 
1485 (s), 1466 (m), 1435 (m), 1319 (w), 1287 (m), 1238 (m), 1108 (m), 1045 (m), 
994 (w), 753 (m) 
 
MS (CI): m/z (%) = 355 (35), 353 (100) [M + H]+ 
 
MS (EI): m/z (%) = 354 (30), 352 (80) [M]+∙, 323 (65), 317 (100) 
 
HR-MS (EI): calcd. for C19H17ClN4O [M]
+∙ 352.1091; found 352.1098 
 
HPLC purity: 89 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C19H17ClN4O 
 
MW: 352.82 g/mol 
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N-(2-Benzoyl-4-chlorophenyl)-1-(2-hydroxyethyl)hydrazinecarbothioamide 
(42) 
(Literature known compound but different procedure
109
) 
 
(5-Chloro-2-isothiocyanatophenyl)(phenyl)methanone 6 (600 mg, 2.19 mmol, 
1.00 equiv) and 2-hydroxyethylhydrazine 41 (178 µL, 2.63 mmol, 1.2 equiv) were 
dissolved in tetrahydrofuran (8 mL) under ice-cooling and stirred for 15 min, 
followed by additional 45 min at room temperature. The reaction mixture was 
concentrated under reduced pressure and crystallization was done in diethyl ether 
(80 mL) yielding compound 42 (641 mg, 1.22 mmol, 84 %) as pale yellow solid. 
 
1H NMR (500 MHz, MeOD):  (ppm) = 3.89 (t, 3JHH = 5.2 Hz, 2 H, 2-H), 4.22 (t, 
3JHH = 5.2 Hz, 2 H, 1-H), 7.42 (d, 
4JHH = 2.5 Hz, 1 H, 3’-H), 7.49 – 7.54 (m, 3 H, 5’-
H, 3’’’-H, 5’’’-H), 7.62 – 7.67 (m, 1 H, 4’’’-H), 7.78 – 7.82 (m, 2 H, 2’’’-H, 6’’’-H), 
8.35 (d, 3JHH = 8.8 Hz, 1 H, 6-H) 
 
13C NMR (100 MHz, MeOD):  (ppm) = 56.9 (C-2), 61.1 (C-1), 123.1 (C-4’), 129.3 
(C-6’), 129.5 (C-3’’’, C-5’’’), 130.2 (C-2’), 131.2 (C-3’), 131.2 (C-2’’’, C-6’’’), 132.3 
(C-5’), 134.4 (C-4’’’), 138.4 (C-1’’’), 139.3 (C-1’), 181.1 (CS), 197.2 (C-1’’) 
 
MS (CI): m/z (%) = 352 (2), 350 (7) [M + H]+, 332 (70), 274 (100) 
 
MF: C16H16ClN3O2S 
 
MW: 349.84 g/mol 
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4-(2-Acetoxyethyl)-8-chloro-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo-
[3,4-c][1,2,4]triazepine (44a) 
 
8-Chloro-4-(2-hydroxyethyl)-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo[3,4-c]-
[1,2,4]triazepine 5 (100 mg, 0.283 mmol, 1.00 equiv) was suspended in 5 mL of 
acetic acid anhydride and treated with 0.2 mL of conc. sulfuric acid. After stirring 
for 1 h at 80 °C the mixture was cooled to room temperature. Water (5 mL) was 
added slowly to the vigorously stirred solution and the mixture was extracted with 
dichloromethane (3 x 7 mL). The combined organic layers were dried over sodium 
sulfate, filtered and concentrated under reduced pressure. Purification was done 
by flash column chromatography on flash silica gel (dichloromethane / methanol 
9:1, Rf = 0.64), giving compound 44a (87 mg, 0.22 mmol, 78 %) as pale yellow 
solid. 
 
mp: 83.2 – 85.4 °C 
 
1H NMR (500 MHz, CD2Cl2):  (ppm) = 1.92 (s, 3 H, O(CO)CH3), 2.55 (s, 3 H, 1-
CH3), 3.90 – 4.03 (m, 1 H, 1’’-HH), 4.07 – 4.18 (m, 1 H, 1’’-HH), 4.32 – 4.42 (m, 
1 H, 2’’-HH), 4.43 – 4.54 (m, 1 H, 2’’-HH), 7.26 (d, 4JHH = 2.4 Hz, 1 H, 7-H), 7.33 
(d, 3JHH = 8.7 Hz, 1 H, 10-H), 7.39 – 7.44 (m, 2 H, 3’-H, 5’-H), 7.45 – 7.50 (m, 1 H, 
4’-H), 7.53 – 7.58 (m, 2 H, 2’-H, 6’-H), 7.61 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 
9-H) 
 
13C NMR (125 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 21.0 (O(CO)CH3), 53.1 (C-
1’’), 61.9 (C-2’’), 124.3 (C-10), 128.8 (C-3’, C-5’), 129.5 (C-2’, C-6’), 130.8 (C-6a), 
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130.9 (C-4’), 131.5 (C-7), 132.1 (C-9), 132.8 (C-8), 133.8 (C-10a), 136.5 (C-1’), 
148.6 (C-1), 160.2 (C-3a), 161.6 (C-6), 171.0 (CO) 
 
IR [cm-1]:    = 3061 (w), 2958 (w), 2925 (w), 2363 (w), 2342 (w), 1739 (s), 1519 (s), 
1490 (m), 1434 (m), 1231 (s), 1050 (w), 829 (w), 696 (w) 
 
MS (CI): m/z (%) = 398 (35), 396 (100) [M + H]+ 
 
MS (EI): m/z (%) = 397 (8), 395 (20) [M]+∙, 240 (100), 77 (65) 
 
HR-MS (EI): calcd. for C20H18ClN5O2 [M]
+∙ 395.1149; found 395.1150 
 
Elemental analysis calcd. (%) for C20H18ClN5O2 (395.8): C 60.68, H 4.58, 
N 17.69; found C 60.22, H 4.63, N 17.32 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C20H18ClN5O2 
 
MW: 395.84 g/mol 
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8-Chloro-4-{2-[(cyclopropanecarbonyl)oxy]ethyl}-1-methyl-6-phenyl-4H-
benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (44b) 
 
8-Chloro-4-(2-hydroxyethyl)-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo[3,4-c]-
[1,2,4]triazepine 5 (100 mg, 0.283 mmol, 1.00 equiv) was dissolved in 2 mL of 
anhydrous tetrahydrofuran and treated with N,N-diisopropylethylamine (48 µL, 
0.28 mmol, 1.0 equiv). After stirring for 10 min at room temperature 
cyclopropanecarbonyl chloride (26 µL, 0.28 mmol, 1.0 equiv) was added and 
stirring was continued for 5 min. The solvent was evaporated and purification was 
done by flash column chromatography on flash silica gel (ethyl acetate / methanol 
9:1, Rf = 0.60), giving compound 44b (32 mg, 0.08 mmol, 38 %) as pale yellow 
solid. 
 
mp: 100.9 – 101.8 °C 
 
1H NMR (400 MHz, CD2Cl2):  (ppm) = 0.67 – 0.82 (m, 4 H, 2’’’-H, 3’’’-H), 1.43 – 
1.52 (m, 1 H, 1’’’-H), 2.55 (s, 3 H, 1-CH3), 3.90 – 4.03 (m, 1 H, 1’’-HH), 4.04 – 4.17 
(m, 1 H, 1’’-HH), 4.28 – 4.39 (m, 1 H, 2’’-HH), 4.48 – 4.60 (m, 1 H, 2’’-HH), 7.26 (d, 
4JHH = 2.4 Hz, 1 H, 7-H), 7.32 (d, 
3JHH = 8.7 Hz, 1 H, 10-H), 7.39 – 7.44 (m, 2 H, 3’-
H, 5’-H), 7.46 – 7.51 (m, 1 H, 4’-H), 7.53 – 7.58 (m, 2 H, 2’-H, 6’-H), 7.61 (dd, 4JHH 
= 2.4 Hz, 3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 8.4 (C-2’’’, C-3’’’), 12.8 (1-CH3), 13.0 (C-
1’’’), 53.3 (C-1’’), 61.7 (C-2’’), 124.3 (C-10), 128.9 (C-3’, C-5’), 129.6 (C-2’, C-6’), 
130.9 (C-4’), 130.9 (C-6a), 131.6 (C-7), 132.0 (C-9), 132.9 (C-8), 133.9 (C-10a), 
136.5 (C-1’), 148.5 (C-1), 160.2 (C-3a), 161.7 (C-6), 174.7 (CO) 
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IR [cm-1]:    = 3063 (w), 2924 (w), 2368 (w), 1726 (s), 1535 (m), 1520 (s), 
1490 (m), 1446 (m), 1381 (m), 1350 (m), 1320 (m), 1272 (m), 1174 (s), 1100 (m), 
1031 (m), 826 (w), 777 (w), 696 (w) 
 
MS (CI): m/z (%) = 424 (30), 422 (100) [M + H]+, 159 (20), 113 (25), 101 (10) 
 
MS (EI): m/z (%) = 423 (4), 421 (15) [M]+∙, 335 (10), 267 (15), 240 (100), 219 (25) 
 
HR-MS (EI): calcd. for C22H20ClN5O2 [M]
+∙ 421.1306; found 421.1305 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C22H20ClN5O2 
 
MW: 421.88 g/mol 
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4-[2-(Benzoyloxy)ethyl]-8-chloro-1-methyl-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine (44c) 
 
Benzoic acid anhydride (96 mg, 0.42 mmol, 3.0 equiv) and 8-chloro-4-(2-
hydroxyethyl)-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine 
5 (50 mg, 0.14 mmol, 1.0 equiv) were dissolved in 2 mL of anhydrous 
tetrahydrofuran. Then 0.2 mL of conc. sulfuric acid was added before the mixture 
was heated to reflux for 1 h. Water (5 mL) was added slowly to the vigorously 
stirred solution and the mixture was extracted with dichloromethane (3 x 7 mL). 
The combined organic layers were dried over sodium sulfate, filtered and 
concentrated under reduced pressure. Purification was done by flash column 
chromatography on flash silica gel (ethyl acetate / methanol 9:1, Rf = 0.55), giving 
compound 44c (24 mg, 0.04 mmol, 37 %) as pale yellow solid. 
 
mp: 101.6 – 102.7 °C 
 
1H NMR (400 MHz, CD2Cl2):  (ppm) = 2.53 (s, 3 H, 1-CH3), 4.04 – 4.15 (m, 1 H, 
1’’-HH), 4.20 – 4.33 (m, 1 H, 1’’-HH), 4.54 – 4.66 (m, 1 H, 2’’-HH), 4.73 – 4.86 (m, 
1 H, 2’’-HH), 7.20 (d, 4JHH = 2.4 Hz, 1 H, 7-H), 7.23 (d, 
3JHH = 8.7 Hz, 1 H, 10-H), 
7.33 – 7.43 (m, 4 H, 3’-H, 5’-H, 3’’’-H, 5’’’-H), 7.44 – 7.57 (m, 5 H, 9-H, 2’-H, 4’-H, 
6’-H, 4’’’-H), 7.81 – 7.87 (m, 2 H, 2’’’-H, 6’’’-H)  
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 53.0 (C-1’’), 62.3 (C-2’’), 
124.1 (C-10), 128.6 (C-3’’’, C-5’’’), 128.8 (C-3’, C-5’), 129.6 (C-2’, C-6’), 129.8 (C-
2’’’, C-6’’’), 130.6 (C-1’’’), 130.9 (C-6a), 130.9 (C-4’), 130.9 (C-6a), 131.5 (C-7), 
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131.9 (C-9), 132.8 (C-8), 133.2 (C-4’’’), 133.9 (C-10a), 136.4 (C-1’), 148.5 (C-1), 
160.2 (C-3a), 162.0 (C-6), 166.5 (CO) 
 
IR [cm-1]:    = 3060 (w), 2926 (w), 2363 (w), 1719 (s), 1535 (m), 1520 (m), 
1490 (m), 1449 (m), 1273 (s), 1175 (m), 1102 (m), 1027 (w), 713 (m) 
 
MS (CI): m/z (%) = 460 (30), 458 (100) [M + H]+, 165 (25), 149 (20), 105 (25) 
 
MS (EI): m/z (%) = 457 (8) [M]+∙, 240 (80), 149 (30), 105 (55), 77 (100) 
 
HR-MS (EI): calcd. for C25H20ClN5O2 [M]
+∙ 457.1306; found 457.1306 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C25H20ClN5O2 
 
MW: 457.91 g/mol 
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8-Chloro-1-methyl-6-phenyl-4-{2-[2-(thiophen-2-yl)acetoxy]ethyl}-4H-benzo-
[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (44d) 
 
A 10 mL flask was charged with 5 mL of dichloromethane, 8-chloro-4-(2-
hydroxyethyl)-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine 
5 (150 mg, 0.424 mmol, 1.00 equiv), 2-thiopheneacetic acid (121 mg, 0.848 mmol, 
2.00 equiv), N,N’-dicyclohexylcarbodiimide (192 mg, 0.933 mmol, 2.20 equiv) and 
4-(dimethylamino)pyridine (16 mg, 0.13 mmol, 0.3 equiv). After stirring for 20 h at 
room temperature the solvent was evaporated. Purification was done by flash 
column chromatography on flash silica gel (dichloromethane / methanol 9:1, Rf = 
0.51), giving compound 44d (124 mg, 0.259 mmol, 61 %) as yellow solid. 
 
mp: 78.2 – 80.5 °C 
 
1H NMR (500 MHz, CD2Cl2):  (ppm) = 2.54 (s, 3 H, 1-CH3), 3.71 (d, 
4JHH = 2.9 Hz, 
2 H, 2’’’-H), 3.93 – 4.02 (m, 1 H, 1’’-HH), 4.12 – 4.22 (m, 1 H, 1’’-HH), 4.37 – 4.47 
(m, 1 H, 2’’-HH), 4.56 – 4.66 (m, 1 H, 2’’-HH), 6.75 – 6.79 (m, 1 H, 3’’’’-H), 6.86 
(dd, 3JHH = 3.5 Hz, 
3JHH = 5.2 Hz, 1 H, 4’’’’-H), 7.13 (dd, 
4JHH = 1.2 Hz, 
3JHH = 
5.2 Hz, 1 H, 5’’’’-H), 7.23 (d, 4JHH = 2.4 Hz, 1 H, 7-H), 7.31 (d, 
3JHH = 8.7 Hz, 1 H, 
10-H), 7.37 – 7.43 (m, 2 H, 3’-H, 5’-H), 7.43 – 7.48 (m, 1 H, 4’-H), 7.53 – 7.56 (m, 
2 H, 2’-H, 6’-H), 7.59 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.7 (1-CH3), 35.4 (C-2’’’), 53.1 (C-1’’), 
62.3 (C-2’’), 124.3 (C-10), 125.3 (C-5’’’’), 127.0 (C-4’’’’), 127.0 (C-3’’’’), 128.8 (C-3’, 
C-5’), 129.5 (C-2’, C-6’), 130.7 (C-6a), 130.8 (C-4’), 131.5 (C-7), 132.1 (C-9), 
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132.8 (C-8), 133.7 (C-10a), 135.5 (C-2’’’’), 136.5 (C-1’), 148.6 (C-1), 160.0 (C-3a), 
161.6 (C-6), 170.4 (C-1’’’) 
 
IR [cm-1]:    = 3062 (w), 2957 (w), 2914 (w), 2360 (w), 1736 (s), 1536 (m), 1519 (s), 
1489 (m), 1433 (m), 1320 (m), 1172 (s), 825 (m), 695 (s) 
 
MS (CI): m/z (%) = 480 (40), 478 (100) [M + H]+ 
 
MS (EI): m/z (%) = 479 (10), 477 (35) [M]+∙, 354 (60), 295 (100), 97 (55), 77 (45) 
 
HR-MS (EI): calcd. for C24H20ClN5O2S [M]
+∙ 477.1026; found 477.1022 
 
Elemental analysis calcd. (%) for C24H20ClN5O2S (478.0): C 60.31, H 4.22, 
N 14.65; found C 59.03, H 4.22, N 14.17 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C24H20ClN5O2S 
 
MW: 477.97 g/mol 
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8-Chloro-4-{2-[(ethoxycarbonyl)oxy]ethyl}-1-methyl-6-phenyl-4H-benzo-
[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (44e) 
 
8-Chloro-4-(2-hydroxyethyl)-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo[3,4-c]-
[1,2,4]triazepine 5 (100 mg, 0.283 mmol, 1.00 equiv) was dissolved in 5 mL of 
diethyl carbonate. Sodium hydride (23 mg, 0.57 mmol, 2.0 equiv) was added 
portionwise as a 60 % dispersion in mineral oil to the well stirred solution and the 
mixture was heated for 3 h at 130 °C. The solvent was evaporated and purification 
was done by flash column chromatography on flash silica gel (ethyl acetate / 
methanol 9:1, Rf = 0.55), giving compound 44e (109 mg, 0.256 mmol, 91 %) as 
pale yellow solid. 
 
mp: 81.0 – 82.1 °C 
 
1H NMR (500 MHz, CD2Cl2):  (ppm) = 1.16 (t, 
3JHH = 7.1 Hz, 3 H, 2’’’-H), 2.55 (s, 
3 H, 1-CH3), 3.93 – 4.01 (m, 1 H, 1’’-HH), 4.02 (q, 
3JHH = 7.1 Hz, 2 H, 1’’’-H), 4.11 
– 4.21 (m, 1 H, 1’’-HH), 4.38 – 4.47 (m, 1 H, 2’’-HH), 4.53 – 4.63 (m, 1 H, 2’’-HH), 
7.27 (d, 4JHH = 2.4 Hz, 1 H, 7-H), 7.34 (d, 
3JHH = 8.7 Hz, 1 H, 10-H), 7.39 – 7.44 
(m, 2 H, 3’-H, 5’-H), 7.46 – 7.50 (m, 1 H, 4’-H), 7.54 – 7.58 (m, 2 H, 2’-H, 6’-H), 
7.62 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 14.3 (C-2’’’), 53.4 (C-1’’), 
64.3 (C-1’’’), 65.0 (C-2’’), 124.4 (C-10), 128.8 (C-3’, C-5’), 129.6 (C-2’, C-6’), 130.8 
(C-6a), 130.9 (C-4’), 131.6 (C-7), 132.1 (C-9), 132.9 (C-8), 133.8 (C-10a), 136.5 
(C-1’), 148.6 (C-1), 155.4 (CO), 160.0 (C-3a), 161.8 (C-6) 
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IR [cm-1]:    = 3063 (w), 2982 (w), 2933 (w), 2346 (w), 1745 (s), 1520 (m), 
1490 (m), 1445 (m), 1373 (w), 1320 (w), 1262 (s), 1173 (w), 1103 (w), 1022 (w) 
 
MS (CI): m/z (%) = 428 (35), 426 (100) [M + H]+ 
 
MS (EI): m/z (%) = 427 (4), 425 (15) [M]+∙, 253 (25), 240 (100), 219 (30) 
 
HR-MS (EI): calcd. for C21H20ClN5O3 [M]
+∙ 425.1255; found 425.1254 
 
Elemental analysis calcd. (%) for C21H20ClN5O3 (425.9): C 59.23, H 4.73, 
N 16.44; found C 59.12, H 4.78, N 16.30 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C21H20ClN5O3 
 
MW: 425.87 g/mol 
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8-Chloro-4-{2-[(dimethylcarbamoyl)oxy]ethyl}-1-methyl-6-phenyl-4H-benzo-
[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (44f) 
 
Dimethylcarbamoyl chloride (117 µL, 1.27 mmol, 3.00 equiv) was added to a 
solution of 8-chloro-4-(2-hydroxyethyl)-1-methyl-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 5 (150 mg, 0.424 mmol, 1.00 equiv) in 2 mL of 
anhydrous tetrahydrofuran. Sodium hydride (34 mg, 0.85 mmol, 2.0 equiv) was 
added portionwise as a 60 % dispersion in mineral oil to the well stirred solution. 
After stirring for 18 h at room temperature, the solvent was evaporated and 
purification was done by flash column chromatography on flash silica gel 
(dichloromethane / methanol 9:1, Rf = 0.56), giving compound 44f (124 mg, 
0.292 mmol, 69 %) as pale yellow solid. 
 
mp: 61.0 – 62.3 °C 
 
1H NMR (500 MHz, CD2Cl2):  (ppm) = 2.55 (s, 3 H, 1-CH3), 2.75 (s, 6 H, N(CH3)2), 
3.88 – 4.03 (m, 1 H, 1’’-HH), 4.06 – 4.20 (m, 1 H, 1’’-HH), 4.29 – 4.39 (m, 1 H, 2’’-
HH), 4.39 – 4.51 (m, 1 H, 2’’-HH), 7.26 (d, 4JHH = 2.4 Hz, 1 H, 7-H), 7.33 (d, 
3JHH = 
8.7 Hz, 1 H, 10-H), 7.38 – 7.44 (m, 2 H, 3’-H, 5’-H), 7.45 – 7.50 (m, 1 H, 4’-H), 
7.54 – 7.58 (m, 2 H, 2’-H, 6’-H), 7.61 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 38.8 (N(CH3)2), 53.4 (C-1’’), 
62.7 (C-2’’), 124.3 (C-10), 128.8 (C-3’, C-5’), 129.5 (C-2’, C-6’), 130.8 (C-4’), 130.9 
(C-6a), 131.4 (C-7), 132.0 (C-9), 132.8 (C-8), 133.9 (C-10a), 136.5 (C-1’), 148.5 
(C-1), 156.5 (CO), 160.3 (C-3a), 161.6 (C-6) 
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IR [cm-1]:    = 3062 (w), 2928 (w), 2369 (w), 1703 (s), 1641 (m), 1520 (m), 
1490 (m), 1445 (m), 1379 (m), 1188 (m), 696 (w) 
 
MS (CI): m/z (%) = 427 (10), 425 (30) [M + H]+, 117 (100) 
 
MS (EI): m/z (%) = 424 (5) [M]+∙, 240 (100), 72 (65) 
 
HR-MS (EI): calcd. for C21H21ClN6O2 [M]
+∙ 424.1415; found 424.1413 
 
Elemental analysis calcd. (%) for C21H21ClN6O2 (424.9): C 59.36, H 4.98, 
N 19.78; found C 57.85, H 5.38, N 19.54 
 
HPLC purity: 94 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C21H21ClN6O2 
 
MW: 424.88 g/mol 
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4-{2-[(tert-Butylcarbamoyl)oxy]ethyl}-8-chloro-1-methyl-6-phenyl-4H-benzo-
[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (44g) 
 
tert-Butyl isocyanate (65 µL, 0.57 mmol, 2.0 equiv) was added to a solution of  
8-chloro-4-(2-hydroxyethyl)-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo[3,4-c]-
[1,2,4]triazepine 5 (100 mg, 0.283 mmol, 1.00 equiv) in 2 mL of anhydrous 
tetrahydrofuran. Sodium hydride (17 mg, 0.42 mmol, 1.5 equiv) was added 
portionwise as a 60 % dispersion in mineral oil to the well stirred solution. After 
stirring for 3 h at room temperature, the solvent was evaporated and purification 
was done by flash column chromatography on flash silica gel (ethyl acetate / 
methanol 9:1, Rf = 0.60), giving compound 44g (85 mg, 0.19 mmol, 66 %) as pale 
yellow solid. 
 
mp: 119.6 – 120.0 °C 
 
1H NMR (500 MHz, CD2Cl2):  (ppm) = 1.18 (bs, 9 H, C(CH3)3), 2.54 (s, 3 H, 1-
CH3), 3.85 – 3.96 (m, 1 H, 1’’-HH), 4.00 – 4.14 (m, 1 H, 1’’-HH), 4.21 – 4.36 (m, 
1 H, 2’’-HH), 4.40 – 4.52 (m, 1 H, 2’’-HH), 4.71 (bs, 1 H, NH), 7.25 (d, 4JHH = 
2.4 Hz, 1 H, 7-H), 7.32 (d, 3JHH = 8.7 Hz, 1 H, 10-H), 7.39 – 7.44 (m, 2 H, 3’-H, 5’-
H), 7.45 – 7.50 (m, 1 H, 4’-H), 7.54 – 7.58 (m, 2 H, 2’-H, 6’-H), 7.59 (dd, 4JHH = 
2.4 Hz, 3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 28.9 (C(CH3)3), 50.4 
(C(CH3)3), 53.9 (C-1’’), 61.3 (C-2’’), 124.3 (C-10), 128.8 (C-3’, C-5’), 129.5 (C-2’, 
C-6’), 130.8 (C-4’), 130.9 (C-6a), 131.6 (C-7), 132.0 (C-9), 132.9 (C-8), 133.8 (C-
10a), 136.6 (C-1’), 148.5 (C-1), 154.8 (CO), 160.2 (C-3a), 161.4 (C-6) 
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IR [cm-1]:    = 3061 (w), 2967 (m), 2933 (m), 2371 (w), 2345 (w), 1720 (s), 
1520 (s), 1446 (m), 1267 (s), 1096 (s), 824 (m), 777 (m), 696 (m) 
 
MS (CI): m/z (%) = 455 (40), 453 (100) [M + H]+, 354 (20) 
 
MS (EI): m/z (%) = 452 (3) [M]+∙, 335 (20), 295 (35), 240 (100), 219 (20), 77 (30) 
 
HR-MS (EI): calcd. for C23H25ClN6O2 [M]
+∙ 452.1728; found 452.1730 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H25ClN6O2 
 
MW: 452.94 g/mol 
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8-Chloro-4-{2-[(ethylcarbamothioyl)oxy]ethyl}-1-methyl-6-phenyl-4H-benzo-
[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (44h) 
 
Ethyl isothiocyanate (50 µL, 0.57 mmol, 2.0 equiv) was added to a solution of  
8-chloro-4-(2-hydroxyethyl)-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo[3,4-c]-
[1,2,4]triazepine 5 (100 mg, 0.283 mmol, 1.00 equiv) in 2 mL of anhydrous 
tetrahydrofuran. Sodium hydride (17 mg, 0.42 mmol, 1.5 equiv) was added 
portionwise as a 60 % dispersion in mineral oil to the well stirred solution. After 
stirring for 3 h at room temperature, the solvent was evaporated and purification 
was done by flash column chromatography on flash silica gel (ethyl acetate / 
methanol 9:1, Rf = 0.50), giving compound 44h (106 mg, 0.240 mmol, 85 %) as 
pale yellow solid. 
 
mp: 115.6 – 117.3 °C 
 
1H NMR (500 MHz, CD2Cl2):  (ppm) = 0.89 (t, 
3JHH = 7.3 Hz, 0.37 x 3 H, 2’’’-H), 
1.11 (t, 3JHH = 7.3 Hz, 0.63 x 3 H, 2’’’-H), 2.54 (s, 0.63 x 3 H, 1-CH3), 2.55 (s, 0.37 
x 3 H, 1-CH3), 3.04 – 3.12 (m, 0.37 x 2 H, 1’’’-H), 3.39 – 3.51 (m, 0.63 x 2 H, 1’’’-
H), 3.93 – 4.33 (m, 2 H, 1’’-H), 4.67 – 4.93 (m, 2 H, 2’’-H), 6.58 (bs, 0.63 x 1 H, 
NH), 6.81 (bs, 0.37 x 1 H, NH), 7.26 (d, 4JHH = 2.3 Hz, 1 H, 7-H), 7.31 (d, 
3JHH = 
8.7 Hz, 1 H, 10-H), 7.38 – 7.45 (m, 2 H, 3’-H, 5’-H), 7.45 – 7.51 (m, 1 H, 4’-H), 
7.54 – 7.59 (m, 2 H, 2’-H, 6’-H), 7.60 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.7 (1-CH3), 12.8 (1-CH3), 13.8 (C-2’’’), 
14.2 (C-2’’’), 38.4 (C-1’’’), 40.5 (C-1’’’), 52.8 (C-1’’), 53.4 (C-1’’), 67.2 (C-2’’), 68.6 
(C-2’’), 124.3 (C-10), 128.8 (C-3’, C-5’), 128.9 (C-3’, C-5’), 129.6 (C-2’, C-6’), 
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129.6 (C-2’, C-6’), 130.8 (C-6a), 130.9 (C-4’), 130.9 (C-4’), 131.5 (C-7), 131.7 (C-
7), 132.0 (C-9), 132.8 (C-8), 133.8 (C-10a), 133.9 (C-10a), 136.3 (C-1’), 136.5 (C-
1’), 148.6 (C-1), 160.2 (C-3a), 161.6 (C-6), 161.8 (C-6), 190.0 (CS), 190.3 (CS) 
 
IR [cm-1]:    = 3209 (w), 3056 (w), 2933 (m), 2972 (w), 2932 (w), 1733 (w), 
1536 (s), 1520 (s), 1489 (m), 1432 (m), 1321 (m), 1194 (m), 824 (w), 695 (w) 
 
MS (CI): m/z (%) = 443 (20), 441 (50) [M + H]+, 354 (100) 
 
HR-MS (EI): calcd. for C21H21ClN6OS [M]
+∙ 440.1186; found 440.1186 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C21H21ClN6OS 
 
MW: 440.95 g/mol 
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8-Chloro-4-{2-[((4-chlorophenyl)carbamoyl)oxy]ethyl}-1-methyl-6-phenyl-4H-
benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (44i) 
 
4-Chlorophenyl isocyanate (72 µL, 0.57 mmol, 2.0 equiv) and 8-chloro-4-(2-
hydroxyethyl)-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine 
5 (100 mg, 0.283 mmol, 1.00 equiv) were dissolved in 2 mL of anhydrous 
tetrahydrofuran. Sodium hydride (17 mg, 0.42 mmol, 1.5 equiv) was added 
portionwise as a 60 % dispersion in mineral oil to the well stirred solution. The 
mixture was stirred at room temperature for 18 h. The solvent was evaporated and 
purification was done by flash column chromatography on flash silica gel (ethyl 
acetate / methanol 9:1, Rf = 0.58), giving compound 44i (92 mg, 0.18 mmol, 64 %) 
as pale yellow solid. 
 
mp: 112.8 – 113.9 °C 
 
1H NMR (500 MHz, CD2Cl2):  (ppm) = 2.53 (s, 0.07 x 3 H, 1-CH3), 2.54 (s, 0.93 x 
3 H, 1-CH3), 3.92 – 4.04 (m, 1 H, 1’’-HH), 4.12 – 4.26 (m, 1 H, 1’’-HH), 4.35 – 4.49 
(m, 1 H, 2’’-HH), 4.54 – 4.68 (m, 1 H, 2’’-HH), 7.18 – 7.21 (m, 2 H, 3’’’-H, 5’’’-H), 
7.23 (d, 4JHH = 2.3 Hz, 0.93 x 1 H, 7-H), 7.25 (d, 
3JHH = 8.7 Hz, 0.93 x 1 H, 10-H), 
7.26 – 7.30 (m, 0.07 x 1 H, 7-H, 2 H, 2’’’-H, 6’’’-H), 7.32 (d, 3JHH = 8.7 Hz, 0.07 x 
1 H, 10-H), 7.37 – 7.43 (m, 2 H, 3’-H, 5’-H), 7.44 – 7.52 (m, 2 H, 4’-H, NH), 7.50 
(dd, 4JHH = 2.3 Hz, 
3JHH = 8.7 Hz, 0.93 x 1 H, 9-H), 7.53 – 7.58 (m, 2 H, 2’-H, 6’-H), 
7.61 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 0.07 x 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 53.6 (C-1’’), 62.4 (C-2’’), 
120.1 (C-2’’’, C-6’’’), 124.2 (C-10), 128.1 (C-4’’’), 128.9 (C-3’, C-5’), 129.2 (C-3’’’, 
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C-5’’’), 129.6 (C-2’, C-6’), 130.8 (C-6a), 130.9 (C-4’), 131.6 (C-7), 132.0 (C-9), 
132.9 (C-8), 133.7 (C-10a), 136.5 (C-1’), 137.5 (C-1’’’), 148.6 (C-1), 153.6 (CO), 
160.1 (C-3a), 161.9 (C-6) 
 
IR [cm-1]:    = 3240 (m), 3183 (m), 3054 (m), 2959 (m), 1731 (s), 1599 (m), 
1537 (s), 1520 (s), 1493 (s), 1308 (m), 1221 (s), 1091 (m), 1074 (m), 826 (m), 
695 (m) 
 
MS (CI): m/z (%) = 509 (10), 507 (3) [M + H]+, 396 (20), 354 (60), 154 (90), 128 
(100) 
 
MS (EI): m/z (%) = 506 (2) [M]+∙, 295 (100), 219 (25), 153 (75) 
 
HR-MS (ESI): calcd. for C25H21Cl2N6O2
+ [M + H]+ 507.1098; found 507.1100 
 
HPLC purity: 93 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C25H20Cl2N6O2 
 
MW: 507.37 g/mol 
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8-Chloro-1-methyl-4-{2-[((4-nitrophenyl)carbamoyl)oxy]ethyl}-6-phenyl-4H-
benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (44j) 
 
4-Nitrophenyl isocyanate (46 µL, 0.34 mmol, 1.2 equiv) and 8-chloro-4-(2-
hydroxyethyl)-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine 
5 (100 mg, 0.283 mmol, 1.00 equiv) were dissolved in 2 mL of anhydrous 
tetrahydrofuran. Sodium hydride (17 mg, 0.42 mmol, 1.5 equiv) was added 
portionwise as a 60 % dispersion in mineral oil to the well stirred solution. The 
mixture was stirred at room temperature for 3 h. The solvent was evaporated and 
purification was done by flash column chromatography on flash silica gel (ethyl 
acetate / methanol 9:1, Rf = 0.53), giving compound 44j (53 mg, 0.10 mmol, 36 %) 
as yellow solid. 
 
mp: 153.2 – 155.6 °C 
 
1H NMR (500 MHz, CD2Cl2):  (ppm) = 2.54 (s, 0.92 x 3 H, 1-CH3), 2.55 (s, 0.08 x 
3 H, 1-CH3), 3.95 – 4.08 (m, 1 H, 1’’-HH), 4.16 – 4.31 (m, 1 H, 1’’-HH), 4.36 – 4.51 
(m, 1 H, 2’’-HH), 4.64 – 4.77 (m, 1 H, 2’’-HH), 7.25 (d, 4JHH = 2.4 Hz, 0.92 x 1 H, 7-
H), 7.26 (d, 3JHH = 8.7 Hz, 0.92 x 1 H, 10-H), 7.27 (d, 
4JHH = 2.4 Hz, 0.08 x 1 H, 7-
H), 7.33 (d, 3JHH = 8.7 Hz, 0.08 x 1 H, 10-H), 7.38 – 7.44 (m, 2 H, 3’-H, 5’-H), 7.45 
– 7.50 (m, 2 H, 9-H, 4’-H), 7.54 (d, 3JHH = 9.2 Hz, 0.92 x 2 H, 2’’’-H, 6’’’-H), 7.55 – 
7.58 (m, 2 H, 2’-H, 6’-H), 7.62 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 0.08 x 1 H, 9-H), 
7.74 (d, 3JHH = 9.2 Hz, 0.08 x 2 H, 2’’’-H, 6’’’-H), 8.10 (d, 
3JHH = 9.2 Hz, 0.08 x 2 H, 
3’’’-H, 5’’’-H), 8.15 (d, 3JHH = 9.2 Hz, 0.92 x 2 H, 3’’’-H, 5’’’-H), 8.42 (bs, 0.92 x 1 H, 
NH), 9.67 (bs, 0.08 x 1 H, NH) 
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13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 53.5 (C-1’’), 62.8 (C-2’’), 
118.1 (C-2’’’, C-6’’’), 124.3 (C-10), 125.3 (C-3’’’, C-5’’’), 128.9 (C-3’, C-5’), 129.6 
(C-2’, C-6’), 130.8 (C-6a), 131.0 (C-4’), 131.7 (C-7), 132.1 (C-9), 133.0 (C-8), 
133.6 (C-10a), 136.3 (C-1’), 143.0 (C-4’’’), 145.1 (C-1’’’), 148.8 (C-1), 153.3 (CO), 
160.1 (C-3a), 162.3 (C-6) 
 
IR [cm-1]:    = 3248 (w), 3150 (w), 3046 (w), 2924 (w), 1736 (m), 1598 (m), 
1540 (m), 1508 (s), 1435 (m), 1331 (s), 1305 (m), 1216 (s), 1176 (m), 1110 (m), 
1071 (m), 854 (m), 694 (m) 
 
MS (ESI): m/z = 520, 518 [M + H]+, 433, 396, 299 
 
HR-MS (ESI): calcd. for C25H21ClN7O4
+ [M + H]+ 518.1338; found 518.1339 
 
HPLC purity: 95 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C25H20ClN7O4 
 
MW: 517.92 g/mol 
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(4-Methoxybenzyl)hydrazine hydrochloride (48) 
(Literature known compound but different procedure
178
) 
 
tert-Butoxycarbonyl hydrazide 46 (2.5 g, 19 mmol, 1.0 equiv) and 4-
methoxybenzaldehyde 45 (2.3 mL, 19 mmol, 1 equiv) were dissolved in ethanol 
(50 mL) and heated to reflux for 1 h. Reaction progress was monitored by TLC 
(ethyl acetate / isohexane 1:1, Rf = 0.53). The solvent was evaporated and the 
colorless solid was re-dissolved in tetrahydrofuran (10 mL), then treated with a 
solution of BH3 x SMe2 in tetrahydrofuran (2.0 M, 9.9 mL, 1.1 equiv) under cooling 
with an ice bath. After complete addition, the ice bath was removed and the 
solution was stirred for 15 min at room temperature. Then concentrated 
hydrochloric acid (4.8 mL, 3.0 equiv) was added dropwise at room temperature 
and the mixture was stirred subsequently at 60 °C for 10 min to complete the 
deprotection of the boc-group. The reaction mixture was evaporated, 
tetrahydrofuran was added and the colorless precipitate was filtered off. Product 
48 (3.51 g, 18.6 mmol, 98 %) was yielded as colorless hydrochloride. 
 
1H NMR (400 MHz, MeOD):  (ppm) = 3.81 (s, 3 H, OCH3), 4.15 (s, 2 H, CH2), 
6.97 (d, 3JHH = 8.6 Hz, 2 H, 3-H, 5-H), 7.40 (d, 
3JHH = 8.5 Hz, 2 H, 2-H, 6-H) 
 
13C NMR (100 MHz, MeOD):  (ppm) = 56.0 (OCH3), 56.2 (CH2), 115.6 (C-3, C-5), 
124.6 (C-1), 132.7 (C-2, C-6), 162.1 (C-4) 
 
MS (CI): m/z (%) = 153 (35) [M + H]+, 136 (75), 121 (100) 
 
MF: C8H13ClN2O   (C8H12N2O) 
 
MW: 188.65 g/mol  (152.19 g/mol) 
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7-Chloro-3-(4-methoxybenzyl)-5-phenyl-1H-benzo[e][1,2,4]triazepine-2(3H)-
thione (50) 
(Literature known compound but different procedure
110
) 
 
(4-Methoxybenzyl)hydrazine hydrochloride 48 (569 mg, 3.01 mmol, 1.10 equiv) 
was dissolved in 15 mL of methanol, cooled to 0 °C and treated with N,N-
diisopropylethylamine (563 µL, 3.29 mmol, 1.20 equiv). After stirring for 30 min at 
room temperature, a solution of (5-chloro-2-isothiocyanatophenyl)(phenyl)- 
methanone 6 (750 mg, 2.74 mmol, 1.00 equiv) in 8 mL of tetrahydrofuran was 
added and stirring was continued for 1 h. The mixture was concentrated under 
reduced pressure, the residue dissolved in ethanol (12 mL), treated with a catalytic 
amount of para-toluenesulfonic acid monohydrate (13 mg, 68 µmol, 2.5 mol%) and 
heated to reflux for 1 h. The solvent was evaporated and purification was done by 
flash column chromatography on flash silica gel (dichloromethane, Rf = 0.56), 
giving compound 50 (751 mg, 1.84 mmol, 67 %) as pale yellow solid. 
 
1H NMR (500 MHz, CDCl3):  (ppm) = 3.79 (s, 3 H, OCH3), 5.28 (s, 2 H, 1’’-H), 
6.83 – 6.88 (m, 2 H, 3’’’-H, 5’’’-H), 6.93 (d, 3JHH = 8.4 Hz, 1 H, 9-H), 6.93 (d, 
4JHH = 
2.6 Hz, 1 H, 6-H), 7.22 – 7.29 (m, 4 H, 3’-H, 5’-H, 2’’’-H, 6’’’-H), 7.32 – 7.37 (m, 
2 H, 2’-H, 6’-H), 7.38 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.6 Hz, 1 H, 8-H), 7.42 – 7.47 (m, 
1 H, 4’-H), 7.73 (bs, 1 H, 1-H) 
 
13C NMR (125 MHz, CDCl3):  (ppm) = 55.2 (OCH3), 59.4 (C-1’’), 113.8 (C-3’’’, C-
5’’’), 121.7 (C-9), 127.4 (C-5a), 128.5 (C-3’, C-5’), 128.6 (C-1’’’), 129.3 (C-2’, C-6’), 
129.5 (C-7), 130.1 (C-2’’’, C-6’’’), 130.1 (C-6), 131.0 (C-4’), 132.7 (C-8), 135.6 (C-
1’), 142.8 (C-9a), 158.9 (C-4’’’), 166.7 (C-5), 192.1 (C-2) 
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MS (CI): m/z (%) = 410 (20), 408 (30) [M + H]+, 376 (10), 300 (10), 158 (10), 136 
(20), 121 (100) 
 
MF: C22H18ClN3OS 
 
MW: 407.92 g/mol 
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8-Chloro-4-(4-methoxybenzyl)-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo 
[3,4-c][1,2,4]triazepine (51) 
(Literature known compound but different procedure
110
) 
 
Synthesis of the triazole-ring followed GP3. 7-Chloro-3-(4-methoxybenzyl)-5-
phenyl-1H-benzo[e][1,2,4]triazepine-2(3H)-thione 50 (375 mg, 0.919 mmol, 
1.00 equiv) was treated first with hydrazine hydrate (223 µL, 4.60 mmol, 
5.00 equiv). Triethyl orthoacetate 43 (218 µL, 1.20 mmol, 1.30 equiv) and para-
toluenesulfonic acid monohydrate (35 mg, 0.18 mmol, 0.20 equiv) were used in 
the second step. Product 51 (285 mg, 0.663 mmol, 72 %) was obtained after 
purification (Rf = 0.37) as pale yellow solid. 
 
mp: 118.1 °C (Lit. 116 – 118 °C)110 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.54 (s, 3 H, 1-CH3), 3.77 (s, 3 H, OCH3), 
4.81 (d, 2JHH = 13.4 Hz, 1 H, 1’’-HH), 5.02 (d, 
2JHH = 13.5 Hz, 1 H, 1’’-HH), 6.83 – 
6.88 (m, 2 H, 3’’’-H, 5’’’-H), 7.21 (d, 4JHH = 2.4 Hz, 1 H, 7-H), 7.31 (d, 
3JHH = 8.7 Hz, 
1 H, 10-H), 7.32 – 7.47 (m, 7 H, 2’-H, 3’-H, 4’-H, 5’-H, 6’-H, 2’’’-H, 6’’’-H), 7.59 (dd, 
4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 55.6 (OCH3), 57.6 (C-1’’), 
113.9 (C-3’’’, C-5’’’), 124.3 (C-10), 128.8 (C-3’, C-5’), 129.5 (C-2’, C-6’), 129.7 (C-
1’’’), 130.7 (C-4’), 130.8 (C-6a), 131.0 (C-2’’’, C-6’’’), 131.5 (C-7), 132.0 (C-9), 
132.8 (C-8), 133.9 (C-10a), 136.6 (C-1’), 148.5 (C-1), 159.4 (C-4’’’), 160.3 (C-3a), 
161.1 (C-6) 
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IR [cm-1]:    = 3060 (w), 2924 (w), 2833 (w), 1612 (m), 1514 (s), 1489 (m), 
1438 (m), 1320 (m), 1250 (m), 1173 (m), 1102 (m), 1032 (m), 822 (m), 697 (m) 
 
MS (CI): m/z (%) = 432 (35), 430 (100) [M + H]+, 121 (30) 
 
MS (EI): m/z (%) = 431 (8), 429 (20) [M]+∙, 121 (100) 
 
HR-MS (EI): calcd. for C24H20ClN5O [M]
+∙ 429.1356; found 429.1364 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C24H20ClN5O 
 
MW: 429.90 g/mol 
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4-[4-(tert-Butyl)benzyl]-8-chloro-1-methyl-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine (53) 
 
Following GP4, N-alkylation of 8-chloro-1-methyl-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 11 (80 mg, 0.26 mmol, 1.0 equiv) was carried out 
using 4-(tert-butyl)benzyl bromide 54 (143 µL, 0.778 mmol, 3.00 equiv) and 
sodium hydride (11 mg, 0.28 mmol, 1.1 equiv). After purification (Rf = 0.55), 
product 53 (50 mg, 0.11 mmol, 42 %) was obtained as pale yellow solid. 
 
mp: 111.3 – 111.8 °C 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 1.30 (s, 9 H, C(CH3)3), 2.54 (s, 3 H, 1-CH3), 
4.84 (d, 2JHH = 13.6 Hz, 1 H, 1’’-HH), 5.09 (d, 
2JHH = 13.6 Hz, 1 H, 1’’-HH), 7.23 (d, 
4JHH = 2.4 Hz, 1 H, 7-H), 7.31 (d, 
3JHH = 8.7 Hz, 1 H, 10-H), 7.33 – 7.35 (m, 4 H, 
2’’’-H, 3’’’-H, 5’’’-H, 6’’’-H), 7.35 – 7.40 (m, 2 H, 3’-H, 5’-H), 7.42 – 7.47 (m, 3 H, 2’-
H, 4’-H, 6’-H), 7.60 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 31.5 (C(CH3)3), 34.8 
(C(CH3)3), 57.9 (C-1’’), 124.3 (C-10), 125.6 (C-3’’’, C-5’’’), 128.8 (C-3’, C-5’), 129.3 
(C-2’’’, C-6’’’), 129.5 (C-2’, C-6’), 130.7 (C-4’), 130.8 (C-6a), 131.5 (C-7), 132.1 (C-
9), 132.9 (C-8), 133.9 (C-10a), 134.7 (C-1’’’), 136.4 (C-1’), 148.5 (C-1), 150.7 (C-
4’’’), 160.4 (C-3a), 161.1 (C-6) 
 
IR [cm-1]:    = 3059 (w), 2961 (m), 2866 (w), 1535 (m), 1518 (s), 1489 (m), 
1445 (m), 1431 (m), 1319 (m), 1270 (m), 1171 (w), 1107 (w), 1031 (w), 826 (m), 
695 (m) 
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MS (CI): m/z (%) = 458 (30), 456 (100) [M + H]+, 190 (20), 147 (70), 132 (20) 
 
MS (EI): m/z (%) = 457 (3), 455 (10) [M]+∙, 427 (10), 295 (15), 147 (100), 132 (20), 
117 (25), 105 (20), 77 (20) 
 
HR-MS (EI): calcd. for C27H26ClN5 [M]
+∙ 455.1877; found 455.1877 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C27H26ClN5 
 
MW: 455.98 g/mol 
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8-Chloro-4-(4-iodobenzyl)-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo- 
[3,4-c][1,2,4]triazepine (56a) 
 
Following GP4, N-alkylation of 8-chloro-1-methyl-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 11 (80 mg, 0.26 mmol, 1.0 equiv) was carried out 
using 4-iodobenzyl bromide 55a (248 µL, 0.775 mmol, 3.00 equiv) and sodium 
hydride (11 mg, 0.28 mmol, 1.1 equiv). After purification (Rf = 0.60), product 56a 
(104 mg, 0.198 mmol, 77 %) was obtained as pale yellow solid. 
 
mp: 175.2 – 176.1 °C 
 
1H NMR (400 MHz, CD2Cl2)  (ppm) = 2.55 (s, 3 H, 1-CH3), 4.82 (d, 
2JHH = 
13.8 Hz, 1 H, 1’’-HH), 5.03 (d, 2JHH = 13.8 Hz, 1 H, 1’’-HH), 7.18 (d, 
3JHH = 8.4 Hz, 
2 H, 2’’’-H, 6’’’-H), 7.22 (d, 4JHH = 2.3 Hz, 1 H, 7-H), 7.32 (d, 
3JHH = 8.7 Hz, 1 H, 10-
H), 7.34 – 7.42 (m, 4 H, 2’-H, 3’-H, 5’-H, 6’-H), 7.42 – 7.48 (m, 1 H, 4’-H), 7.61 (dd, 
4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H), 7.66 (d, 
3JHH = 8.4 Hz, 2 H, 3’’’-H, 5’’’-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 57.6 (C-1’’), 93.1 (C-4’’’), 
124.3 (C-10), 128.8 (C-3’, C-5’), 129.5 (C-2’, C-6’), 130.7 (C-6a), 130.9 (C-4’), 
131.5 (C-7), 131.6 (C-2’’’, C-6’’’), 132.2 (C-9), 132.9 (C-8), 133.8 (C-10a), 136.4 
(C-1’), 137.6 (C-1’’’), 137.8 (C-3’’’, C-5’’’), 148.6 (C-1), 160.1 (C-3a), 161.5 (C-6) 
 
IR [cm-1]:    = 3059 (w), 2924 (w), 2362 (w), 1734 (w), 1637 (w), 1535 (m), 
1519 (s), 1487 (m), 1444 (m), 1431 (m), 1345 (m), 1319 (m), 1272 (w), 1171 (w), 
1008 (m), 825 (m), 695 (m) 
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MS (CI): m/z (%) = 528 (35), 526 (100) [M + H]+, 217 (15), 124 (20) 
 
MS (EI): m/z (%) = 527 (8), 525 (25) [M]+∙, 497 (35), 295 (65), 280 (70), 239 (20), 
217 (75), 90 (70), 77 (100) 
 
HR-MS (EI): calcd. for C23H17ClIN5 [M]
+∙ 525.0217; found 525.0215 
 
HPLC purity: 95 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H17ClIN5 
 
MW: 525.77 g/mol 
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8-Chloro-1-methyl-4-(4-nitrobenzyl)-6-phenyl-4H-benzo[e][1,2,4]triazolo- 
[3,4-c][1,2,4]triazepine (56b) 
 
Following GP4, N-alkylation of 8-chloro-1-methyl-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 11 (80 mg, 0.26 mmol, 1.0 equiv) was carried out 
using 4-nitrobenzyl bromide 55b (168 mg, 0.778 mmol, 3.00 equiv) and sodium 
hydride (11 mg, 0.28 mmol, 1.1 equiv). After purification (Rf = 0.58), product 56b 
(50 mg, 0.11 mmol, 43 %) was obtained as dark yellow solid. 
 
mp: 93.0 °C (decomposition) 
 
1H NMR (400 MHz, CD2Cl2)  (ppm) = 2.57 (s, 3 H, 1-CH3), 5.01 (d, 
2JHH = 
14.5 Hz, 1 H, 1’’-HH), 5.19 (d, 2JHH = 14.4 Hz, 1 H, 1’’-HH), 7.25 (d, 
4JHH = 2.3 Hz, 
1 H, 7-H), 7.35 (d, 3JHH = 8.6 Hz, 1 H, 10-H), 7.36 – 7.38 (m, 4 H, 2’-H, 3’-H, 5’-H, 
6’-H), 7.42 – 7.48 (m, 1 H, 4’-H), 7.56 – 7.61 (m, 2 H, 2’’’-H, 6’’’-H), 7.65 (dd, 4JHH = 
2.4 Hz, 3JHH = 8.7 Hz, 1 H, 9-H), 8.15 – 8.20 (m, 2 H, 3’’’-H, 5’’’-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 57.4 (C-1’’), 123.9 (C-3’’’, C-
5’’’), 124.4 (C-10), 128.9 (C-3’, C-5’), 129.5 (C-2’, C-6’), 130.2 (C-2’’’, C-6’’’), 130.6 
(C-6a), 131.0 (C-4’), 131.6 (C-7), 132.4 (C-9), 133.1 (C-8), 133.7 (C-10a), 136.3 
(C-1’), 145.4 (C-1’’’), 147.7 (C-4’’’), 148.9 (C-1), 160.0 (C-3a), 162.0 (C-6) 
 
IR [cm-1]:    = 3060 (w), 2923 (w), 2852 (w), 1602 (w), 1519 (s), 1489 (m), 
1432 (w), 1344 (s), 1321 (m), 1170 (w), 1108 (w), 1066 (w), 831 (w), 738 (w), 
696 (w) 
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MS (CI): m/z (%) = 447 (35), 445 (100) [M + H]+, 415 (20), 154 (100) 
 
MS (EI): m/z (%) = 444 (5) [M]+∙, 416 (10), 295 (15), 219 (10), 106 (100), 77 (50), 
51 (20) 
 
HR-MS (EI): calcd. for C23H17ClN6O2 [M]
+∙ 444.1102; found 444.1082 
 
HPLC purity: 96 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H17ClN6O2 
 
MW: 444.87 g/mol 
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8-Chloro-1-methyl-6-phenyl-4-[4-(trifluoromethyl)benzyl]-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine (56c) 
 
Following GP4, N-alkylation of 8-chloro-1-methyl-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 11 (80 mg, 0.26 mmol, 1.0 equiv) was carried out 
using 4-(trifluoromethyl)benzyl bromide 55c (120 µL, 0.778 mmol, 3.00 equiv) and 
sodium hydride (11 mg, 0.28 mmol, 1.1 equiv). After purification (Rf = 0.51), 
product 56c (104 mg, 0.222 mmol, 86 %) was obtained as pale yellow solid. 
 
mp: 107.4 – 108.6 °C 
 
1H NMR (400 MHz, CD2Cl2)  (ppm) = 2.56 (s, 3 H, 1-CH3), 4.96 (d, 
2JHH = 
14.2 Hz, 1 H, 1’’-HH), 5.17 (d, 2JHH = 14.1 Hz, 1 H, 1’’-HH), 7.24 (d, 
4JHH = 2.4 Hz, 
1 H, 7-H), 7.34 (d, 3JHH = 8.7 Hz, 1 H, 10-H), 7.34 – 7.48 (m, 5 H, 2’-H, 3’-H, 4’-H, 
5’-H, 6’-H), 7.55 (d, 3JHH = 8.2 Hz, 2 H, 2’’’-H, 6’’’-H), 7.59 (d, 
3JHH = 8.3 Hz, 2 H, 
3’’’-H, 5’’’-H), 7.63 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 57.6 (C-1’’), 124.3 (C-10), 
124.8 (q, 1JCF = 271.8 Hz, CF3), 125.5 (q, 
3JCF = 3.9 Hz, C-3’’’, C-5’’’), 128.8 (C-3’, 
C-5’), 129.5 (C-2’, C-6’), 129.6 (q, 2JCF = 32.0 Hz, C-4’’’), 129.8 (C-2’’’, C-6’’’), 
130.7 (C-6a), 130.9 (C-4’), 131.6 (C-7), 132.2 (C-9), 133.0 (C-8), 133.8 (C-10a), 
136.4 (C-1’), 142.1 (q, 5JCF = 1.3 Hz, C-1’’’), 148.7 (C-1), 160.1 (C-3a), 161.7 (C-6) 
 
IR [cm-1]:    = 3063 (w), 2926 (w), 1618 (m), 1535 (m), 1519 (m), 1490 (m), 
1437 (m), 1325 (s), 1165 (m), 1123 (m), 1066 (m), 1019 (m), 824 (m), 695 (m) 
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MS (CI): m/z (%) = 470 (35), 468 (100) [M + H]+, 159 (20), 107 (35) 
 
MS (EI): m/z (%) = 469 (8), 467 (20) [M]+∙, 439 (35), 295 (30), 280 (20), 253 (15), 
239 (15), 219 (25), 159 (30), 109 (20), 77 (100), 51 (20) 
 
HR-MS (EI): calcd. for C24H17ClF3N5 [M]
+∙ 467.1125; found 467.1131 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C24H17ClF3N5 
 
MW: 467.87 g/mol 
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8-Chloro-4-(3-chlorobenzyl)-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo-
[3,4-c][1,2,4]triazepine (56d) 
 
Following GP4, N-alkylation of 8-chloro-1-methyl-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 11 (80 mg, 0.26 mmol, 1.0 equiv) was carried out 
using 3-chlorobenzyl bromide 55d (102 µL, 0.778 mmol, 3.00 equiv) and sodium 
hydride (11 mg, 0.28 mmol, 1.1 equiv). After purification (Rf = 0.51), product 56d 
(78 mg, 0.18 mmol, 70 %) was obtained as pale yellow solid. 
 
mp: 104.5 – 105.8 °C 
 
1H NMR (400 MHz, CD2Cl2)  (ppm) = 2.55 (s, 3 H, 1-CH3), 4.85 (d, 
2JHH = 
13.8 Hz, 1 H, 1’’-HH), 5.08 (d, 2JHH = 13.7 Hz, 1 H, 1’’-HH), 7.23 (d, 
4JHH = 2.4 Hz, 
1 H, 7-H), 7.25 – 7.27 (m, 1 H, 4’’’-H), 7.28 (td, 5JHH = 0.6 Hz, 
3JHH = 7.8 Hz, 1 H, 
5’’’-H), 7.31 (d, 3JHH = 8.8 Hz, 1 H, 10-H), 7.31 – 7.34 (m, 1 H, 2’’’-H), 7.34 – 7.43 
(m, 5 H, 2’-H, 3’-H, 5’-H, 6’-H, 6’’’-H), 7.43 – 7.48 (m, 1 H, 4’-H), 7.62 (dd, 4JHH = 
2.4 Hz, 3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 57.6 (C-1’’), 124.3 (C-10), 
127.8 (C-5’’’), 127.9 (C-2’’’), 128.8 (C-3’, C-5’), 129.5 (C-2’, C-6’), 129.7 (C-6’’’), 
130.0 (C-4’’’), 130.7 (C-6a), 130.9 (C-4’), 131.6 (C-7), 132.2 (C-9), 133.0 (C-8), 
133.8 (C-10a), 134.3 (C-3’’’), 136.5 (C-1’), 139.9 (C-1’’’), 148.7 (C-1), 160.1 (C-
3a), 161.5 (C-6) 
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IR [cm-1]:    = 3058 (w), 2923 (w), 2361 (m), 2342 (m), 1598 (m), 1576 (m), 
1535 (m), 1518 (s), 1488 (m), 1429 (m), 1344 (m), 1319 (m), 1171 (m), 1031 (m), 
832 (m), 775 (m), 694 (m) 
 
MS (CI): m/z (%) = 438 (20), 436 (75), 434 (100) [M + H]+, 255 (10), 230 (25), 125 
(35) 
 
MS (EI): m/z (%) = 437 (2), 435 (10), 433 (20) [M]+∙, 405 (30), 295 (40), 208 (35), 
219 (30), 125 (40), 77 (100), 51 (25) 
 
HR-MS (EI): calcd. for C23H17Cl2N5 [M]
+∙ 433.0861; found 433.0860 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H17Cl2N5 
 
MW: 434.32 g/mol 
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4-(2-Bromobenzyl)-8-chloro-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo-
[3,4-c][1,2,4]triazepine (56e) 
 
Following GP4, N-alkylation of 8-chloro-1-methyl-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 11 (80 mg, 0.26 mmol, 1.0 equiv) was carried out 
using 2-bromobenzyl bromide 55e (194 mg, 0.778 mmol, 3.00 equiv) and sodium 
hydride (11 mg, 0.28 mmol, 1.1 equiv). After purification (Rf = 0.66), product 56e 
(76 mg, 0.16 mmol, 61 %) was obtained as pale yellow solid. 
 
mp: 215.2 °C 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.56 (s, 3 H, 1-CH3), 5.00 (d, 
2JHH = 
14.2 Hz, 1 H, 1’’-HH), 5.23 (d, 2JHH = 14.1 Hz, 1 H, 1’’-HH), 7.15 (td, 
4JHH = 1.7 Hz, 
3JHH = 7.7 Hz, 1 H, 4’’’-H), 7.23 (d, 
4JHH = 2.4 Hz, 1 H, 7-H), 7.28 (td, 
4JHH = 1.2 Hz, 
3JHH = 7.5 Hz, 1 H, 5’’’-H), 7.33 (d, 
3JHH = 8.7 Hz, 1 H, 10-H), 7.35 – 7.39 (m, 2 H, 
3’-H, 5’-H), 7.41 – 7.47 (m, 4 H, 2’-H, 4’-H, 6’-H, 6’’’-H), 7.56 (dd, 4JHH = 1.2 Hz, 
3JHH = 8.0 Hz, 1 H, 3’’’-H), 7.61 (dd, 
4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.9 (1-CH3), 58.1 (CH2), 124.3 (C-10), 
124.9 (C-2’’’), 127.6 (C-5’’’), 128.8 (C-3’, C-5’), 129.3 (C-4’’’), 129.5 (C-2’, C-6’), 
130.7 (C-6a), 130.8 (C-4’), 131.5 (C-7), 131.6 (C-6’’’), 132.2 (C-9), 132.9 (C-8), 
133.1 (C-3’’’), 133.9 (C-10a), 136.5 (C-1’), 137.0 (C-1’’’), 148.7 (C-1), 160.2 (C-
3a), 161.6 (C-6) 
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IR [cm-1]:    = 3062 (w), 2927 (w), 2360 (m), 2341 (m), 1635 (m), 1537 (m), 
1520 (s), 1489 (m), 1439 (m), 1381 (m), 1346 (m), 1319 (m), 1272 (m), 1170 (m), 
1101 (m), 1027 (m), 829 (m), 744 (m), 696 (m) 
 
 
MS (CI): m/z (%) = 482 (25), 480 (95), 478 (65) [M + H]+, 400 (10), 283 (10), 255 
(15), 230 (10), 182 (10), 171 (15), 124 (30), 107 (100) 
 
MS (EI): m/z (%) = 481 (1), 479 (5), 477 (4) [M]+∙, 451 (15), 398 (70), 382 (20), 280 
(10), 219 (10), 169 (15), 77 (100), 51 (30) 
 
HR-MS (EI): calcd. for C23H17BrClN5 [M]
+∙ 477.0356; found 477.0352 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H17BrClN5 
 
MW: 478.77 g/mol 
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8-Chloro-1-methyl-4-(2-methylbenzyl)-6-phenyl-4H-benzo[e][1,2,4]triazolo-
[3,4-c][1,2,4]triazepine (58a) 
 
Following GP5, N-alkylation of 8-chloro-1-methyl-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 11 (80 mg, 0.26 mmol, 1.0 equiv) was carried out 
using 2-methylbenzyl chloride 57a (102 µL, 0.778 mmol, 3.00 equiv) and sodium 
hydride (11 mg, 0.28 mmol, 1.1 equiv). After purification (Rf = 0.52), product 58a 
(79 mg, 0.19 mmol, 74 %) was obtained as pale yellow solid. 
 
mp: 236.5 – 238.2 °C 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.30 (s, 3 H, 2’’’-CH3), 2.55 (s, 3 H, 1-CH3), 
4.88 (d, 2JHH = 13.8 Hz, 1 H, 1’’-HH), 5.13 (d, 
2JHH = 13.9 Hz, 1 H, 1’’-HH), 7.12 – 
7.19 (m, 3 H, 3’’’-H, 4’’’-H, 5’’’-H), 7.21 (d, 4JHH = 2.4 Hz, 1 H, 7-H), 7.31 (d, 
3JHH = 
8.7 Hz, 1 H, 10-H), 7.34 – 7.42 (m, 5 H, 2’-H, 3’-H, 5’-H, 6’-H, 6’’’-H), 7.42 – 7.46 
(m, 1 H, 4’-H), 7.59 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 19.6 (2’’’-CH3), 56.2 (C-1’’), 
124.3 (C-10), 126.0 (C-5’’’), 127.8 (C-4’’’), 128.8 (C-3’, C-5’), 129.5 (C-2’, C-6’), 
130.5 (C-3’’’), 130.6 (C-6’’’), 130.7 (C-6a), 130.7 (C-4’), 131.5 (C-7), 132.1 (C-9), 
132.8 (C-8), 133.9 (C-10a), 135.7 (C-2’’’), 136.6 (C-1’), 137.9 (C-1’’’), 148.6 (C-1), 
160.4 (C-3a), 161.2 (C-6) 
 
IR [cm-1]:    = 3060 (w), 3023 (w), 2924 (w), 2361 (w), 2343 (w), 1595 (w), 
1560 (w), 1535 (m), 1518 (s), 1489 (m), 1445 (m), 1430 (m), 1379 (w), 1344 (m), 
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1319 (m), 1272 (w), 1171 (w), 1099 (w), 1030 (w), 830 (w), 775 (w), 742 (m), 
695 (m) 
 
MS (CI): m/z (%) = 416 (55), 414 (100) [M + H]+, 255 (10), 190 (5), 176 (5), 105 
(30) 
 
MS (EI): m/z (%) = 413 (5) [M]+∙, 397 (10), 385 (15), 295 (15), 281 (20), 105 (100), 
77 (60), 51 (15) 
 
HR-MS (EI): calcd. for C24H20ClN5 [M]
+∙ 413.1407; found 413.1406 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C24H20ClN5 
 
MW: 413.90 g/mol 
209 
 
CHAPTER VI   –   Experimental section 
 
 
 
 
 
8-Chloro-4-(3,4-dichlorobenzyl)-1-methyl-6-phenyl-4H-benzo[e][1,2,4]triazolo-
[3,4-c][1,2,4]triazepine (58b) 
 
Following GP5, N-alkylation of 8-chloro-1-methyl-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 11 (80 mg, 0.26 mmol, 1.0 equiv) was carried out 
using 3,4-dichlorobenzyl chloride 57b (107 µL, 0.778 mmol, 3.00 equiv) and 
sodium hydride (11 mg, 0.28 mmol, 1.1 equiv). After purification (Rf = 0.62), 
product 58b (87 mg, 0.19 mmol, 72 %) was obtained as pale yellow solid. 
 
mp: 166.5 – 167.8 °C 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.55 (s, 3 H, 1-CH3), 4.83 (d, 
2JHH = 
13.6 Hz, 1 H, 1’’-HH), 5.04 (d, 2JHH = 13.6 Hz, 1 H, 1’’-HH), 7.23 (d, 
4JHH = 2.4 Hz, 
1 H, 7-H), 7.28 (dd, 4JHH = 2.0 Hz, 
3JHH = 8.2 Hz, 1 H, 6’’’-H), 7.32 (d, 
3JHH = 
8.7 Hz, 1 H, 10-H), 7.35 – 7.41 (m, 4 H, 2’-H, 3’-H, 5’-H, 6’-H), 7.41 (d, 3JHH = 
8.3 Hz, 1 H, 5’’’-H), 7.43 – 7.48 (m, 1 H, 4’-H), 7.53 (d, 4JHH = 2.0 Hz, 1 H, 2’’’-H), 
7.62 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 57.1 (C-1’’), 124.3 (C-10), 
128.9 (C-3’, C-5’), 129.3 (C-6’’’), 129.5 (C-2’, C-6’), 130.6 (C-5’’’), 130.6 (C-6a), 
130.9 (C-4’), 131.5 (C-4’’’), 131.6 (C-7), 131.6 (C-2’’’), 132.3 (C-9), 132.4 (C-3’’’), 
133.0 (C-8), 133.7 (C-10a), 136.4 (C-1’), 138.2 (C-1’’’), 148.8 (C-1), 160.0 (C-3a), 
161.7 (C-6) 
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IR [cm-1]:    = 3060 (w), 2925 (w), 2366 (w), 1637 (w), 1561 (m), 1535 (m), 
1518 (s), 1489 (m), 1472 (m), 1432 (m), 1398 (m), 1380 (m), 1345 (m), 1319 (m), 
1271 (w), 1171 (w), 1133 (w), 1101 (w), 1131 (m), 821 (m), 694 (m) 
 
MS (CI): m/z (%) = 474 (8), 472 (35), 470 (100), 468 (100) [M + H]+, 280 (10), 255 
(6), 176 (5), 159 (20), 124 (75), 107 (55), 101 (7) 
 
MS (EI): m/z (%) = 471 (3), 469 (10), 467 (10) [M]+∙, 439 (150), 295 (35), 280 (40), 
253 (5), 239 (15), 219 (15), 204 (5), 177 (10), 159 (20), 151 (5), 123 (10), 110 (7), 
77 (100), 51 (20), 
 
HR-MS (EI): calcd. for C23H16Cl3N5 [M]
+∙ 467.0472; found 467.0475 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H16Cl3N5 
 
MW: 468.77 g/mol 
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8-Chloro-1-methyl-6-phenyl-4-(3,4,5-trimethoxybenzyl)-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine (58c) 
 
Following GP5, N-alkylation of 8-chloro-1-methyl-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 11 (80 mg, 0.26 mmol, 1.0 equiv) was carried out 
using 3,4,5-trimethoxybenzyl chloride 57c (168 mg, 0.775 mmol, 3.00 equiv) and 
sodium hydride (11 mg, 0.28 mmol, 1.1 equiv). After purification (Rf = 0.49), 
product 58c (112 mg, 0.229 mmol, 89 %) was obtained as pale yellow solid. 
 
mp: 220.5 – 221.8 °C 
 
1H NMR (400 MHz, CD2Cl2)  (ppm) = 2.56 (s, 3 H, 1-CH3), 3.74 (s, 3 H, 4’’’-
OCH3), 3.77 (s, 6 H, 3’’’-OCH3, 5’’’-OCH3), 4.81 (d, 
2JHH = 14.0 Hz, 1 H, 1’’-HH), 
5.04 (d, 2JHH = 14.0 Hz, 1 H, 1’’-HH), 6.64 (s, 2 H, 2’’’-H, 6’’’-H), 7.24 (d, 
4JHH = 
2.4 Hz, 1 H, 7-H), 7.34 (d, 3JHH = 8.7 Hz, 1 H, 10-H), 7.36 – 7.42 (m, 2 H, 3’-H, 5’-
H), 7.42 – 7.49 (m, 3 H, 2’-H, 4’-H, 6’-H), 7.62 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 
1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 56.3 (3’’’-OCH3, 5’’’-OCH3), 
58.1 (C-1’’), 60.8 (4’’’-OCH3), 106.3 (C-2’’’, C-6’’’), 124.4 (C-10), 128.8 (C-3’, C-5’), 
129.5 (C-2’, C-6’), 130.8 (C-4’), 130.8 (C-6a), 131.3 (C-7), 132.1 (C-9), 132.9 (C-
8), 133.4 (C-1’’’), 133.9 (C-10a), 136.4 (C-1’), 137.5 (C-4’’’), 148.6 (C-1), 153.5 (C-
3’’’, C-5’’’), 160.3 (C-3a), 161.5 (C-6) 
 
IR [cm-1]:    = 3431 (m), 3062 (w), 2934 (m), 2836 (w), 2360 (w), 2344 (w), 
1592 (m), 1535 (m), 1518 (s), 1508 (s), 1458 (m), 1422 (m), 1345 (m), 1327 (m), 
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1272 (w), 1234 (m), 1173 (w), 1126 (s), 1033 (w), 1008 (m), 825 (m), 778 (m), 
695 (m) 
 
 
MS (APCI): m/z = 492, 490 [M + H]+, 295, 255, 196, 181 
 
HR-MS (ESI): calcd. for C26H25ClN5O3
+ [M + H]+ 490.1640; found 490.1646 
 
HPLC purity: 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C26H24ClN5O3 
 
MW: 489.95 g/mol 
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8-Chloro-1-methyl-4-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]-6-phenyl-4H-
benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (59) 
 
Formation of the 1,2,3-triazole was accomplished according to GP6, using 8-
chloro-1-methyl-6-phenyl-4-(prop-2-yn-1-yl)-4H-benzo[e][1,2,4]triazolo[3,4-c][1,2,4] 
triazepine 13 (80 mg, 0.23 mmol, 1.1 equiv), sodium azide (15 mg, 0.23 mmol, 
1.1 equiv), iodomethane (13 µL, 0.21 mmol, 1.0 equiv), sodium L-ascorbate 
(8.2 mg, 42 µmol, 0.2 equiv) and copper(II) sulfate pentahydrate (5.8 mg, 10 µmol, 
5.0 mol%). After purification (Rf = 0.18), product 59 (41 mg, 0.10 mmol, 49 %) was 
yielded as pale yellow solid. 
 
mp: 191.6 °C 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.55 (s, 3 H, 1-CH3), 4.03 (s, 3 H, 1’’’-CH3), 
4.95 (d, 2JHH = 14.0 Hz, 1 H, 1’’-HH), 5.15 (d, 
2JHH = 13.9 Hz, 1 H, 1’’-HH), 7.24 (d, 
4JHH = 2.4 Hz, 1 H, 7-H), 7.30 (d, 
3JHH = 8.7 Hz, 1 H, 10-H), 7.38 – 7.43 (m, 2 H, 3’-
H, 5’-H), 7.45 – 7.50 (m, 3 H, 2’-H, 4’-H, 6’-H), 7.59 (dd, 4JHH = 2.4 Hz, 
3JHH = 
8.7 Hz, 1 H, 9-H), 7.66 (s, 1 H, 5’’’-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 36.9 (1’’’-CH3), 49.7 (C-1’’), 
124.4 (C-10), 125.5 (C-5’’’), 128.9 (C-3’, C-5’), 129.5 (C-2’, C-6’), 130.7 (C-6a), 
130.9 (C-4’), 131.6 (C-7), 132.2 (C-9), 133.0 (C-8), 133.7 (C-10a), 136.5 (C-1’), 
144.0 (C-4’’’), 148.7 (C-1), 159.9 (C-3a), 161.2 (C-6) 
 
IR [cm-1]:    = 3424 (s), 3049 (w), 2928 (w), 2361 (w), 2344 (w), 1793 (m), 
1637 (w), 1596 (w), 1560 (m), 1535 (s), 1518 (s), 1489 (s), 1437 (m), 1381 (w), 
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1347 (m), 1320 (m), 1272 (w), 1220 (w), 1172 (m), 1140 (w), 1101 (w), 1050 (m), 
831 (m), 775 (m), 744 (w), 696 (m), 661 (w), 593 (w), 534 (m) 
 
MS (ESI): m/z = 407, 405 [M + H]+, 366, 207, 184 
 
HR-MS (EI): calcd. for C20H17ClN8 [M]
+∙ 404.1265; found 404.1264 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C20H17ClN8 
 
MW: 404.86 g/mol 
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8-Chloro-1-methyl-6-phenyl-4-[(1-propyl-1H-1,2,3-triazol-4-yl)methyl]-4H-
benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (61a) 
 
Formation of the 1,2,3-triazole was accomplished according to GP6, using 8-
chloro-1-methyl-6-phenyl-4-(prop-2-yn-1-yl)-4H-benzo[e][1,2,4]triazolo[3,4-c][1,2,4] 
triazepine 13 (80 mg, 0.23 mmol, 1.1 equiv), sodium azide (15 mg, 0.23 mmol, 
1.1 equiv), 1-bromopropane 60a (19 µL, 0.21 mmol, 1.0 equiv), sodium L-
ascorbate (8.3 mg, 42 µmol, 0.2 equiv) and copper(II) sulfate pentahydrate 
(5.8 mg, 10 µmol, 5.0 mol%). After purification (Rf = 0.25), product 61a (37 mg, 
85 µmol, 41 %) was yielded as pale yellow solid. 
 
mp: 143.9 °C 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 0.93 (t, 
3JHH = 7.4 Hz, 3 H, 3’’’’-H), 1.87 – 
1.95 (m, 2 H, 2’’’’-H), 2.55 (s, 3 H, 1-CH3), 4.24 – 4.32 (m, 2 H, 1’’’’-H), 4.96 (d, 
2JHH = 13.8 Hz, 1 H, 1’’-HH), 5.14 (d, 
2JHH = 13.8 Hz, 1 H, 1’’-HH), 7.23 (d, 
4JHH = 
2.4 Hz, 1 H, 7-H), 7.31 (d, 3JHH = 8.7 Hz, 1 H, 10-H), 7.37 – 7.42 (m, 2 H, 3’-H, 5’-
H), 7.44 – 7.49 (m, 3 H, 2’-H, 4’-H, 6’-H), 7.59 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 
1 H, 9-H), 7.68 (s, 1 H, 5’’’-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 11.2 (C-3’’’’), 12.8 (1-CH3), 24.1 (C-2’’’’), 
49.8 (C-1’’), 52.2 (C-1’’’’), 124.4 (C-10), 125.5 (C-5’’’), 128.9 (C-3’, C-5’), 129.5 (C-
2’, C-6’), 130.7 (C-6a), 130.9 (C-4’), 131.6 (C-7), 132.2 (C-9), 133.0 (C-8), 133.7 
(C-10a), 136.5 (C-1’), 143.6 (C-4’’’), 148.7 (C-1), 160.0 (C-3a), 161.2 (C-6) 
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IR [cm-1]:    = 3136 (w), 3064 (w), 2965 (m), 2932 (m), 2875 (w), 2362 (w), 
2344 (w), 1595 (w), 1536 (s), 1519 (s), 1489 (s), 1436 (s), 1381 (m), 1347 (m), 
1320 (m), 1273 (w), 1221 (w), 1172 (w), 1140 (w), 1101 (w), 1049 (m), 1032 (m), 
830 (m), 775 (w), 744 (w), 696 (w), 662 (w), 593 (m), 534 (m) 
 
MS (ESI): m/z = 435, 433 [M + H]+ 
 
HR-MS (EI): calcd. for C22H21ClN8 [M]
+∙ 432.1578; found 432.1581 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C22H21ClN8 
 
MW: 432.91 g/mol 
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4-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-8-chloro-1-methyl-6-phenyl-4H-
benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (61b) 
 
Formation of the 1,2,3-triazole was accomplished according to GP6, using 8-
chloro-1-methyl-6-phenyl-4-(prop-2-yn-1-yl)-4H-benzo[e][1,2,4]triazolo[3,4-c][1,2,4] 
triazepine 13 (80 mg, 0.23 mmol, 1.1 equiv), sodium azide (15 mg, 0.23 mmol, 
1.1 equiv), benzyl bromide 60b (25 µL, 0.21 mmol, 1.0 equiv), sodium L-ascorbate 
(8.3 mg, 42 µmol, 0.2 equiv) and copper(II) sulfate pentahydrate (5.8 mg, 10 µmol, 
5.0 mol%). After purification (dichloromethane / methanol 9:1, Rf = 0.43), product 
61b (81 mg, 0.17 µmol, 80 %) was yielded as pale yellow solid. 
 
mp: 152.1 °C 
 
1H NMR (400 MHz, CD2Cl2)  (ppm) = 2.54 (s, 3 H, 1-CH3), 4.95 (d, 
2JHH = 
13.8 Hz, 1 H, 1’’-HH), 5.09 (d, 2JHH = 13.7 Hz, 1 H, 1’’-HH), 5.46 (d, 
2JHH = 14.4 Hz, 
1 H, 1’’’’-HH), 5.54 (d, 2JHH = 14.4 Hz, 1 H, 1’’’’-HH), 7.18 (d, 
4JHH = 2.4 Hz, 1 H, 7-
H), 7.26 – 7.29 (m, 2 H, 2’’’’’-H, 6’’’’’-H), 7.30 (d, 3JHH = 8.7 Hz, 1 H, 10-H), 7.33 – 
7.38 (m, 7 H, 2’-H, 3’-H, 5’-H, 6’-H, 3’’’’’-H, 4’’’’’-H, 5’’’’’-H), 7.42 – 7.48 (m, 1 H, 4’-
H), 7.58 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H), 7.64 (s, 1 H, 5’’’-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.7 (1-CH3), 49.7 (C-1’’), 54.4 (C-1’’’’), 
124.4 (C-10), 124.6 (C-5’’’), 128.4 (C-2’’’’’, C-6’’’’’), 128.8 (C-3’, C-5’), 128.9 (C-
4’’’’’), 129.4 (C-3’’’’’, C-5’’’’’), 129.5 (C-2’, C-6’), 130.6 (C-6a), 130.8 (C-4’), 131.6 
(C-7), 132.2 (C-9), 133.0 (C-8), 133.7 (C-10a), 135.6 (C-1’’’’’), 136.5 (C-1’), 144.2 
(C-4’’’), 148.7 (C-1), 159.9 (C-3a), 161.3 (C-6) 
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IR [cm-1]:    = 3062 (w), 2924 (w), 2362 (w), 2344 (w), 1637 (w), 1535 (m), 
1518 (s), 1490 (m), 1432 (m), 1380 (w), 1347 (w), 1320 (m), 1272 (w), 1221 (w), 
1172 (w), 1129 (w), 1102 (w), 1048 (m), 1031 (w), 827 (w), 696 (m) 
 
MS (CI): m/z (%) = 483 (35), 481 (90) [M + H]+, 295 (5), 255 (15), 210 (100), 199 
(25), 144 (40), 103 (40) 
 
MS (EI): m/z (%) = 482 (10), 480 (30) [M]+∙, 295 (20), 281 (55), 253 (10), 219 (15), 
205 (20), 177 (10), 144 (10), 111 (15), 91 (100), 77 (45), 65 (15), 51 (10) 
 
HR-MS (EI): calcd. for C26H21ClN8 [M]
+∙ 480.1578; found 480.1579 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C26H21ClN8 
 
MW: 480.95 g/mol 
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(2-Isothiocyanato-5-nitrophenyl)(phenyl)methanone (64) 
(Literature known compound but different procedure
110
) 
 
Compound 64 was prepared according to GP2 using 2-amino-5-nitro-
benzophenone 62 (5.0 g, 21 mmol, 1.0 equiv) as starting material, calcium 
carbonate (3.1 g, 31 mmol, 1.5 equiv) and thiophosgene 16 (1.7 mL, 23 mmol, 
1.1 equiv). After purification (dichloromethane, Rf = 0.74), product 64 (4.0 g, 
14 mmol, 69 %) was yielded as yellow solid. 
 
1H NMR (500 MHz, CDCl3):  (ppm) = 7.50 (d, 
3JHH = 8.6 Hz, 1 H, 3-H), 7.52 – 
7.57 (m, 2 H, 3’-H, 5’-H), 7.67 – 7.71 (m, 1 H, 4’-H), 7.80 – 7.83 (m, 2 H, 2’-H, 6’-
H), 8.36 (d, 4JHH = 2.5 Hz, 1 H, 6-H), 8.38 (dd, 
4JHH = 2.6 Hz, 
3JHH = 8.6 Hz, 1 H, 4-
H),  
 
13C NMR (100 MHz, CDCl3):  (ppm) = 125.4 (C-6), 126.6 (C-4), 128.3 (C-3), 
129.1 (C-3’, C-5’), 130.1 (C-2’, C-6’), 134.6 (C-4’), 135.5 (C-1’), 135.8 (C-1), 135.9 
(C-2), 140.9 (NCS), 145.0 (C-5), 192.2 (CO) 
 
MS (CI): m/z (%) = 285 (100) [M + H]+ 
 
MF: C14H8N2O3S 
 
MW: 284.29 g/mol 
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(5-Chloro-2-isothiocyanatophenyl)(2-chlorophenyl)methanone (65) 
(Literature known compound but different procedure
110
) 
 
Compound 65 was prepared according to GP2 using 2-amino-2,5-dichloro-
benzophenone 63 (5.0 g, 19 mmol, 1.0 equiv) as starting material, calcium 
carbonate (2.8 g, 28 mmol, 1.5 equiv) and thiophosgene 16 (1.6 mL, 21 mmol, 
1.1 equiv). No purification was needed after workup procedure, yielding product 65 
(5.5 g, 18 mmol, 96 %) as red-brown solid. 
 
1H NMR (500 MHz, CDCl3):  (ppm) = 7.27 (d, 
3JHH = 8.5 Hz, 1 H, 3-H), 7.42 (ddd, 
4JHH = 2.7 Hz, 
3JHH = 6.0 Hz, 
3JHH = 7.5 Hz, 1 H, 5’-H), 7.49 (dd, 
4JHH = 2.5 Hz, 
3JHH 
= 8.6 Hz, 1 H, 4-H), 7.47 – 7.49 (m, 2 H, 3’-H, 4’-H), 7.52 (ddd, 5JHH = 0.7 Hz, 
4JHH 
= 1.4 Hz, 3JHH = 7.5 Hz, 1 H, 6’-H), 7.57 (d, 
4JHH = 2.5 Hz, 1 H, 6-H) 
 
13C NMR (100 MHz, CDCl3):  (ppm) = 127.3 (C-5’), 128.7 (C-2), 129.4 (C-3), 
130.3 (C-6’), 130.6 (C-3’), 130.8 (C-6), 131.9 (C-2’), 132.8 (C-4’), 132.8 (C-5), 
133.3 (C-4), 134.7 (C-1), 137.3 (NCS), 137.4 (C-1’), 192.0 (CO) 
 
MS (CI): m/z (%) = 312 (15), 310 (70), 308 (100) [M + H]+, 196 (20), 139 (40) 
 
MF: C14H7Cl2NOS 
 
MW: 308.18 g/mol 
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3-(4-Methoxybenzyl)-7-nitro-5-phenyl-1H-benzo[e][1,2,4]triazepine-2(3H)-
thione (66) 
(Literature known compound but different procedure
110
) 
 
(4-Methoxybenzyl)hydrazine hydrochloride 48 (2.1 g, 11 mmol, 1.1 equiv) was 
dissolved in 35 mL of methanol, cooled to 0 °C and treated with N,N-
diisopropylethylamine (2.1 mL, 12 mmol, 1.2 equiv). After stirring for 30 min at 
room temperature, a solution of (2-isothiocyanato-5-nitrophenyl)(phenyl)-
methanone 64 (2.9 g, 10 mmol, 1.0 equiv) in 20 mL of tetrahydrofuran was added 
and stirring was continued for 1 h. The mixture was concentrated under reduced 
pressure, the residue dissolved in ethanol (30 mL), treated with a catalytic amount 
of para-toluenesulfonic acid monohydrate (49 mg, 0.26 mmol, 2.5 mol%) and 
heated to reflux for 1 h. The solvent was evaporated and purification was done by 
flash column chromatography on flash silica gel (dichloromethane, Rf = 0.39), 
giving compound 66 (2.67 g, 6.38 mmol, 63 %) as yellow solid. 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 3.80 (s, 3 H, OCH3), 5.30 (s, 2 H, 1’’-H), 
6.84 – 6.89 (m, 2 H, 3’’’-H, 5’’’-H), 7.09 (d, 3JHH = 8.9 Hz, 1 H, 9-H), 7.20 – 7.24 (m, 
2 H, 2’-H’, 6’-H), 7.27 – 7.32 (m, 2 H, 2’’’-H, 6’’’-H), 7.35 – 7.40 (m, 2 H, 3’-H, 5’-H), 
7.46 – 7.52 (m, 1 H, 4’-H), 7.86 (d, 4JHH = 2.6 Hz, 1 H, 6-H), 7.87 (bs, 1 H, 1-H), 
8.30 (dd, 4JHH = 2.6 Hz, 
3JHH = 8.8 Hz, 1 H, 8-H) 
 
13C NMR (100 MHz, CDCl3):  (ppm) = 55.3 (OCH3), 59.7 (C-1’’), 113.9 (C-3’’’, C-
5’’’), 121.0 (C-9), 126.0 (C-5a), 126.6 (C-6), 127.8 (C-8), 128.0 (C-1’’’), 128.8 (C-
3’, C-5’), 129.2 (C-2’, C-6’), 130.2 (C-2’’’, C-6’’’), 131.5 (C-4’), 135.2 (C-1’), 143.4 
(C-7), 148.8 (C-9a), 159.1 (C-4’’’), 166.2 (C-5), 190.3 (C-2) 
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MS (CI): m/z (%) = 419 (20) [M + H]+, 391 (15), 121 (100) 
 
MF: C22H18N4O3S 
 
MW: 418.47 g/mol 
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7-Chloro-5-(2-chlorophenyl)-3-(4-methoxybenzyl)-1H-benzo[e][1,2,4]-
triazepine-2(3H)-thione (67) 
(Literature known compound but different procedure
110
) 
 
(4-Methoxybenzyl)hydrazine hydrochloride 48 (673 mg, 3.57 mmol, 1.10 equiv) 
was dissolved in 20 mL of methanol, cooled to 0 °C and treated with N,N-
diisopropylethylamine (667 µL, 3.89 mmol, 1.20 equiv). After stirring for 30 min at 
room temperature, a solution of (5-chloro-2-isothiocyanatophenyl)(2-chlorophenyl)-
methanone 65 (1.0 g, 3.2 mmol, 1.0 equiv) in 10 mL of tetrahydrofuran was added 
and stirring was continued for 1 h. The mixture was concentrated under reduced 
pressure, the residue dissolved in ethanol (20 mL), treated with a catalytic amount 
of para-toluenesulfonic acid monohydrate (15 mg, 81 µmol, 2.5 mol%) and heated 
to reflux for 1 h. The solvent was evaporated and purification was done by flash 
column chromatography on flash silica gel (dichloromethane, Rf = 0.46), giving 
compound 67 (915 mg, 2.07 mmol, 64 %) as yellow solid. 
 
1H NMR (400 MHz, CDCl3):  (ppm) = 3.82 (s, 3 H, OCH3), 5.26 (s, 2 H, 1’’-H), 
6.63 (d, 4JHH = 2.4 Hz, 1 H, 6-H), 6.83 – 6.90 (m, 4 H, 9-H, 6’-H, 3’’’-H, 5’’’-H), 7.23 
– 7.28 (m, 3 H, 5’-H, 2’’’-H, 6’’’-H), 7.34 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.6 Hz, 1 H, 8-
H), 7.36 – 7.39 (m, 2 H, 3’-H, 4’-H), 7.62 (bs, 1 H, 1-H) 
 
13C NMR (100 MHz, CDCl3):  (ppm) = 55.3 (OCH3), 59.5 (C-1’’), 113.8 (C-3’’’, C-
5’’’), 121.4 (C-9), 127.0 (C-5’), 128.1 (C-5a), 128.6 (C-1’’’), 128.7 (C-6), 129.9 (C-
7), 130.2 (C-2’’’, C-6’’’), 130.2 (C-3’), 131.3 (C-6’), 131.4 (C-4’), 132.7 (C-8), 133.3 
(C-2’), 135.0 (C-1’), 141.7 (C-9a), 159.0 (C-4’’’), 165.5 (C-5), 192.3 (C-2) 
 
MS (CI): m/z (%) = 446 (5), 444 (25), 442 (30) [M + H]+, 121 (100) 
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MF: C22H17Cl2N3OS 
 
MW: 442.36 g/mol 
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4-(4-Methoxybenzyl)-1-methyl-8-nitro-6-phenyl-4H-benzo[e][1,2,4]triazolo-
[3,4-c][1,2,4]triazepine (68) 
(Literature known compound but different procedure
110
) 
 
Synthesis of the triazole-ring followed GP3. 3-(4-Methoxybenzyl)-7-nitro-5-phenyl-
1H-benzo[e][1,2,4]triazepine-2(3H)-thione 66 (2.6 g, 6.2 mmol, 1.0 equiv) was 
treated first with hydrazine hydrate (1.5 mL, 31 mmol, 5.0 equiv). Triethyl 
orthoacetate (1.5 mL, 8.1 mmol, 1.3 equiv) and para-toluenesulfonic acid 
monohydrate (236 mg, 1.24 mmol, 0.20 equiv) were used in the second step. 
Product 68 (2.1 g, 4.9 mmol, 78 %) was obtained after purification (Rf = 0.34) as 
bright yellow solid. 
 
mp: 188.7 °C (lit. 189 °C)110 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.58 (s, 3 H, 1-CH3), 3.76 (s, 3 H, OCH3), 
3.72 – 3.79 (m, 1 H, 1’’-HH), 4.77 – 4.92 (m, 1 H, 1’’-HH), 6.81 – 6.87 (m, 2 H, 3’’’-
H, 5’’’-H), 7.32 – 7.36 (m, 2 H, 2’’’-H, 6’’’-H), 7.36 – 7.44 (m, 4 H, 2’-H, 3’-H, 5’-H, 
6’-H), 7.44 – 7.49 (m, 1 H, 4’-H), 7.53 (d, 3JHH = 8.9 Hz, 1 H, 10-H), 8.05 (d, 
4JHH = 
2.6 Hz, 1 H, 7-H), 8.44 (dd, 4JHH = 2.6 Hz, 
3JHH = 8.9 Hz, 1 H, 9-H) 
 
13C NMR (125 MHz, CD2Cl2):  (ppm) = 13.0 (1-CH3), 55.6 (OCH3), 57.7 (C-1’’), 
114.0 (C-3’’’, C-5’’’), 124.0 (C-10), 126.8 (C-9), 126.9 (C-7), 129.0 (C-3’, C-5’), 
129.4 (C-1’’’), 129.4 (C-2’, C-6’), 130.4 (C-6a), 131.1 (C-2’’’, C-6’’’), 131.1 (C-4’), 
136.1 (C-1’), 140.4 (C-10a), 145.8 (C-8), 148.6 (C-1), 159.5 (C-4’’’), 160.5 (C-3a), 
160.7 (C-6) 
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IR [cm-1]:    = 3060 (w), 2934 (w), 1685 (m), 1613 (m), 1596 (m), 1535 (m), 
1515 (s), 1445 (m), 1400 (m), 1346 (s), 1326 (m), 1250 (m), 1174 (m), 1100 (m), 
1032 (m), 695 (w) 
 
MS (CI): m/z (%) = 441 (100) [M + H]+, 411 (30), 181 (30), 121 (75) 
 
MS (EI): m/z (%) = 440 (3) [M]+∙, 410 (5), 121 (100), 77 (15) 
 
HR-MS (EI): calcd. for C24H20N6O3 [M]
+∙ 440.1597; found 440.1597 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C24H20N6O3 
 
MW: 440.45 g/mol 
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8-Chloro-6-(2-chlorophenyl)-4-(4-methoxybenzyl)-1-methyl-4H-benzo-
[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (69) 
(Literature known compound but different procedure
110
) 
 
Synthesis of the triazole-ring followed GP3. 7-Chloro-5-(2-chlorophenyl)-3-(4-
methoxybenzyl)-1H-benzo[e][1,2,4]triazepine-2(3H)-thione 67 (850 mg, 
1.92 mmol, 1.00 equiv) was treated first with hydrazine hydrate (467 µL, 
9.61 mmol, 5.00 equiv). Triethyl orthoacetate (456 µL, 2.50 mmol, 1.30 equiv) and 
para-toluenesulfonic acid monohydrate (73 mg, 0.38 mmol, 0.2 equiv) were used 
in the second step. Product 69 (675 g, 1.45 mmol, 76 %) was obtained after 
purification (Rf = 0.29) as yellow solid. 
 
mp: 192.8 °C (lit. 188 – 191 °C)110 
 
1H NMR (400 MHz, CD2Cl2)  (ppm) = 2.52 (s, 3 H, 1-CH3), 3.78 (s, 3 H, OCH3), 
4.91 (bs, 2 H, 1’’-H), 6.82 – 6.88 (m, 2 H, 3’’’-H, 5’’’-H), 6.96 (d, 4JHH = 2.4 Hz, 1 H, 
7-H), 7.29 (d, 3JHH = 8.7 Hz, 1 H, 10-H), 7.30 – 7.44 (m, 6 H, 3’-H, 4’-H, 5’-H, 6’-H, 
2’’’-H, 6’’’-H), 7.55 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.6 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.7 (1-CH3), 55.6 (OCH3), 57.5 (C-1’’), 
113.9 (C-3’’’, C-5’’’), 124.2 (C-10), 127.6 (C-5’), 129.5 (C-7), 129.6 (C-1’’’), 130.6 
(C-3’), 130.9 (C-2’’’, C-6’’’), 131.6 (C-6’), 131.7 (C-6a), 132.0 (C-4’), 132.0 (C-9), 
133.1 (C-8), 133.2 (C-2’), 133.3 (C-10a), 135.7 (C-1’), 148.6 (C-1), 159.4 (C-4’’’), 
159.7 (C-3a), 160.3 (C-6) 
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IR [cm-1]:    = 3060 (w), 2929 (w), 2833 (w), 2361 (m), 2343 (m), 1612 (m), 
1514 (s), 1493 (m), 1436 (m), 1320 (m), 1249 (m), 1174 (m), 1100 (w), 1032 (m), 
820 (m) 
 
MS (CI): m/z (%) = 468 (8), 466 (30), 464 (55) [M + H]+, 211 (100), 121 (80) 
 
MS (EI): m/z (%) = 463 (2) [M]+∙, 329 (5), 121 (100), 77 (10) 
 
HR-MS (EI): calcd. for C24H19Cl2N5O [M]
+∙ 463.0967; found 463.0966 
 
HPLC purity: 96 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C24H19Cl2N5O 
 
MW: 464.35 g/mol 
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4-[4-(tert-Butyl)benzyl]-1-methyl-8-nitro-6-phenyl-4H-benzo[e][1,2,4]triazolo-
[3,4-c][1,2,4]triazepine (71a) 
 
Following GP4, N-alkylation of 1-methyl-8-nitro-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 14 (80 mg, 0.25 mmol, 1.0 equiv) was carried out 
using 4-(tert-butyl)benzyl bromide 54 (138 µL, 0.749 mmol, 3.00 equiv) and 
sodium hydride (11 mg, 0.28 mmol, 1.1 equiv). After purification (ethyl acetate / 
methanol 9:1, Rf = 0.55), product 71a (84 mg, 0.18 mmol, 72 %) was obtained as 
yellow solid. 
 
mp: 245.6 °C 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 1.29 (s, 9 H, C(CH3)3), 2.59 (s, 3 H, 1-CH3), 
4.77 – 5.24 (m, 2 H, 1’’-H), 7.31 – 7.36 (m, 4 H, 2’’’-H, 3’’’-H, 5’’’-H, 6’’’-H), 7.37 – 
7.41 (m, 2 H, 3’-H, 5’-H), 7.42 – 7.45 (m, 2 H, 2’-H, 6’-H), 7.45 – 7.50 (m, 1 H, 4’-
H), 7.54 (d, 3JHH = 8.9 Hz, 1 H, 10-H), 8.08 (d, 
4JHH = 2.6 Hz, 1 H, 7-H), 8.45 (dd, 
4JHH = 2.6 Hz, 
3JHH = 8.9 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 13.0 (1-CH3), 31.5 (C(CH3)3), 34.8 
(C(CH3)3), 57.9 (C-1’’), 124.0 (C-10), 125.6 (C-3’’’, C-5’’’), 126.8 (C-9), 127.0 (C-7), 
129.0 (C-3’, C-5’), 129.3 (C-2’’’, C-6’’’), 129.4 (C-2’, C-6’), 130.5 (C-6a), 131.2 (C-
4’), 134.4 (C-1’’’), 136.0 (C-1’), 140.4 (C-10a), 145.8 (C-8), 148.6 (C-1), 150.8 (C-
4’’’), 160.5 (C-3a), 160.7 (C-6) 
 
IR [cm-1]:    = 3087 (w), 2961 (m), 2867 (w), 2360 (m), 2342 (m), 1618 (m), 
1535 (s), 1521 (s), 1489 (m), 1445 (m), 1432 (m), 1346 (s), 1325 (m), 1268 (w), 
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1253 (w), 1100 (w), 1032 (w), 916 (w), 885 (w), 840 (w), 794 (m), 750 (m), 
737 (m), 695 (m) 
 
MS (ESI): m/z = 467 [M + H]+, 229 
 
HR-MS (EI): calcd. for C27H26N6O2 [M]
+∙ 466.2117; found 466.2115 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C27H26N6O2 
 
MW: 466.53 g/mol 
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4-(4-Iodobenzyl)-1-methyl-8-nitro-6-phenyl-4H-benzo[e][1,2,4]triazolo[3,4-c]-
[1,2,4]triazepine (71b) 
 
Following GP4, N-alkylation of 1-methyl-8-nitro-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 14 (80 mg, 0.25 mmol, 1.0 equiv) was carried out 
using 4-iodobenzyl bromide 55a (240 µL, 0.749 mmol, 3.00 equiv) and sodium 
hydride (11 mg, 0.28 mmol, 1.1 equiv). After purification (ethyl acetate, Rf = 0.42), 
product 71b (91 mg, 0.17 mmol, 68 %) was obtained as yellow solid. 
 
mp: 201.2 °C 
 
1H NMR (400 MHz, CD2Cl2)  (ppm) = 2.60 (s, 3 H, 1-CH3), 4.79 – 4.91 (m, 1 H, 
1’’-HH), 4.98 – 5.11 (m, 1 H, 1’’-HH), 7.14 – 7.20 (m, 2 H, 2’’’-H, 6’’’-H), 7.36 – 7.43 
(m, 4 H, 2’-H, 3’-H, 5’-H, 6’-H), 7.45 – 7.51 (m, 1 H, 4’-H), 7.55 (d, 3JHH = 8.9 Hz, 
1 H, 10-H), 7.62 – 7.67 (m, 2 H, 3’’’-H, 5’’’-H), 8.08 (d, 4JHH = 2.6 Hz, 1 H, 7-H), 
8.46 (dd, 4JHH = 2.6 Hz, 
3JHH = 8.9 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 13.0 (1-CH3), 57.6 (C-1’’), 93.3 (C-4’’’), 
124.1 (C-10), 126.9 (C-9), 127.0 (C-7), 129.0 (C-3’, C-5’), 129.4 (C-2’, C-6’), 130.3 
(C-6a), 131.3 (C-4’), 131.7 (C-2’’’, C-6’’’), 135.9 (C-1’), 137.2 (C-1’’’), 140.2 (C-
10a), 137.8 (C-3’’’, C-5’’’), 145.7 (C-8), 148.7 (C-1), 160.3 (C-3a), 161.1 (C-6) 
 
IR [cm-1]:    = 3079 (w), 3057 (w), 2924 (w), 2859 (w), 2361 (w), 2342 (w), 
1731 (m), 1618 (m), 1596 (m), 1536 (s), 1519 (s), 1486 (s), 1445 (m), 1432 (m), 
1400 (m), 1344 (s), 1326 (s), 1250 (m), 1099 (m), 1059 (m), 1032 (m), 1007 (m), 
915 (m), 885 (m), 842 (m), 790 (m), 748 (m), 737 (m), 694 (w) 
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MS (ESI): m/z = 537 [M + H]+, 491, 368, 340, 337, 335, 170 
 
HR-MS (EI): calcd. for C23H17IN6O2 [M]
+∙ 536.0458; found 536.0463 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H17IN6O2 
 
MW: 536.32 g/mol 
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1-Methyl-8-nitro-4-(4-nitrobenzyl)-6-phenyl-4H-benzo[e][1,2,4]triazolo[3,4-c]-
[1,2,4]triazepine (71c) 
 
Following GP4, N-alkylation of 1-methyl-8-nitro-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 14 (80 mg, 0.25 mmol, 1.0 equiv) was carried out 
using 4-nitrobenzyl bromide 55b (162 mg, 0.749 mmol, 3.00 equiv) and sodium 
hydride (11 mg, 0.28 mmol, 1.1 equiv). After purification (ethyl acetate, Rf = 0.38), 
product 71c (68 mg, 0.15 mmol, 60 %) was obtained as yellow solid. 
 
mp: 207.1 °C 
 
1H NMR (400 MHz, CD2Cl2)  (ppm) = 2.62 (s, 3 H, 1-CH3), 4.98 – 5.10 (m, 1 H, 
1’’-HH), 5.15 – 5.28 (m, 1 H, 1’’-HH), 7.35 – 7.42 (m, 4 H, 2’-H, 3’-H, 5’-H, 6’-H), 
7.44 – 7.52 (m, 1 H, 4’-H), 7.59 (d, 3JHH = 8.8 Hz, 2 H, 2’’’-H, 6’’’-H), 7.60 (d, 
3JHH = 
8.9 Hz, 1 H, 10-H), 8.11 (d, 4JHH = 2.5 Hz, 1 H, 7-H), 8.16 (d, 
3JHH = 8.8 Hz, 2 H, 
3’’’-H, 5’’’-H), 8.50 (dd, 4JHH = 2.6 Hz, 
3JHH = 8.9 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 13.0 (1-CH3), 57.5 (C-1’’), 123.9 (C-3’’’, C-
5’’’), 124.2 (C-10), 127.1 (C-9), 127.1 (C-7), 129.1 (C-3’, C-5’), 129.4 (C-2’, C-6’), 
130.2 (C-6a), 130.2 (C-2’’’, C-6’’’), 131.4 (C-4’), 135.7 (C-1’), 140.2 (C-10a), 145.0 
(C-1’’’), 145.9 (C-8), 147.7 (C-4’’’), 149.0 (C-1), 160.1 (C-3a), 161.6 (C-6) 
 
IR [cm-1]:    = 3080 (w), 2925 (w), 2855 (w), 2362 (w), 2344 (w), 1735 (w), 
1618 (m), 1603 (m), 1519 (s), 1490 (m), 1445 (m), 1433 (m), 1401 (w), 1381 (w), 
1345 (s), 1252 (m), 1177 (w), 1100 (m), 1032 (m), 913 (m), 843 (m), 737 (m), 
695 (m), 592 (m) 
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MS (ESI): m/z = 456 [M + H]+, 397, 235, 229, 157 
 
HR-MS (EI): calcd. for C23H17N7O4 [M]
+∙ 455.1342; found 455.1350 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H17N7O4 
 
MW: 455.43 g/mol 
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4-(3-Chlorobenzyl)-1-methyl-8-nitro-6-phenyl-4H-benzo[e][1,2,4]triazolo- 
[3,4-c][1,2,4]triazepine (71d) 
 
Following GP4, N-alkylation of 1-methyl-8-nitro-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 14 (80 mg, 0.25 mmol, 1.0 equiv) was carried out 
using 3-chlorobenzyl bromide 55d (98 µL, 0.75 mmol, 3.0 equiv) and sodium 
hydride (11 mg, 0.28 mmol, 1.1 equiv). After purification (ethyl acetate, Rf = 0.25), 
product 71d (78 mg, 0.18 mmol, 70 %) was obtained as yellow solid. 
 
mp: 178.2 °C 
 
1H NMR (400 MHz, CD2Cl2)  (ppm) = 2.60 (s, 3 H, 1-CH3), 4.79 – 4.99 (m, 1 H, 
1’’-HH), 4.99 – 5.18 (m, 1 H, 1’’-HH), 7.23 – 7.34 (m, 3 H, 2’’’-H, 4’’’-H, 5’’’-H), 7.36 
– 7.44 (m, 5 H, 2’-H, 3’-H, 5’-H, 6’-H, 6’’’-H), 7.45 – 7.51 (m, 1 H, 4’-H), 7.56 (d, 
3JHH = 8.9 Hz, 1 H, 10-H), 8.08 (d, 
4JHH = 2.5 Hz, 1 H, 7-H), 8.47 (dd, 
4JHH = 
2.6 Hz, 3JHH = 8.9 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 13.0 (1-CH3), 57.7 (C-1’’), 124.1 (C-10), 
127.0 (C-9), 127.0 (C-7), 128.0 (C-5’’’), 128.0 (C-2’’’), 129.1 (C-3’, C-5’), 129.4 (C-
2’, C-6’), 129.7 (C-6’’’), 130.1 (C-4’’’), 130.3 (C-6a), 131.3 (C-4’), 134.3 (C-3’’’), 
135.9 (C-1’), 139.5 (C-1’’’), 140.2 (C-10a), 145.9 (C-8), 148.8 (C-1), 160.2 (C-3a), 
161.1 (C-6) 
 
IR [cm-1]:    = 3062 (w), 2924 (w), 2857 (w), 2367 (w), 2345 (w), 1618 (m), 
1598 (m), 1578 (m), 1535 (s), 1519 (s), 1488 (m), 1445 (m), 1431 (m), 1401 (m), 
1381 (m), 1345 (s), 1325 (s), 1282 (m), 1252 (m), 1210 (m), 1099 (m), 1077 (m), 
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1032 (m), 1001 (w), 974 (w), 915 (w), 886 (m), 840 (w), 784 (m), 748 (m), 737 (m), 
694 (m), 654 (m), 596 (m) 
 
MS (ESI): m/z = 447, 445 [M + H]+, 366, 239 
 
HR-MS (EI): calcd. for C23H17ClN6O2 [M]
+∙ 444.1102; found 444.1101 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H17ClN6O2 
 
MW: 444.87 g/mol 
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4-(2-Bromobenzyl)-1-methyl-8-nitro-6-phenyl-4H-benzo[e][1,2,4]triazolo- 
[3,4-c][1,2,4]triazepine (71e) 
 
Following GP4, N-alkylation of 1-methyl-8-nitro-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 14 (80 mg, 0.25 mmol, 1.0 equiv) was carried out 
using 2-bromobenzyl bromide 55e (187 mg, 0.749 mmol, 3.00 equiv) and sodium 
hydride (11 mg, 0.28 mmol, 1.1 equiv). After purification (ethyl acetate, Rf = 0.49), 
product 71e (77 mg, 0.16 mmol, 63 %) was obtained as yellow solid. 
 
mp: 231.7 °C 
 
1H NMR (400 MHz, CD2Cl2)  (ppm) = 2.61 (s, 3 H, 1-CH3), 5.02 (d, 
2JHH = 
13.9 Hz, 1 H, 1’’-HH), 5.25 (d, 2JHH = 14.0 Hz, 1 H, 1’’-HH), 7.16 (td, 
4JHH = 1.7 Hz, 
3JHH = 7.7 Hz, 1 H, 4’’’-H), 7.29 (td, 
4JHH = 1.2 Hz, 
3JHH = 7.5 Hz, 1 H, 5’’’-H), 7.36 – 
7.51 (m, 6 H, 2’-H, 3’-H, 4’-H, 5’-H, 6’-H, 6’’’-H), 7.53 – 7.57 (m, 2 H, 10-H, 3’’’-H), 
8.08 (d, 4JHH = 2.6 Hz, 1 H, 7-H), 8.46 (dd, 
4JHH = 2.6 Hz, 
3JHH = 8.9 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 13.0 (1-CH3), 58.1 (C-1’’), 124.0 (C-10), 
125.0 (C-2’’’), 127.0 (C-9), 127.0 (C-7), 127.6 (C-5’’’), 129.0 (C-3’, C-5’), 129.4 (C-
2’, C-6’), 129.5 (C-4’’’), 130.4 (C-6a), 131.3 (C-4’), 131.9 (C-6’’’), 133.2 (C-3’’’), 
135.9 (C-1’), 136.6 (C-1’’’), 140.4 (C-10a), 145.8 (C-8), 148.7 (C-1), 160.3 (C-3a), 
161.1 (C-6) 
 
IR [cm-1]:    = 3058 (w), 2927 (w), 2362 (w), 2343 (w), 1734 (w), 1618 (m), 
1596 (m), 1536 (s), 1519 (s), 1489 (m), 1434 (m), 1345 (s), 1325 (s), 1252 (w), 
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1099 (w), 1027 (m), 915 (w), 885 (w), 840 (w), 774 (w), 748 (m), 695 (m), 657 (w), 
597 (w) 
 
MS (ESI): m/z = 491, 489 [M + H]+, 264 
 
HR-MS (EI): calcd. for C23H17BrN6O2 [M]
+∙ 488.0596; found 488.0601 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H17BrN6O2 
 
MW: 489.32 g/mol 
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4-(3,4-Dichlorobenzyl)-1-methyl-8-nitro-6-phenyl-4H-benzo[e][1,2,4]triazolo-
[3,4-c][1,2,4]triazepine (71f) 
 
Following GP5, N-alkylation of 1-methyl-8-nitro-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 14 (80 mg, 0.25 mmol, 1.0 equiv) was carried out 
using 3,4-dichlorobenzyl chloride 57b (104 µL, 0.749 mmol, 3.00 equiv) and 
sodium hydride (11 mg, 0.28 mmol, 1.1 equiv). After purification (ethyl acetate, Rf 
= 0.34), product 71f (57 mg, 0.12 mmol, 48 %) was obtained as yellow solid. 
 
mp: 193.6 °C 
 
1H NMR (400 MHz, CD2Cl2)  (ppm) = 2.61 (s, 3 H, 1-CH3), 4.79 – 4.94 (m, 1 H, 
1’’-HH), 5.00 – 5.13 (m, 1 H, 1’’-HH), 7.29 (dd, 4JHH = 1.9 Hz, 
3JHH = 8.3 Hz, 1 H, 
6’’’-H), 7.37 – 7.44 (m, 5 H, 2’-H, 3’-H, 5’-H, 6’-H, 5’’’-H), 7.46 – 7.51 (m, 1 H, 4’-H), 
7.53 (d, 4JHH = 1.9 Hz, 1 H, 2’’’-H), 7.56 (d, 
3JHH = 8.9 Hz, 1 H, 10-H), 8.09 (d, 
4JHH 
= 2.6 Hz, 1 H, 7-H), 8.47 (dd, 4JHH = 2.6 Hz, 
3JHH = 8.9 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 13.0 (1-CH3), 57.2 (C-1’’), 124.1 (C-10), 
127.0 (C-9), 127.1 (C-7), 129.1 (C-3’, C-5’), 129.4 (C-6’’’), 129.4 (C-2’, C-6’), 130.3 
(C-6a), 130.7 (C-5’’’), 131.4 (C-4’), 131.7 (C-4’’’), 131.7 (C-2’’’), 132.5 (C-3’’’), 
135.9 (C-1’), 137.8 (C-1’’’), 140.2 (C-10a), 145.9 (C-8), 148.8 (C-1), 160.1 (C-3a), 
161.3 (C-6) 
 
IR [cm-1]:    = 3081 (w), 2926 (w), 2859 (w), 2361 (w), 2342 (w), 1733 (w), 
1618 (m), 1596 (m), 1536 (s), 1519 (s), 1489 (m), 1472 (m), 1445 (m), 1433 (m), 
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1398 (m), 1381 (m), 1345 (s), 1325 (s), 1282 (w), 1251 (w), 1132 (w), 1099 (w), 
1031 (m), 915 (w), 886 (w), 790 (m), 749 (m), 736 (m), 694 (m) 
 
MS (ESI): m/z = 483, 481, 479 [M + H]+, 130 
 
HR-MS (EI): calcd. for C23H16Cl2N6O2 [M]
+∙ 478.0712; found 478.0718 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H16Cl2N6O2 
 
MW: 479.32 g/mol 
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1-Methyl-8-nitro-6-phenyl-4-(3,4,5-trimethoxybenzyl)-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine (71g) 
 
Following GP5, N-alkylation of 1-methyl-8-nitro-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 14 (80 mg, 0.25 mmol, 1.0 equiv) was carried out 
using 3,4,5-trimethoxybenzyl chloride 57c (162 mg, 0.749 mmol, 3.00 equiv) and 
sodium hydride (11 mg, 0.28 mmol, 1.1 equiv). After purification (ethyl acetate / 
N,N-dimethylethylamine 39:1, Rf = 0.38), product 71g (48 mg, 96 µmol, 38 %) was 
obtained as yellow solid. 
 
mp: 212.8 – 214.3 °C 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.61 (s, 3 H, 1-CH3), 3.74 (s, 3 H, 4’’’-
OCH3), 3.76 (s, 6 H, 3’’’-OCH3, 5’’’-OCH3), 4.78 – 4.87 (m, 1 H, 1’’-HH), 5.00 – 
5.09 (m, 1 H, 1’’-HH), 6.64 (s, 2 H, 2’’’-H, 6’’’-H), 7.38 – 7.43 (m, 2 H, 3’-H, 5’-H), 
7.44 – 7.47 (m, 2 H, 2’-H, 6’-H), 7.47 – 7.51 (m, 1 H, 4’-H), 7.56 (d, 3JHH = 8.9 Hz, 
1 H, 10-H), 8.09 (d, 4JHH = 2.6 Hz, 1 H, 7-H), 8.46 (dd, 
4JHH = 2.6 Hz, 
3JHH = 
8.9 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 13.0 (1-CH3), 56.3 (3’’’-OCH3, 5’’’-OCH3), 
58.3 (C-1’’), 60.8 (4’’’-OCH3), 106.6 (C-2’’’, C-6’’’), 124.1 (C-10), 126.8 (C-9), 126.9 
(C-7), 129.1 (C-3’, C-5’), 129.4 (C-2’, C-6’), 130.5 (C-6a), 131.3 (C-4’), 133.0 (C-
1’’’), 136.0 (C-1’), 137.7 (C-4’’’), 140.4 (C-10a), 145.8 (C-8), 148.7 (C-1), 153.6 (C-
3’’’, C-5’’’), 160.4 (C-3a), 161.0 (C-6) 
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IR [cm-1]:    = 3425 (w), 3081 (w), 2936 (m), 2837 (w), 2362 (w), 2343 (w), 
1618 (m), 1592 (m), 1536 (m), 1521 (s), 1508 (m), 1459 (m), 1422 (m), 1345 (s), 
1328 (w), 1235 (m), 1182 (w), 1126 (s), 1033 (w), 1006 (m), 916 (w), 884 (w), 
841 (w), 793 (w), 780 (w), 749 (w), 737 (w), 695 (w) 
 
MS (APCI): m/z = 501 [M + H]+, 471, 276, 266, 236, 196, 181 
 
HR-MS (ESI): calcd. for C26H25N6O5
+ [M + H]+ 501.1881; found 501.1888 
 
HPLC purity: 91 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C26H24N6O5 
 
MW: 500.51 g/mol 
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4-(3-Methoxybenzyl)-1-methyl-8-nitro-6-phenyl-4H-benzo[e][1,2,4]triazolo-
[3,4-c][1,2,4]triazepine (71h) 
 
Following GP4, N-alkylation of 1-methyl-8-nitro-6-phenyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine 14 (80 mg, 0.25 mmol, 1.0 equiv) was carried out 
using 3-methoxybenzyl bromide 70 (105 µL, 0.749 mmol, 3.00 equiv) and sodium 
hydride (11 mg, 0.28 mmol, 1.1 equiv). After purification (ethyl acetate, Rf = 0.33), 
product 71h (68 mg, 0.15 mmol, 62 %) was obtained as pale yellow solid. 
 
mp: 169.8 °C 
 
1H NMR (400 MHz, CD2Cl2)  (ppm) = 2.60 (s, 3 H, 1-CH3), 3.74 (s, 3 H, OCH3), 
4.81 – 4.96 (m, 1 H, 1’’-HH), 5.02 – 5.19 (m, 1 H, 1’’-HH), 6.80 (dd, 4JHH = 2.3 Hz, 
3JHH = 8.0 Hz, 1 H, 4’’’-H), 6.92 – 6.95 (m, 1 H, 2’’’-H), 6.96 – 7.01 (m, 1 H, 6’’’-H), 
7.23 (t, 3JHH = 7.9 Hz, 1 H, 5’’’-H), 7.35 – 7.45 (m, 4 H, 2’-H, 3’-H, 5’-H, 6’-H), 7.45 
– 7.51 (m, 1 H, 4’-H), 7.55 (d, 3JHH = 8.9 Hz, 1 H, 10-H), 8.08 (d, 
4JHH = 2.6 Hz, 
1 H, 7-H), 8.46 (dd, 4JHH = 2.6 Hz, 
3JHH = 8.9 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 13.0 (1-CH3), 55.5 (OCH3), 58.1 (C-1’’), 
113.1 (C-4’’’), 115.1 (C-2’’’), 121.7 (C-6’’’), 124.1 (C-10), 126.9 (C-9), 126.9 (C-7), 
129.0 (C-3’, C-5’), 129.4 (C-2’, C-6’), 129.7 (C-5’’’), 130.4 (C-6a), 131.2 (C-4’), 
136.0 (C-1’), 139.0 (C-1’’’), 140.3 (C-10a), 145.8 (C-8), 148.7 (C-1), 160.0 (C-3’’’), 
160.5 (C-3a), 160.9 (C-6) 
 
IR [cm-1]:    = 3056 (w), 2962 (w), 2927 (w), 2834 (w), 2368 (w), 1617 (m), 
1597 (m), 1535 (s), 1519 (s), 1489 (m), 1445 (m), 1432 (m), 1400 (w), 1345 (s), 
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1324 (m), 1263 (s), 1157 (m), 1098 (m), 1031 (m), 918 (w), 883 (w), 800 (m), 
785 (m), 747 (w), 736 (w), 694 (m) 
 
MS (ESI): m/z = 441 [M + H]+, 248, 235 
 
HR-MS (EI): calcd. for C24H20N6O3 [M]
+∙ 440.1597; found 440.1598 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C24H20N6O3 
 
MW: 440.45 g/mol 
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4-[4-(tert-Butyl)benzyl]-8-chloro-6-(2-chlorophenyl)-1-methyl-4H-benzo-
[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (72a) 
 
Following GP4, N-alkylation of 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-
benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine 15 (80 mg, 0.23 mmol, 1.0 equiv) 
was carried out using 4-(tert-butyl)benzyl bromide 54 (128 µL, 0.697 mmol, 
3.00 equiv) and sodium hydride (10 mg, 0.26 mmol, 1.1 equiv). After purification 
(ethyl acetate / methanol 9:1, Rf = 0.78), product 72a (111 mg, 0.226 mmol, 97 %) 
was obtained as pale yellow solid. 
 
mp: 190.2 °C 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 1.31 (s, 9 H, C(CH3)3), 2.52 (s, 3 H, 1-CH3), 
4.96 (bs, 2 H, 1’’-H), 6.97 (d, 4JHH = 2.4 Hz, 1 H, 7-H), 7.30 (d, 
3JHH = 8.7 Hz, 1 H, 
10-H), 7.31 – 7.38 (m, 7 H, 3’-H, 5’-H, 6’-H, 2’’’-H, 3’’’-H, 5’’’-H, 6’’’-H), 7.38 – 7.42 
(m, 1 H, 4’-H), 7.55 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.6 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.7 (1-CH3), 31.5 (C(CH3)3), 34.8 
(C(CH3)3), 57.8 (C-1’’), 124.2 (C-10), 125.5 (C-3’’’, C-5’’’), 127.6 (C-5’), 129.2 (C-
2’’’, C-6’’’), 129.6 (C-7), 130.6 (C-3’), 131.6 (C-4’), 131.7 (C-6a), 132.0 (C-6’), 
132.0 (C-9), 133.1 (C-10a), 133.3 (C-8), 133.3 (C-2’), 134.5 (C-1’’’), 135.7 (C-1’), 
148.6 (C-1), 150.7 (C-4’’’), 159.7 (C-6), 160.3 (C-3a) 
 
IR [cm-1]:    = 3059 (w), 2961 (m), 2866 (w), 1594 (m), 1535 (s), 1518 (s), 1494 (s), 
1436 (s), 1380 (m), 1361 (m), 1345 (m), 1320 (m), 1268 (w), 1174 (m), 1101 (m), 
1053 (m), 1034 (m), 828 (m), 762 (m), 749 (m), 733 (m), 649 (m), 595 (m), 561 (m) 
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MS (ESI): m/z = 494, 492, 490 [M + H]+, 317, 239 
 
HR-MS (EI): calcd. for C27H25Cl2N5 [M]
+∙ 489.1487; found 489.1495 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C27H25Cl2N5 
 
MW: 490.43 g/mol 
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8-Chloro-6-(2-chlorophenyl)-4-(4-iodobenzyl)-1-methyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine (72b) 
 
Following GP4, N-alkylation of 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-
benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine 15 (80 mg, 0.23 mmol, 1.0 equiv) 
was carried out using 4-iodobenzyl bromide 55a (223 µL, 0.697 mmol, 3.00 equiv) 
and sodium hydride (10 mg, 0.26 mmol, 1.1 equiv). After purification (ethyl acetate 
/ methanol 9:1, Rf = 0.63), product 72b (87 mg, 0.16 mmol, 67 %) was obtained as 
colorless solid. 
 
mp: 217.3 – 218.3 °C 
 
1H NMR (400 MHz, CD2Cl2)  (ppm) = 2.53 (s, 3 H, 1-CH3), 4.93 (bs, 2 H, 1’’-H), 
6.97 (dd, 5JHH = 0.3 Hz, 
4JHH = 2.4 Hz, 1 H, 7-H), 7.14 – 7.19 (m, 2 H, 2’’’-H, 6’’’-H), 
7.29 (ddd, 5JHH = 0.7 Hz, 
4JHH = 1.8 Hz, 
3JHH = 7.5 Hz, 1 H, 6’-H), 7.31 (dd, 
5JHH = 
0.3 Hz, 3JHH = 8.7 Hz, 1 H, 10-H), 7.35 (ddd, 
4JHH = 1.5 Hz, 
3JHH = 7.1 Hz, 
3JHH = 
7.5 Hz, 1 H, 5’-H), 7.37 (ddd, 5JHH = 0.5 Hz, 
4JHH = 1.5 Hz, 
3JHH = 8.0 Hz, 1 H, 3’-
H), 7.41 (ddd, 4JHH = 1.8 Hz, 
3JHH = 7.1 Hz, 
3JHH = 8.1 Hz, 1 H, 4’-H), 7.57 (dd, 
4JHH 
= 2.4 Hz, 3JHH = 8.6 Hz, 1 H, 9-H), 7.63 – 7.68 (m, 2 H, 3’’’-H, 5’’’-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.7 (1-CH3), 57.5 (C-1’’), 93.1 (C-4’’’), 
124.2 (C-10), 127.6 (C-5’), 129.6 (C-7), 130.6 (C-3’), 131.5 (C-2’’’, C-6’’’), 131.6 
(C-6a), 131.7 (C-4’), 131.9 (C-6’), 132.1 (C-9), 133.0 (C-10a), 133.2 (C-8), 133.4 
(C-2’), 135.6 (C-1’), 137.4 (C-1’’’), 137.8 (C-3’’’, C-5’’’), 148.7 (C-1), 160.1 (C-3a), 
160.1 (C-6) 
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IR [cm-1]:    = 3062 (w), 2926 (w), 2360 (w), 2341 (w), 1793 (w), 1636 (m), 
1593 (m), 1576 (w), 1535 (m), 1519 (s), 1494 (m), 1435 (m), 1400 (w), 1381 (w), 
1346 (m), 1320 (m), 1281 (w), 1250 (w), 1175 (m), 1101 (w), 1056 (w), 1034 (w), 
1008 (m), 827 (m) 
 
MS (ESI): m/z = 564, 562, 560 [M + H]+, 405, 315, 301, 279, 229, 207, 184, 59 
 
HR-MS (EI): calcd. for C23H16Cl2IN5 [M]
+∙ 558.9828; found 558.9808 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H16Cl2IN5 
 
MW: 560.22 g/mol 
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8-Chloro-6-(2-chlorophenyl)-1-methyl-4-(4-nitrobenzyl)-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine (72c) 
 
Following GP4, N-alkylation of 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-
benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine 15 (80 mg, 0.23 mmol, 1.0 equiv) 
was carried out using 4-nitrobenzyl bromide 55b (151 mg, 0.697 mmol, 3.00 equiv) 
and sodium hydride (10 mg, 0.26 mmol, 1.1 equiv). After purification (ethyl acetate 
/ methanol 9:1, Rf = 0.69), product 72c (73 mg, 0.15 mmol, 66 %) was obtained as 
yellow solid. 
 
mp: 199.1 °C (decomposition) 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.54 (s, 3 H, 1-CH3), 5.09 (bs, 2 H, 1’’-H), 
6.99 (d, 4JHH = 2.4 Hz, 1 H, 7-H), 7.22 (dd, 
4JHH = 1.7 Hz, 
3JHH = 7.6 Hz, 1 H, 6’-H), 
7.32 (ddd, 4JHH = 1.5 Hz, 
3JHH = 7.2 Hz, 
3JHH = 7.6 Hz, 1 H, 5’-H), 7.34 (d, 
3JHH = 
8.7 Hz, 1 H, 10-H), 7.36 (dd, 4JHH = 1.5 Hz, 
3JHH = 8.1 Hz, 1 H, 3’-H), 7.40 (ddd, 
4JHH = 1.7 Hz, 
3JHH = 7.2 Hz, 
3JHH = 8.0 Hz, 1 H, 4’-H), 7.56 – 7.60 (m, 2 H, 2’’’-H, 
6’’’-H), 7.60 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H), 8.14 – 8.20 (m, 2 H, 3’’’-H, 
5’’’-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 57.4 (C-1’’), 123.9 (C-3’’’, C-
5’’’), 124.3 (C-10), 127.7 (C-5’), 129.7 (C-7), 130.1 (C-2’’’, C-6’’’), 130.7 (C-3’), 
131.4 (C-6a), 131.8 (C-4’), 131.8 (C-6’), 132.3 (C-9), 133.0 (C-10a), 133.2 (C-2’), 
133.5 (C-8), 135.4 (C-1’), 145.2 (C-1’’’), 147.7 (C-4’’’), 148.9 (C-1), 159.9 (C-3a), 
162.6 (C-6) 
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IR [cm-1]:    = 3440 (s), 2924 (w), 2364 (w), 1735 (w), 1637 (m), 1606 (m), 
1519 (s), 1493 (m), 1436 (m), 1381 (w), 1345 (s), 1320 (m), 1281 (w), 1249 (w), 
1174 (w), 1108 (w), 1053 (w), 1053 (w), 832 (m), 763 (w), 739 (m) 
 
MS (ESI): m/z = 481, 479 [M + H]+, 380, 229 
 
HR-MS (EI): calcd. for C23H16Cl2N6O2 [M]
+∙ 478.0712; found 478.0719 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H16Cl2N6O2 
 
MW: 479.32 g/mol 
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8-Chloro-4-(3-chlorobenzyl)-6-(2-chlorophenyl)-1-methyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine (72d) 
 
Following GP4, N-alkylation of 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-
benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine 15 (80 mg, 0.23 mmol, 1.0 equiv) 
was carried out using 3-chlorobenzyl bromide 55d (92 µL, 0.70 mmol, 3.0 equiv) 
and sodium hydride (10 mg, 0.26 mmol, 1.1 equiv). After purification (ethyl 
acetate, Rf = 0.35), product 72d (84 mg, 0.18 mmol, 77 %) was obtained as pale 
yellow solid. 
 
mp: 116.1 °C 
 
1H NMR (400 MHz, CD2Cl2)  (ppm) = 2.54 (s, 3 H, 1-CH3), 4.81 – 5.13 (m, 2 H, 
1’’-H), 6.98 (d, 4JHH = 2.3 Hz, 1 H, 7-H), 7.24 – 7.43 (m, 9 H, 10-H, 3’-H, 4’-H, 5’-H, 
6’-H, 2’’’-H, 4’’’-H, 5’’’-H, 6’’’-H), 7.58 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.7 (1-CH3), 57.6 (C-1’’), 124.2 (C-10), 
127.6 (C-5’), 127.9 (C-5’’’), 127.9 (C-2’’’), 129.6 (C-7), 129.7 (C-6’’’), 130.0 (C-4’’’), 
130.6 (C-3’), 131.7 (C-4’), 131.5 (C-6a), 131.9 (C-6’), 132.1 (C-9), 133.0 (C-10a), 
133.2 (C-8), 133.4 (C-2’), 134.3 (C-3’’’), 135.6 (C-1’), 139.7 (C-1’’’), 148.8 (C-1), 
160.0 (C-3a), 160.1 (C-6) 
 
IR [cm-1]:    = 3061 (w), 2924 (w), 2360 (w), 2345 (w), 1746 (m), 1598 (m), 
1576 (m), 1534 (s), 1518 (s), 1493 (s), 1474 (m), 1431 (s), 1379 (m), 1343 (m), 
1320 (m), 1280 (m), 1252 (m), 1208 (m), 1174 (m), 1099 (m), 1077 (w), 1052 (m), 
1033 (m), 884 (m), 833 (m), 768 (m), 747 (m), 734 (m), 712 (m), 682 (m), 598 (m) 
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MS (ESI): m/z = 472, 472, 468 [M + H]+, 280, 263, 248 
 
HR-MS (EI): calcd. for C23H16Cl3N5 [M]
+∙ 467.0472; found 467.0480 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H16Cl3N5 
 
MW: 468.77 g/mol 
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4-(2-Bromobenzyl)-8-chloro-6-(2-chlorophenyl)-1-methyl-4H-benzo[e][1,2,4]-
triazolo[3,4-c][1,2,4]triazepine (72e) 
 
Following GP4, N-alkylation of 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-
benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine 15 (80 mg, 0.23 mmol, 1.0 equiv) 
was carried out using 2-bromobenzyl bromide 55e (174 mg, 0.697 mmol, 
3.00 equiv) and sodium hydride (10 mg, 0.26 mmol, 1.1 equiv). After purification 
(ethyl acetate / methanol 9:1, Rf = 0.73), product 72e (91 mg, 0.18 mmol, 76 %) 
was obtained as colorless solid. 
 
mp: 245.0 – 246.4 °C 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.54 (s, 3 H, 1-CH3), 4.84 – 5.31 (m, 2 H, 
1’’-H), 6.98 (d, 4JHH = 2.4 Hz, 1 H, 7-H), 7.16 (ddd, 
4JHH = 1.7 Hz, 
3JHH = 7.5 Hz, 
3JHH = 7.9 Hz, 1 H, 4’’’-H), 7.29 (td, 
4JHH = 1.3 Hz, 
3JHH = 7.6 Hz, 1 H, 5’’’-H), 7.31 
(ddd, 5JHH = 0.5 Hz, 
4JHH = 1.9 Hz, 
3JHH = 7.6 Hz, 1 H, 6’-H), 7.31 (d, 
3JHH = 8.7 Hz, 
1 H, 10-H), 7.34 (ddd, 4JHH = 1.5 Hz, 
3JHH = 7.0 Hz, 
3JHH = 7.5 Hz, 1 H, 5’-H), 7.37 
(ddd, 5JHH = 0.5 Hz, 
4JHH = 1.5 Hz, 
3JHH = 8.0 Hz, 1 H, 3’-H), 7.41 (ddd, 
4JHH = 
1.9 Hz, 3JHH = 6.9 Hz, 
3JHH = 8.1 Hz, 1 H, 4’-H), 7.46 (dd, 
4JHH = 1.7 Hz, 
3JHH = 
7.7 Hz, 1 H, 6’’’-H), 7.56 (dd, 4JHH = 1.2 Hz, 
3JHH = 8.0 Hz, 1 H, 3’’’-H), 7.57 (dd, 
4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 58.0 (C-1’’), 124.2 (C-10), 
124.9 (C-2’’’), 127.6 (C-5’), 127.6 (C-5’’’), 129.4 (C-4’’’), 129.6 (C-7), 130.6 (C-3’), 
131.6 (C-4’), 131.6 (C-6a), 131.7 (C-6’’’), 132.0 (C-6’), 132.1 (C-9), 133.1 (C-10a), 
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133.2 (C-3’’’), 133.3 (C-8), 133.4 (C-2’), 135.6 (C-1’), 136.8 (C-1’’’), 148.8 (C-1), 
160.1 (C-3a), 160.1 (C-6) 
 
IR [cm-1]:    = 3062 (w), 2917 (w), 2864 (w), 2365 (w), 1772 (w), 1594 (m), 
1568 (m), 1536 (s), 1512 (s), 1494 (s), 1473 (s), 1439 (s), 1380 (m), 1364 (m), 
1344 (m), 1323 (s), 1282 (m), 1238 (m), 1208 (m), 1177 (m), 1098 (m), 1046 (m), 
1024 (s), 910 (m), 887 (m), 832 (s), 769 (s), 746 (s), 732 (s) 
 
MS (ESI): m/z = 518, 516, 514, 512 [M + H]+, 404, 391 
 
HR-MS (EI): calcd. for C23H16BrCl2N5 [M]
+∙ 510.9966; found 510.9959 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H16BrCl2N5 
 
MW: 513.22 g/mol 
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8-Chloro-6-(2-chlorophenyl)-4-(3,4-dichlorobenzyl)-1-methyl-4H-benzo-
[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (72f) 
 
Following GP5, N-alkylation of 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-
benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine 15 (80 mg, 0.23 mmol, 1.0 equiv) 
was carried out using 3,4-dichlorobenzyl chloride 57b (97 µL, 0.70 mmol, 
3.0 equiv) and sodium hydride (10 mg, 0.26 mmol, 1.1 equiv). After purification 
(ethyl acetate / methanol 9:1, Rf = 0.63), product 72f (69 mg, 0.14 mmol, 59 %) 
was obtained as colorless solid. 
 
mp: 219.6 °C 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.54 (s, 3 H, 1-CH3), 4.95 (bs, 2 H, 1’’-H), 
6.98 (d, 4JHH = 2.4 Hz, 1 H, 7-H), 7.28 (dd, 
4JHH = 2.0 Hz, 
3JHH = 8.2 Hz, 1 H, 6’’’-
H), 7.30 (ddd, 5JHH = 0.5 Hz, 
4JHH = 1.8 Hz, 
3JHH = 7.5 Hz, 1 H, 6’-H), 7.32 (d, 
3JHH 
= 8.7 Hz, 1 H, 10-H), 7.36 (ddd, 4JHH = 1.6 Hz, 
3JHH = 7.0 Hz, 
3JHH = 7.4 Hz, 1 H, 
5’-H), 7.37 (ddd, 5JHH = 0.5 Hz, 
4JHH = 1.5 Hz, 
3JHH = 8.0 Hz, 1 H, 3’-H), 7.41 (ddd, 
4JHH = 1.8 Hz, 
3JHH = 7.0 Hz, 
3JHH = 8.0 Hz, 1 H, 4’-H), 7.41 (d, 
3JHH = 8.2 Hz, 1 H, 
5’’’-H), 7.53 (d, 4JHH = 2.0 Hz, 1 H, 2’’’-H), 7.58 (dd, 
4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 
1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.8 (1-CH3), 57.0 (C-1’’), 124.2 (C-10), 
127.7 (C-5’), 129.2 (C-6’’’), 129.7 (C-7), 130.6 (C-3’), 130.6 (C-5’’’), 131.4 (C-4’’’), 
131.6 (C-2’’’), 131.6 (C-6a), 131.7 (C-4’), 131.9 (C-6’), 132.2 (C-9), 132.4 (C-3’’’), 
132.9 (C-10a), 133.2 (C-8), 133.4 (C-2’), 135.5 (C-1’), 138.0 (C-1’’’), 148.8 (C-1), 
159.9 (C-3a), 160.3 (C-6) 
256 
 
CHAPTER VI   –   Experimental section 
 
 
 
 
IR [cm-1]:    = 3067 (w), 2914 (w), 2360 (w), 2343 (w), 1735 (w), 1637 (m), 
1594 (m), 1538 (m), 1511 (s), 1496 (s), 1473 (m), 1432 (m), 1378 (m), 1361 (m), 
1347 (m), 1323 (m), 1280 (w), 1215 (m), 1178 (m), 1132 (m), 1032 (m), 926 (w), 
884 (m), 832 (m), 818 (s), 777 (w), 595 (m) 
 
MS (ESI): m/z = 506, 504, 502 [M + H]+, 239 
 
HR-MS (EI): calcd. for C23H15Cl4N5 [M]
+∙ 501.0081; found 501.0082 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H15Cl4N5 
 
MW: 503.21 g/mol 
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8-Chloro-6-(2-chlorophenyl)-1-methyl-4-(3,4,5-trimethoxybenzyl)-4H-benzo-
[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (72g) 
 
Following GP5, N-alkylation of 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-
benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine 15 (80 mg, 0.23 mmol, 1.0 equiv) 
was carried out using 3,4,5-trimethoxybenzyl chloride 57c (151 mg, 0.697 mmol, 
3.00 equiv) and sodium hydride (10 mg, 0.26 mmol, 1.1 equiv). After purification 
(Rf = 0.48), product 72g (83 mg, 0.16 mmol, 68 %) was obtained as pale yellow 
solid. 
 
mp: 258.1 – 260.0 °C 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.54 (s, 3 H, 1-CH3), 3.75 (s, 3 H, 4’’’-
OCH3), 3.76 (s, 6 H, 3’’’-OCH3, 5’’’-OCH3), 4.76 – 5.08 (m, 2 H, 1’’-H), 6.64 (s, 2 H, 
2’’’-H, 6’’’-H), 6.98 (d, 4JHH = 2.4 Hz, 1 H, 7-H), 7.33 (d, 
3JHH = 8.7 Hz, 1 H, 10-H), 
7.34 – 7.43 (m, 4 H, 3’-H, 4’-H, 5’-H, 6’-H), 7.57 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 
1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.7 (1-CH3), 56.3 (3’’’-OCH3, 5’’’-OCH3), 
58.1 (C-1’’), 60.8 (4’’’-OCH3), 106.4 (C-2’’’, C-6’’’), 124.3 (C-10), 127.6 (C-5’), 
129.4 (C-7), 130.6 (C-3’), 131.7 (C-4’), 131.7 (C-6a), 131.9 (C-6’), 132.1 (C-9), 
133.1 (C-10a), 133.2 (C-8), 133.2 (C-2’), 133.3 (C-1’’’), 135.6 (C-1’), 137.6 (C-4’’’), 
148.6 (C-1), 153.5 (C-3’’’, C-5’’’), 160.0 (C-6), 160.2 (C-3a) 
 
IR [cm-1]:    = 3422 (w), 3061 (w), 2992 (w), 2930 (w), 2835 (w), 2361 (w), 
2343 (m), 1591 (m), 1537 (m), 1521 (m), 1508 (m), 1494 (m), 1456 (m), 1421 (m), 
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1351 (m), 1327 (m), 1236 (w), 1181 (m), 1125 (s), 1055 (m), 1010 (m), 832 (m), 
760 (m) 
 
MS (APCI): m/z = 528, 526, 524 [M + H]+, 490, 329, 291, 289, 259, 196, 181 
 
HR-MS (ESI): calcd. for C26H24Cl2N5O3
+ [M + H]+ 524.1251; found 524.1259 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C26H23Cl2N5O3 
 
MW: 524.40 g/mol 
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8-Chloro-6-(2-chlorophenyl)-4-(3-methoxybenzyl)-1-methyl-4H-benzo-
[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (72h) 
 
Following GP4, N-alkylation of 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-
benzo[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine 15 (80 mg, 0.23 mmol, 1.0 equiv) 
was carried out using 3-methoxybenzyl bromide 70 (98 µL, 0.70 mmol, 3.0 equiv) 
and sodium hydride (10 mg, 0.26 mmol, 1.1 equiv). After purification (ethyl 
acetate, Rf = 0.26), product 72h (87 mg, 0.19 mmol, 81 %) was obtained as pale 
yellow solid. 
 
mp: 184.4 °C 
 
1H NMR (400 MHz, CD2Cl2)  (ppm) = 2.53 (s, 3 H, 1-CH3), 3.74 (s, 3 H, OCH3), 
4.73 – 5.20 (m, 2 H, 1’’-H), 6.78 – 6.83 (m, 1 H, 4’’’-H), 6.92 – 6.95 (m, 1 H, 2’’’-H), 
6.96 – 7.00 (m, 2 H, 7-H, 6’’’-H), 7.23 (t, 3JHH = 7.9 Hz, 1 H, 5’’’-H), 7.29 – 7.42 (m, 
5 H, 10-H, 3’-H, 4’-H, 5’-H, 6’-H), 7.56 (dd, 4JHH = 2.4 Hz, 
3JHH = 8.7 Hz, 1 H, 9-H) 
 
13C NMR (100 MHz, CD2Cl2):  (ppm) = 12.7 (1-CH3), 55.5 (OCH3), 58.0 (C-1’’), 
113.1 (C-4’’’), 114.8 (C-2’’’), 121.6 (C-6’’’), 124.2 (C-10), 127.6 (C-5’), 129.5 (C-7), 
129.6 (C-5’’’), 130.6 (C-3’), 131.6 (C-4’), 131.6 (C-6a), 132.0 (C-6’), 132.0 (C-9), 
133.1 (C-10a), 133.2 (C-8), 133.3 (C-2’), 135.6 (C-1’), 139.2 (C-1’’’), 148.7 (C-1), 
159.9 (C-3’’’), 160.0 (C-6), 160.2 (C-3a) 
 
IR [cm-1]:    = 3058 (w), 2997 (w), 2930 (w), 2833 (w), 2363 (w), 2343 (w), 
1596 (m), 1535 (s), 1518 (s), 1492 (s), 1434 (s), 1380 (m), 1344 (m), 1320 (s), 
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1265 (s), 1172 (m), 1156 (m), 1099 (m), 1050 (m), 1034 (m), 884 (w), 831 (m), 
769 (m), 746 (m), 693 (m), 598 (m) 
 
MS (ESI): m/z = 468, 466, 464 [M + H]+, 280, 239 
 
HR-MS (EI): calcd. for C24H19Cl2N5O [M]
+∙ 463.0967; found 463.0983 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C24H19Cl2N5O 
 
MW: 464.35 g/mol 
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2-Chloro-N-(4-methoxyphenyl)benzamide (75) 
(Literature known compound but different procedure
159
) 
 
4-Aminoanisole 73 (3.5 g, 28 mmol, 1.0 equiv) was dissolved in anhydrous 
tetrahydrofuran (25 mL) and cooled with an ice bath to 0 °C before 2-
chlorobenzoyl chloride 74 (4.5 mL, 31 mmol, 1.1 equiv) and N,N-
diisopropylethylamine (5.0 mL, 28 mmol, 1.0 equiv) were added consecutively to 
the well stirred solution. After complete addition the mixture was allowed to warm 
to room temperature and stirring was continued for 15 min. The reaction mixture 
was concentrated under reduced pressure and 60 mL of a water / methanol (2:1) 
mixture were added. The precipitate was filtered off and washed three times with 
methanol (10 mL) to obtain product 75 (7.3 g, 28 mmol, 98 %) as colorless solid. 
 
1H NMR (500 MHz, acetone-d6)  (ppm) = 3.80 (s, 3 H, OCH3), 6.91 – 6.96 (m, 
2 H, 3’-H, 5’-H), 7.41 (ddd, 4JHH = 1.8 Hz, 
3JHH = 7.1 Hz, 
3JHH = 7.3 Hz, 1 H, 5-H), 
7.46 (ddd, 4JHH = 1.7 Hz, 
3JHH = 7.0 Hz, 
3JHH = 8.0 Hz, 1 H, 4-H), 7.49 (dd, 
4JHH = 
1.7 Hz, 3JHH = 8.0 Hz, 1 H, 3-H), 7.58 (dd, 
4JHH = 1.5 Hz, 
3JHH = 7.4 Hz, 1 H, 6-H), 
7.71 – 7.76 (m, 2 H, 2’-H, 6’-H), 9.39 (s, 1 H, NH) 
 
13C NMR (125 MHz, acetone-d6):  (ppm) = 55.8 (OCH3), 114.8 (C-3’, C-5’), 122.1 
(C-2’, C-6’), 128.0 (C-5), 130.0 (C-6), 130.7 (C-3), 131.5 (C-2), 131.8 (C-4), 133.3 
(C-1’), 138.3 (C-1), 157.3 (C-4’), 165.4 (CO) 
 
MS (APCI): m/z = 264, 262 [M + H]+ 
 
MF: C14H12ClNO2 
 
MW: 261.70 g/mol 
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(2-Amino-5-methoxyphenyl)(2-chlorophenyl)methanone (76) 
(Literature known compound but different procedure
161
) 
 
2-Chloro-N-(4-methoxyphenyl)benzamide157 75 (2.0 g, 7.6 mmol, 1.0 equiv) was 
dissolved in 75 mL of deoxygenated acetonitrile and filled into a quartz glass tube. 
Photo-Fries rearrangement was carried out by irradiation for 1 d with 254 nm while 
using a cooling fan to maintain the reaction mixture at room temperature. The 
solvent was evaporated and purification was done by flash column 
chromatography on flash silica gel (ethyl acetate / isohexane / TEA 13:26:1, Rf = 
0.57), yielding product 76 (248 mg, 0.948 mmol, 12 %) as yellow solid. 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 3.55 (s, 3 H, OCH3), 6.19 (bs, 2 H, NH2), 
6.61 (d, 4JHH = 3.0 Hz, 1 H, 6-H), 6.70 (d, 
3JHH = 9.0 Hz, 1 H, 3-H), 7.00 (dd, 
4JHH = 
3.0 Hz, 3JHH = 9.0 Hz, 1 H, 4-H), 7.32 (dd, 
4JHH = 1.8 Hz, 
3JHH = 7.5 Hz, 1 H, 6’-H), 
7.37 (ddd, 4JHH = 1.5 Hz, 
3JHH = 7.3 Hz, 
3JHH = 7.5 Hz, 1 H, 5’-H), 7.41 (ddd, 
4JHH = 
1.8 Hz, 3JHH = 7.3 Hz, 
3JHH = 7.9 Hz, 1 H, 4’-H), 7.46 (dd, 
4JHH = 1.5 Hz, 
3JHH = 
7.9 Hz, 1 H, 3’-H) 
 
13C NMR (125 MHz, CD2Cl2):  (ppm) = 56.1 (OCH3), 116.8 (C-6), 117.4 (C-1), 
118.7 (C-3), 124.7 (C-4), 127.2 (C-5’), 128.8 (C-6’), 130.2 (C-3’), 130.8 (C-2’), 
130.8 (C-4’), 140.2 (C-1’), 146.8 (C-2), 150.2 (C-5), 196.9 (CO) 
 
MS (APCI): m/z = 264, 262 [M + H]+, 226, 150, 141, 139 
 
MF: C14H12ClNO2 
 
MW: 261.70 g/mol 
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(3-Methoxybenzyl)hydrazine hydrochloride (86) 
(Literature known compound but different procedure
178
) 
 
tert-Butoxycarbonyl hydrazide 46 (2.5 g, 19 mmol, 1.0 equiv) and 3-
methoxybenzaldehyde 84 (2.3 mL, 19 mmol, 1.0 equiv) were dissolved in ethanol 
(50 mL) and heated to reflux for 1 h. Reaction progress was monitored by TLC 
(ethyl acetate / isohexane 1:1, Rf = 0.53). The solvent was evaporated and the 
colorless solid was re-dissolved in tetrahydrofuran (10 mL), then treated with a 
solution of BH3 x SMe2 in tetrahydrofuran (2.0 M, 9.9 mL, 1.1 equiv) under cooling 
with an ice bath. After complete addition, the ice bath was removed and the 
solution was stirred for 15 min at room temperature. Then concentrated 
hydrochloric acid (4.8 mL, 3.0 equiv) was added dropwise at room temperature 
and the mixture was stirred subsequently at 60 °C for 10 min to complete the 
deprotection of the boc-group. After the reaction mixture was taken to dryness, 
tetrahydrofuran was added and the colorless precipitate was filtered off. Product 
86 (3.2 g, 17 mmol, 90 %) was yielded as colorless hydrochloride. 
 
1H NMR (500 MHz, MeOD):  (ppm) = 3.82 (s, 3 H, OCH3), 4.16 (s, 2 H, CH2), 
6.95 – 6.98 (m, 1 H, 4-H), 7.01 – 7.04 (m, 1 H, 6-H), 7.04 – 7.05 (m, 1 H, 2-H), 
7.32 – 7.36 (m, 1 H, 5-H) 
 
13C NMR (100 MHz, MeOD):  (ppm) = 55.9 (OCH3), 56.3 (CH2), 115.9 (C-4), 
116.3 (C-2), 123.0 (C-6), 131.3 (C-5), 134.9 (C-1), 161.7 (C-3) 
 
MS (APCI): m/z = 153 [M + H]+, 136, 121 
 
MF: C8H13ClN2O   (C8H12N2O) 
 
MW: 188.65 g/mol   (152.19 g/mol) 
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(2-Chlorophenyl)(2-isothiocyanato-5-methoxyphenyl)methanone (87) 
 
Compound 87 was prepared according to GP2 using (2-amino-5-
methoxyphenyl)(2-chlorophenyl)methanone 76 (277 mg, 1.06 mmol, 1.00 equiv) 
as starting material, calcium carbonate (159 mg, 1.59 mmol, 1.50 equiv) and 
thiophosgene 16 (89 µL, 1.2 mmol, 1.1 equiv). After purification (Rf = 0.73), 
product 87 (227 mg, 0.747 mmol, 71 %) was yielded as yellow solid. 
 
mp: 79.1 – 80.2 °C 
 
1H NMR (500 MHz, CDCl3)  (ppm) = 3.83 (s, 3 H, OCH3), 7.06 (dd, 
4JHH = 3.0 Hz, 
3JHH = 8.8 Hz, 1 H, 4-H), 7.14 (d, 
4JHH = 3.0 Hz, 1 H, 6-H), 7.25 (d, 
3JHH = 8.8 Hz, 
1 H, 3-H), 7.41 (ddd, 4JHH = 2.2 Hz, 
3JHH = 6.5 Hz, 
3JHH = 7.4 Hz, 1 H, 5’-H), 7.45 
(ddd, 4JHH = 1.7 Hz, 
3JHH = 6.5 Hz, 
3JHH = 7.9 Hz, 1 H, 4’-H), 7.47 (ddd, 
5JHH = 
0.6 Hz, 4JHH = 2.2 Hz, 
3JHH = 7.9 Hz, 1 H, 3’-H), 7.50 (ddd, 
5JHH = 0.6 Hz, 
4JHH = 
1.6 Hz, 3JHH = 7.4 Hz, 1 H, 6’-H) 
 
13C NMR (100 MHz, CDCl3):  (ppm) = 55.8 (OCH3), 115.2 (C-6), 119.6 (C-4), 
122.7 (C-2), 127.2 (C-5’), 129.5 (C-3), 130.0 (C-6’), 130.5 (C-3’), 131.8 (C-2’), 
132.4 (C-4’), 134.5 (C-1), 135.1 (NCS), 138.0 (C-1’), 158.2 (C-5), 193.1 (CO) 
 
IR [cm-1]:    = 3433 (w), 3086 (w), 3001 (w), 2965 (w), 2937 (w), 2903 (w), 
2835 (w), 2361 (w), 2343 (w), 2183 (w), 2085 (s), 1648 (s), 1591 (m), 1567 (m), 
1488 (s), 1461 (m), 1432 (m), 1410 (m), 1333 (s), 1286 (m), 1231 (s), 1146 (m), 
1095 (m), 1054 (m), 1035 (m), 981 (w), 955 (w), 934 (w), 879 (w), 833 (m), 
826 (m), 760 (m), 743 (m), 711 (w), 633 (m) 
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MS (APCI): m/z = 306, 304 [M + H]+, 290, 288, 274, 272, 264, 262, 237, 226, 192, 
139 
 
HR-MS (ESI): calcd. for C15H11ClNO2S
+ [M + H]+ 304.0194; found 304.0198 
 
HPLC purity: 96 % [ = 210 nm], 97 % [ = 254 nm] 
 
MF: C15H10ClNO2S 
 
MW: 303.76 g/mol 
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(2-Chlorophenyl)(2-isothiocyanato-4,5-dimethoxyphenyl)methanone (88) 
 
Compound 88 as prepared according to GP2 using (2-amino-4,5-
dimethoxyphenyl)(2-chlorophenyl)methanone162 81 (990 mg, 3.39 mmol, 
1.00 equiv) as starting material, calcium carbonate (509 g, 5.09 mmol, 1.50 equiv) 
and thiophosgene 16 (286 µL, 3.73 mmol, 1.10 equiv). After purification (ethyl 
acetate / isohexane 1:2, Rf = 0.49), product 88 (1.0 g, 3.1 mmol, 91 %) was 
yielded as red oily substance. 
 
1H NMR (500 MHz, CDCl3)  (ppm) = 3.91 (s, 3 H, 5-OCH3), 3.95 (s, 3 H, 4-
OCH3), 6.73 (s, 1 H, 3-H), 7.26 (s, 1 H, 6-H), 7.39 – 7.47 (m, 3 H, 4’-H, 5’-H, 6’-H), 
7.47 – 7.51 (m, 1 H, 3’-H) 
 
13C NMR (125 MHz, CDCl3):  (ppm) = 56.3 (5-OCH3), 56.5 (4-OCH3), 110.6 (C-3), 
112.1 (C-6), 124.9 (C-2), 125.4 (C-1), 127.3 (C-5’), 129.3 (C-6’), 130.3 (C-3’), 
131.2 (C-2’), 131.9 (C-4’), 135.4 (NCS), 139.1 (C-1’), 148.2 (C-5), 153.5 (C-4), 
191.9 (CO) 
 
IR [cm-1]:    = 3065 (w), 3009 (w), 2964 (w), 2936 (w), 2850 (w), 2642 (w), 
2432 (w), 2360 (w), 2342 (w), 2115 (s), 1657 (m), 1591 (s), 1566 (m), 1514 (s), 
1464 (m), 1436 (m), 1399 (m), 1360 (m), 1282 (s), 1225 (s), 1209 (s), 1179 (m), 
1161 (w), 1122 (s), 1057 (m), 1034 (m), 1007 (m), 963 (w), 942 (w), 868 (m), 
840 (m), 787 (m), 754 (m), 709 (w), 629 (m) 
 
MS (ESI): m/z = 336, 334 [M + H]+, 314, 292, 237, 222, 139, 102 
 
HR-MS (ESI): calcd. for C16H13ClNO3S
+ [M + H]+ 334.0299; found 334.0305 
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HPLC purity: 90 % [ = 210 nm], 91 % [ = 254 nm] 
 
MF: C16H12ClNO3S 
 
MW: 333.79 g/mol 
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(2-Chlorophenyl)(6-isothiocyanatobenzo[d][1,3]dioxol-5-yl)methanone (89) 
 
Compound 89 was prepared according to GP2 using (6-aminobenzo[d][1,3]dioxol-
5-yl)(2-chlorophenyl)methanone162 83 (170 mg, 0.617 mmol, 1.00 equiv) as 
starting material, calcium carbonate (93 mg, 0.93 mmol, 1.5 equiv) and 
thiophosgene 16 (52 µL, 0.68 mmol, 1.1 equiv). After purification (ethyl acetate / 
isohexane 1:3, Rf = 0.33), product 89 (124 mg, 0.390 mmol, 63 %) was yielded as 
orange oily substance. 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 6.10 (s, 2 H, 2-H), 6.79 (s, 1 H, 7-H), 7.04 
(s, 1 H, 4-H), 7.40 – 7.50 (m, 4 H, 3’-H, 4’-H, 5’-H, 6’-H) 
 
13C NMR (125 MHz, CD2Cl2):  (ppm) = 103.7 (C-2), 108.7 (C-7), 110.2 (C-4), 
126.3 (C-6), 127.6 (C-5’), 127.8 (C-5), 129.9 (C-6’), 130.7 (C-3’), 131.6 (C-2’), 
132.3 (C-4’), 135.8 (NCS), 139.2 (C-1’), 147.5 (C-3a), 152.4 (C-7a), 191.9 (CO) 
 
IR [cm-1]:    = 3060 (w), 2983 (w), 2908 (w), 2772 (w), 2642 (w), 2461 (w), 
2286 (w), 2111 (s), 1729 (w), 1664 (m), 1612 (m), 1589 (w), 1503 (s), 1481 (s), 
1434 (m), 1421 (m), 1380 (m), 1282 (m), 1262 (s), 1243 (m), 1201 (m), 1156 (w), 
1124 (w), 1089 (m), 1035 (s), 934 (m), 872 (w), 849 (w), 824 (w), 756 (m) 
 
MS (APCI): m/z = 320, 318 [M + H]+, 304, 302, 278, 276, 206 
 
HR-MS (ESI): calcd. for C15H9ClNO3S
+ [M + H]+ 317.9986; found 317.9991 
 
HPLC purity: 90 % [ = 210 nm], 94 % [ = 254 nm] 
 
269 
 
CHAPTER VI   –   Experimental section 
 
 
 
MF: C15H8ClNO3S 
 
MW: 317.75 g/mol 
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N-[2-(2-Chlorobenzoyl)-4,5-dimethoxyphenyl]-1-(3-methoxybenzyl)hydrazine-
carbothioamide (91) 
 
(3-Methoxybenzyl)hydrazine hydrochloride 86 (615 mg, 3.26 mmol, 1.10 equiv) 
was dissolved in 5 mL of methanol, cooled to 0 °C and treated with N,N-
diisopropylethylamine (609 µL, 3.56 mmol, 1.20 equiv). After stirring for 1 h at 
room temperature, a solution of (2-chlorophenyl)(2-isothiocyanato-4,5-dimethoxy-
phenyl)methanone 88 (990 mg, 2.97 mmol, 1.00 equiv) in 7 mL of tetrahydrofuran 
was added and stirring was continued for 1 h. The solvent was evaporated and 
purification was done by flash column chromatography on flash silica gel (ethyl 
acetate / isohexane 1:1, Rf = 0.48), giving compound 91 (1.3 g, 2.7 mmol, 91 %) 
as pale yellow solid. 
 
mp: 167.5 – 168.1 °C 
 
1H NMR (500 MHz, CDCl3)  (ppm) = 3.66 (s, 3 H, 4’’-OCH3), 3.80 (s, 3 H, 3’-
OCH3), 3.90 (bs, 2 H, NH2), 4.04 (s, 3 H, 5’’-OCH3), 5.48 (s, 2 H, 1-H), 6.78 (s, 
1 H, 3’’-H), 6.86 (ddd, 4JHH = 0.8 Hz, 
4JHH = 2.5 Hz, 
3JHH = 8.3 Hz, 1 H, 4’-H), 6.93 
– 6.97 (m, 2 H, 2’-H, 6’-H), 7.26 – 7.32 (m, 1 H, 5’-H), 7.32 – 7.38 (m, 2 H, 5’’’’-H, 
6’’’’-H), 7.41 (ddd, 4JHH = 2.5 Hz, 
3JHH = 6.5 Hz, 
3JHH = 8.0 Hz, 1 H, 4’’’’-H), 7.46 
(ddd, 5JHH = 0.5 Hz, 
4JHH = 1.1 Hz, 
3JHH = 8.0 Hz, 1 H, 3’’’’-H), 9.33 (s, 1 H, 6’’-H), 
13.09 (s, 1 H, NH) 
 
13C NMR (125 MHz, CDCl3):  (ppm) = 55.3 (3’-OCH3), 56.2 (4’’-OCH3), 56.6 (5’’-
OCH3), 57.2 (C-1), 106.0 (C-6’’), 113.6 (C-4’), 113.8 (C-2’), 115.7 (C-3’’), 117.0 (C-
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2’’), 120.4 (C-6’), 126.7 (C-5’’’’), 129.1 (C-6’’’’), 130.1 (C-5’), 130.1 (C-3’’’’), 131.0 
(C-4’’’’), 131.1 (C-2’’’’), 136.9 (C-1’), 138.7 (C-1’’), 139.3 (C-1’’’’), 143.9 (C-4’’), 
154.0 (C-5’’), 160.2 (C-3’), 180.2 (CS), 195.9 (CO) 
 
IR [cm-1]:    = 3334 (w), 3094 (w), 3002 (w), 2935 (w), 2832 (w), 2366 (w), 
2345 (w), 1611 (m), 1573 (m), 1521 (s), 1489 (m), 1463 (m), 1433 (m), 1408 (w), 
1377 (w), 1348 (m), 1321 (m), 1284 (m), 1263 (s), 1213 (m), 1184 (m), 1160 (m), 
1117 (m), 1039 (m), 866 (w), 836 (w), 787 (w), 758 (w), 739 (w), 699 (w), 649 (w), 
595 (w) 
 
MS (ESI): m/z = 488, 486 [M + H]+, 334, 292, 238, 193, 153 
 
HR-MS (ESI): calcd. for C24H24ClN3NaO4S
+ [M + Na]+ 508.1068; found 508.1075 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C24H24ClN3O4S 
 
MW: 485.98 g/mol 
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N-[6-(2-Chlorobenzoyl)benzo[d][1,3]dioxol-5-yl]-1-(3-methoxybenzyl)-
hydrazinecarbothioamide (92) 
 
(3-Methoxybenzyl)hydrazine hydrochloride 86 (72 mg, 0.38 mmol, 1.1 equiv) was 
dissolved in 5 mL of methanol, cooled to 0 °C and treated with N,N-
diisopropylethylamine (71 µL, 0.42 mmol, 1.2 equiv). After stirring for 1 h at room 
temperature, a solution of (2-chlorophenyl)(6-isothiocyanatobenzo[d][1,3]dioxol-5-
yl)methanone 89 (110 mg, 0.346 mmol, 1.00 equiv) in 5 mL of tetrahydrofuran was 
added and stirring was continued for 1 h. The solvent was evaporated and 
purification was done by flash column chromatography on flash silica gel (ethyl 
acetate / isohexane 2:3, Rf = 0.42), giving compound 92 (82 mg, 0.17 mmol, 50 %) 
as yellow solid. 
 
mp: 170.5 – 172.1 °C 
 
1H NMR (500 MHz, CDCl3)  (ppm) = 3.79 (s, 3 H, 3’-OCH3), 3.87 (bs, 2 H, NH2), 
5.46 (s, 2 H, 1-H), 6.02 (s, 2 H, 2’’-H), 6.73 (s, 1 H, 7’’-H), 6.86 (ddd, 4JHH = 1.0 Hz, 
4JHH = 2.5 Hz, 
3JHH = 8.3 Hz, 1 H, 4’-H), 6.93 – 6.97 (m, 2 H, 2’-H, 6’-H), 7.26 – 
7.32 (m, 1 H, 5’-H), 7.32 – 7.35 (m, 2 H, 5’’’’-H, 6’’’’-H), 7.37 – 7.43 (m, 1 H, 4’’’’-H), 
7.43 – 7.46 (m, 1 H, 3’’’’-H), 8.92 (s, 1 H, 4’’-H), 12.94 (s, 1 H, NH) 
 
13C NMR (125 MHz, CDCl3):  (ppm) = 55.3 (3’-OCH3), 57.3 (C-1), 102.2 (C-2’’), 
104.5 (C-4’’), 111.5 (C-7’’), 113.7 (C-2’), 113.7 (C-4’), 119.0 (C-6’’), 120.5 (C-6’), 
126.7 (C-5’’’’), 129.0 (C-6’’’’), 130.1 (C-5’), 130.1 (C-3’’’’), 131.1 (C-4’’’’), 131.1 (C-
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2’’’’), 136.9 (C-1’), 139.2 (C-1’’’’), 140.0 (C-5’’), 143.0 (C-7a’’), 152.1 (C-3a’’), 160.2 
(C-3’), 180.5 (CS), 195.7 (CO) 
 
IR [cm-1]:    = 3094 (w), 3002 (w), 2905 (w), 2364 (m), 2345 (m), 1654 (w), 
1637 (m), 1618 (m), 1601 (m), 1507 (s), 1490 (s), 1432 (m), 1387 (m), 1350 (m), 
1315 (m), 1271 (m), 1244 (m), 1141 (w), 1083 (m), 1036 (s), 935 (w), 866 (w), 
847 (w), 782 (w), 762 (w), 741 (w), 693 (w) 
 
MS (APCI): m/z = 472, 470 [M + H]+, 320, 318, 302, 286, 278, 276, 240, 206, 193, 
153, 136 
 
HR-MS (ESI): calcd. for C23H20ClN3NaO4S
+ [M + Na]+ 492.0755; found 492.0762 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H20ClN3O4S 
 
MW: 469.94 g/mol 
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5-(2-Chlorophenyl)-7-methoxy-3-(3-methoxybenzyl)-1H-benzo[e][1,2,4]-
triazepine-2(3H)-thione (93) 
 
(3-Methoxybenzyl)hydrazine hydrochloride 86 (102 mg, 0.543 mmol, 1.10 equiv) 
was dissolved in 5 mL of methanol, cooled to 0 °C and treated with N,N-
diisopropylethylamine (101 µL, 0.593 mmol, 1.20 equiv). After stirring for 30 min at 
room temperature, a solution of (2-chlorophenyl)(2-isothiocyanato-5-
methoxyphenyl)methanone 87 (150 mg, 0.494 mmol, 1.00 equiv) in 5 mL of 
tetrahydrofuran was added and stirring was continued for 3 h. The mixture was 
concentrated under reduced pressure, dissolved in ethanol (10 mL), treated with a 
catalytic amount of para-toluenesulfonic acid monohydrate (2.0 mg, 12 µmol, 
2.5 mol%) and heated to reflux for 1 h. The solvent was evaporated and 
purification was done by flash column chromatography on flash silica gel 
(dichloromethane, Rf = 0.33), giving compound 93 (126 mg, 0.288 mmol, 58 %) as 
yellow solid. 
 
mp: 134.5 – 136.7 °C 
 
1H NMR (500 MHz, CDCl3):  (ppm) = 3.63 (s, 3 H, 7-OCH3), 3.70 (s, 3 H, 3’’’-
OCH3), 5.31 (s, 2 H, 1’’-H), 6.19 (d, 
4JHH = 2.0 Hz, 1 H, 6-H), 6.82 (dd, 
4JHH = 
2.5 Hz, 3JHH = 8.2 Hz, 1 H, 4’’’-H), 6.84 – 6.88 (m, 2 H, 6’-H, 2’’’-H), 6.88 – 6.95 (m, 
3 H, 8-H, 9-H, 6’’’-H), 7.17 – 7.35 (m, 2 H, 5’-H, 5’’’-H), 7.30 – 7.35 (m, 2 H, 3’-H, 
4’-H), 8.02 (bs, 1 H, 1-H) 
 
13C NMR (125 MHz, CDCl3):  (ppm) = 55.1 (3’’’-OCH3), 55.6 (7-OCH3), 59.6 (C-
1’’), 113.3 (C-4’’’), 113.4 (C-2’’’), 113.9 (C-6), 118.0 (C-8), 120.8 (C-6’’’), 121.4 (C-
9), 126.9 (C-5’), 128.0 (C-5a), 129.3 (C-5’’’), 130.1 (C-3’), 131.1 (C-4’), 131.3 (C-
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6’), 133.4 (C-2’), 135.4 (C-1’), 136.8 (C-9a), 138.6 (C-1’’’), 156.2 (C-7), 159.6 (C-
3’’’), 166.6 (C-5), 193.4 (C-2) 
 
IR [cm-1]:    = 3432 (w), 3087 (w), 3005 (w), 2930 (w), 2832 (w), 2360 (s), 
2342 (m), 1587 (m), 1500 (s), 1434 (m), 1373 (w), 1328 (m), 1300 (m), 1261 (m), 
1235 (m), 1219 (s), 1174 (m), 1152 (s), 1112 (m), 1035 (m), 1002 (m), 975 (w), 
872 (w), 814 (w), 758 (m), 727 (m), 690 (m), 668 (m) 
 
MS (APCI): m/z = 440, 438 [M + H]+, 422, 406, 303, 262, 241, 185, 136 
 
HR-MS (ESI): calcd. for C23H21ClN3O2S
+ [M + H]+ 438.1038; found 438.1044 
 
HPLC purity: 96 % [ = 210 nm], 97 % [ = 254 nm] 
 
MF: C23H20ClN3O2S 
 
MW: 437.94 g/mol 
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5-(2-Chlorophenyl)-7,8-dimethoxy-3-(3-methoxybenzyl)-1H-benzo[e][1,2,4]-
triazepine-2(3H)-thione (94) 
 
N-[2-(2-Chlorobenzoyl)-4,5-dimethoxyphenyl]-1-(3-methoxybenzyl)hydrazine-
carbothioamide 91 (580 mg, 1.19 mmol, 1.00 equiv) was dissolved in ethyl acetate 
(15 mL), treated with a catalytic amount of para-toluenesulfonic acid monohydrate 
(6.0 mg, 30 µmol, 2.5 mol%) and heated to reflux for 1 h. The solvent was 
evaporated and purification was done by flash column chromatography on flash 
silica gel (ethyl acetate / isohexane 2:3, Rf = 0.46), giving compound 94 (469 mg, 
1.00 mmol, 84 %) as yellow solid. 
 
mp: 152.5 – 154.8 °C 
 
1H NMR (500 MHz, CDCl3):  (ppm) = 3.59 (s, 3 H, 7-OCH3), 3.71 (s, 3 H, 3’’’-
OCH3), 3.88 (s, 3 H, 8-OCH3), 5.31 (s, 2 H, 1’’-H), 6.09 (s, 1 H, 6-H), 6.55 (s, 1 H, 
9-H), 6.82 (ddd, 4JHH = 0.8 Hz, 
4JHH = 2.6 Hz, 
3JHH = 8.2 Hz, 1 H, 4’’’-H), 6.85 (ddd, 
5JHH = 0.4 Hz, 
4JHH = 1.5 Hz, 
3JHH = 7.7 Hz, 1 H, 6’-H), 6.87 (dd, 
4JHH = 1.5 Hz, 
4JHH 
= 2.5 Hz, 1 H, 2’’’-H), 6.93 (ddd, 4JHH = 0.8 Hz, 
4JHH = 1.5 Hz, 
3JHH = 7.6 Hz, 1 H, 
6’’’-H), 7.19 – 7.23 (m, 1 H, 5’-H), 7.23 (dd, 3JHH = 7.6 Hz, 
3JHH = 8.2 Hz, 1 H, 5’’’-
H), 7.31 – 7.36 (m, 2 H, 3’-H, 4’-H), 8.08 (s, 1 H, 1-H) 
 
13C NMR (125 MHz, CDCl3):  (ppm) = 55.1 (3’’’-OCH3), 56.3 (8-OCH3), 56.3 (7-
OCH3), 59.5 (C-1’’), 103.6 (C-9), 111.0 (C-6), 113.3 (C-4’’’), 113.3 (C-2’’’), 118.8 
(C-5a), 120.8 (C-6’’’), 126.9 (C-5’), 129.3 (C-5’’’), 130.1 (C-3’), 131.1 (C-4’), 131.5 
(C-6’), 133.4 (C-2’), 135.4 (C-1’), 138.3 (C-9a), 138.6 (C-1’’’), 145.9 (C-7), 152.8 
(C-8), 159.6 (C-3’’’), 167.2 (C-5), 193.3 (C-2) 
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IR [cm-1]:    = 3072 (w), 3000 (w), 2933 (w), 2834 (w), 2645 (w), 2363 (w), 
2344 (w), 1609 (m), 1520 (s), 1492 (s), 1463 (m), 1435 (m), 1374 (m), 1339 (m), 
1315 (m), 1270 (s), 1222 (s), 1202 (m), 1175 (m), 1123 (s), 1036 (m), 998 (m), 
945 (w), 852 (w), 756 (m), 737 (w), 691 (w), 609 (w) 
 
MS (ESI): m/z = 470, 468 [M + H]+, 238, 406, 303, 262, 241, 185, 136 
 
HR-MS (ESI): calcd. for C24H23ClN3O3S
+ [M + H]+ 468.1143; found 468.1150 
 
HPLC purity: 98 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C24H22ClN3O3S 
 
MW: 467.97 g/mol 
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5-(2-Chlorophenyl)-3-(3-methoxybenzyl)-1H-[1,3]dioxolo[4’,5’:4,5]benzo- 
[1,2-e][1,2,4]triazepine-2(3H)-thione (95) 
 
N-[6-(2-Chlorobenzoyl)benzo[d][1,3]dioxol-5-yl]-1-(3-methoxybenzyl)hydrazine-
carbothioamide 92 (70 mg, 0.15 mmol, 1.0 equiv) was dissolved in ethyl acetate 
(6 mL), treated with a catalytic amount of para-toluenesulfonic acid monohydrate 
(0.7 mg, 4 µmol, 2.5 mol%) and heated to reflux for 1 h. The solvent was 
evaporated and purification was done by flash column chromatography on flash 
silica gel (ethyl acetate / isohexane 2:3, Rf = 0.53), giving compound 95 (64 mg, 
0.14 mmol, 95 %) as yellow solid. 
 
mp: 191.2 – 193.5 °C 
 
1H NMR (500 MHz, CDCl3):  (ppm) = 3.74 (s, 3 H, 3’’’-OCH3), 5.29 (s, 2 H, 1’’-H), 
5.99 (s, 2 H, 8-H), 6.10 (s, 1 H, 6-H), 6.44 (s, 1 H, 10-H), 6.80 (ddd, 5JHH = 0.5 Hz, 
4JHH = 1.4 Hz, 
3JHH = 7.7 Hz, 1 H, 6’-H), 6.83 (ddd, 
4JHH = 0.8 Hz, 
4JHH = 2.6 Hz, 
3JHH = 8.3 Hz, 1 H, 4’’’-H), 6.87 (dd, 
4JHH = 1.6 Hz, 
4JHH = 2.5 Hz, 1 H, 2’’’-H), 6.91 
(ddd, 4JHH = 0.9 Hz, 
4JHH = 1.5 Hz, 
3JHH = 7.6 Hz, 1 H, 6’’’-H), 7.18 – 7.21 (m, 1 H, 
5’-H), 7.21 – 7.25 (m, 1 H, 5’’’-H), 7.31 – 7.36 (m, 2 H, 3’-H, 4’-H), 7.43 (s, 1 H, 1-
H) 
 
13C NMR (125 MHz, CDCl3):  (ppm) = 55.2 (3’’’-OCH3), 59.5 (C-1’’), 101.3 (C-10), 
102.3 (C-8), 107.6 (C-6), 113.2 (C-4’’’), 113.5 (C-2’’’), 120.2 (C-5a), 120.8 (C-6’’’), 
126.9 (C-5’), 129.4 (C-5’’’), 130.1 (C-3’), 131.1 (C-4’), 131.3 (C-6’), 133.4 (C-2’), 
135.5 (C-1’), 138.4 (C-1’’’), 139.3 (C-10a), 144.7 (C-6a), 151.2 (C-9a), 159.6 (C-
3’’’), 166.8 (C-5), 193.4 (C-2) 
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IR [cm-1]:    = 3074 (w), 2909 (w), 2364 (w), 2345 (w), 1602 (m), 1503 (s), 1485 (s), 
1434 (m), 1409 (m), 1364 (w), 1340 (w), 1312 (m), 1255 (s), 1200 (m), 1162 (m), 
1081 (w), 1037 (s), 1003 (w), 930 (w), 853 (w), 760 (w), 740 (w), 692 (w) 
 
MS (APCI): m/z = 454, 452 [M + H]+, 420, 316, 283 
 
HR-MS (ESI): calcd. for C23H19ClN3O3S
+ [M + H]+ 452.0830; found 452.0838 
 
HPLC purity: 94 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C23H18ClN3O3S 
 
MW: 451.93 g/mol 
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6-(2-Chlorophenyl)-8-methoxy-4-(3-methoxybenzyl)-1-methyl-4H-benzo-
[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (96) 
 
Synthesis of the triazole-ring followed GP3. 5-(2-Chlorophenyl)-7-methoxy-3-(3-
methoxybenzyl)-1H-benzo[e][1,2,4]triazepine-2(3H)-thione 93 (110 mg, 
0.251 mmol, 1.00 equiv) was treated first with hydrazine hydrate (61 µL, 1.3 mmol, 
5.0 equiv). Triethyl orthoacetate 43 (60 µL, 0.33 mmol, 1.3 equiv) and para-
toluenesulfonic acid monohydrate (10 mg, 0.05 mmol, 0.2 equiv) were used in the 
second step. Product 96 (59 mg, 0.13 mmol, 51 %) was obtained after purification 
(Rf = 0.24) as yellow solid. 
 
mp: 170.9 – 172.4 °C 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.52 (s, 3 H, 1-CH3), 3.70 (s, 3 H, 8-OCH3), 
3.74 (s, 3 H, 3’’’-OCH3), 4.75 – 5.19 (m, 2 H, 1’’-H), 6.47 (d, 
4JHH = 2.9 Hz, 1 H, 7-
H), 6.80 (ddd, 4JHH = 0.9 Hz, 
4JHH = 2.6 Hz, 
3JHH = 8.2 Hz, 1 H, 4’’’-H), 6.95 (dd, 
4JHH = 1.6 Hz, 
4JHH = 2.6 Hz, 1 H, 2’’’-H), 6.98 (ddd, 
4JHH = 0.9 Hz, 
4JHH = 1.5 Hz, 
3JHH = 7.5 Hz, 1 H, 6’’’-H), 7.10 (dd, 
4JHH = 2.9 Hz, 
3JHH = 8.9 Hz, 1 H, 9-H), 7.22 
(dd, 3JHH = 7.5 Hz, 
3JHH = 8.2 Hz, 1 H, 5’’’-H), 7.29 (d, 
3JHH = 8.9 Hz, 1 H, 10-H), 
7.31 – 7.33 (m, 2 H, 5’-H, 6’-H), 7.33 – 7.35 (m, 1 H, 3’-H), 7.35 – 7.40 (m, 1 H, 4’-
H) 
 
13C NMR (125 MHz, CD2Cl2):  (ppm) = 12.7 (1-CH3), 55.5 (3’’’-OCH3), 56.1 (8-
OCH3), 57.9 (C-1’’), 113.1 (C-4’’’), 114.8 (C-2’’’), 115.3 (C-7), 116.8 (C-9), 121.6 
(C-6’’’), 124.1 (C-10), 127.4 (C-5’), 127.4 (C-10a), 129.6 (C-5’’’), 130.4 (C-3’), 
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131.3 (C-6a), 131.3 (C-4’), 131.9 (C-6’), 133.3 (C-2’), 136.3 (C-1’), 139.6 (C-1’’’), 
148.7 (C-1), 158.4 (C-8), 160.0 (C-3’’’), 160.1 (C-3a), 160.9 (C-6) 
 
IR [cm-1]:    = 3431 (w), 3058 (w), 3000 (w), 2932 (m), 2835 (m), 1794 (w), 
1683 (w), 1602 (m), 1585 (m), 1520 (s), 1505 (s), 1491 (m), 1455 (m), 1436 (s), 
1380 (w), 1338 (m), 1316 (m), 1297 (m), 1268 (s), 1229 (m), 1189 (w), 1157 (m), 
1136 (w), 1051 (m), 1006 (m), 973 (w), 882 (w), 823 (w), 773 (m), 745 (m), 
734 (m), 690 (w), 621 (w) 
 
MS (APCI): m/z = 462, 460 [M + H]+, 325, 315, 287, 285 
 
HR-MS (ESI): calcd. for C25H23ClN5O2
+ [M + H]+ 460.1535; found 460.1542 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C25H22ClN5O2 
 
MW: 459.93 g/mol 
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6-(2-Chlorophenyl)-8,9-dimethoxy-4-(3-methoxybenzyl)-1-methyl-4H-benzo-
[e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (97) 
 
Synthesis of the triazole-ring followed GP3. 5-(2-Chlorophenyl)-7,8-dimethoxy-3-
(3-methoxybenzyl)-1H-benzo[e][1,2,4]triazepine-2(3H)-thione 94 (470 mg, 
1.00 mmol, 1.00 equiv) was treated first with hydrazine hydrate (244 µL, 
5.02 mmol, 5.00 equiv). Triethyl orthoacetate 43 (238 µL, 1.31 mmol, 1.30 equiv) 
and para-toluenesulfonic acid monohydrate (38 mg, 0.20 mmol, 0.20 equiv) were 
used in the second step. Product 97 (171 mg, 0.349 mmol, 35 %) was obtained 
after purification (Rf = 0.21) as colorless solid. 
 
mp: 232.0 – 233.9 °C 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.55 (s, 3 H, 1-CH3), 3.61 (s, 3 H, 8-OCH3), 
3.75 (s, 3 H, 3’’’-OCH3), 3.92 (s, 3 H, 9-OCH3), 4.75 – 4.95 (m, 1 H, 1’’-HH), 4.96 – 
5.17 (m, 1 H, 1’’-HH), 6.37 (s, 1 H, 7-H), 6.80 (ddd, 4JHH = 0.9 Hz, 
4JHH = 2.6 Hz, 
3JHH = 8.3 Hz, 1 H, 4’’’-H), 6.81 (s, 1 H, 10-H), 6.96 (dd, 
5JHH = 0.4 Hz, 
4JHH = 
1.6 Hz, 4JHH = 2.6 Hz, 1 H, 2’’’-H), 6.99 (ddd, 
4JHH = 0.9 Hz, 
4JHH = 1.5 Hz, 
3JHH = 
7.5 Hz, 1 H, 6’’’-H), 7.22 (dd, 5JHH = 0.4 Hz, 
3JHH = 7.6 Hz, 
3JHH = 8.2 Hz, 1 H, 5’’’-
H), 7.29 – 7.39 (m, 4 H, 3’-H, 4’-H, 5’-H, 6’-H) 
 
13C NMR (125 MHz, CD2Cl2):  (ppm) = 13.0 (1-CH3), 55.5 (3’’’-OCH3), 56.5 (8-
OCH3), 56.7 (9-OCH3), 57.9 (C-1’’), 106.2 (C-10), 111.9 (C-7), 113.1 (C-4’’’), 114.8 
(C-2’’’), 121.6 (C-6’’’), 122.5 (C-6a), 127.4 (C-5’), 128.3 (C-10a), 129.5 (C-5’’’), 
130.5 (C-3’), 131.2 (C-4’), 132.0 (C-6’), 133.4 (C-2’), 136.3 (C-1’), 139.6 (C-1’’’), 
148.1 (C-8), 148.4 (C-1), 151.9 (C-9), 160.0 (C-3’’’), 160.3 (C-3a), 161.1 (C-6) 
283 
 
CHAPTER VI   –   Experimental section 
 
 
 
 
IR [cm-1]:    = 3089 (w), 3061 (w), 2998 (w), 2954 (w), 2931 (w), 2835 (w), 
2364 (w), 2345 (w), 1610 (m), 1588 (m), 1526 (s), 1513 (s), 1493 (w), 1459 (m), 
1439 (m), 1373 (m), 1341 (m), 1290 (m), 1263 (s), 1220 (m), 1147 (m), 1048 (m), 
1019 (m), 865 (m), 811 (m), 761 (w), 741 (w), 694 (w) 
 
MS (APCI): m/z = 492, 490 [M + H]+, 355, 315 
 
HR-MS (ESI): calcd. for C26H25ClN5O3
+ [M + H]+ 490.1640; found 490.1647 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C26H24ClN5O3 
 
MW: 489.95 g/mol 
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6-(2-Chlorophenyl)-4-(3-methoxybenzyl)-1-methyl-4H-[1,3]dioxolo[4’,5’:4,5]-
benzo[1,2-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine (98) 
 
Synthesis of the triazole-ring followed GP3. 5-(2-Chlorophenyl)-3-(3-
methoxybenzyl)-1H-[1,3]dioxolo[4’,5’:4,5]benzo[1,2-e][1,2,4]triazepine-2(3H)-
thione 95 (50 mg, 0.11 mmol, 1.0 equiv) was treated first with hydrazinie hydrate 
(27 µL, 0.55 mmol, 5.0 equiv). Triethyl orthoacetate 43 (26 µL, 0.14 mmol, 
1.3 equiv) and para-toluenesulfonic acid monohydrate (4.2 mg, 22 µmol, 0.2 equiv) 
were used in the second step. Product 98 (21 mg, 44 µmol, 40 %) was obtained 
after purification (Rf = 0.46) as colorless solid. 
 
mp: 213.1 – 214.4 °C 
 
1H NMR (500 MHz, CD2Cl2)  (ppm) = 2.52 (s, 3 H, 1-CH3), 3.76 (s, 3 H, 3’’’-
OCH3), 4.80 (d, 
2JHH = 13.7 Hz, 1 H, 1’’-HH), 5.09 (d, 
2JHH = 13.7 Hz, 1 H, 1’’-HH), 
6.08 (s, 2 H, 9-H), 6.39 (s, 1 H, 7-H), 6.81 (ddd, 4JHH = 0.9 Hz, 
4JHH = 2.6 Hz, 
3JHH 
= 8.2 Hz, 1 H, 4’’’-H), 6.83 (s, 1 H, 11-H), 6.96 (dd, 4JHH = 1.6 Hz, 
4JHH = 2.5 Hz, 
1 H, 2’’’-H), 6.99 (ddd, 4JHH = 0.9 Hz, 
4JHH = 1.5 Hz, 
3JHH = 7.5 Hz, 1 H, 6’’’-H), 7.22 
(dd, 3JHH = 7.5 Hz, 
3JHH = 8.1 Hz, 1 H, 5’’’-H), 7.27 – 7.39 (m, 4 H, 3’-H, 4’-H, 5’-H, 
6’-H) 
 
13C NMR (125 MHz, CD2Cl2):  (ppm) = 12.9 (1-CH3), 55.5 (3’’’-OCH3), 57.8 (C-
1’’), 103.4 (C-9), 103.8 (C-11), 108.7 (C-7), 113.0 (C-4’’’), 114.8 (C-2’’’), 121.5 (C-
6’’’), 124.2 (C-6a), 127.5 (C-5’), 129.4 (C-11a), 129.6 (C-5’’’), 130.5 (C-3’), 131.3 
(C-4’), 131.9 (C-6’), 133.4 (C-2’), 136.3 (C-1’), 139.6 (C-1’’’), 147.0 (C-7a), 148.6 
(C-1), 150.5 (C-10a), 160.0 (C-3’’’), 160.3 (C-3a), 161.0 (C-6) 
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IR [cm-1]:    = 3057 (w), 2912 (w), 2834 (w), 2362 (w), 2344 (w), 1708 (w), 
1626 (w), 1594 (m), 1520 (m), 1506 (s), 1489 (s), 1455 (m), 1436 (m), 1400 (m), 
1358 (w), 1342 (w), 1303 (w), 1283 (m), 1265 (m), 1235 (s), 1155 (m), 1105 (w), 
1035 (s), 989 (w), 926 (w), 867 (w), 836 (w), 775 (m), 758 (m), 742 (m), 688 (w) 
 
MS (APCI): m/z = 476, 474 [M + H]+, 460, 341, 339, 304, 301, 299, 136 
 
HR-MS (ESI): calcd. for C25H21ClN5O3
+ [M + H]+ 474.1327; found 474.1335 
 
HPLC purity: > 99 % [ = 210 nm], > 99 % [ = 254 nm] 
 
MF: C25H20ClN5O3 
 
MW: 473.91 g/mol 
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ABBREVIATIONS 
°C degree Celsius 
5mC 5-methylcytosine 
Å Ångström 
Ac acetyl 
ADT agar diffusion test 
APCI atmospheric-pressure chemical ionization 
BET bromodomain and extra-terminal 
bp base pair 
BRD bromodomain 
BRD [number] bromodomain-containing protein [number] 
BzD benzodiazepine 
BzT benzotriazepine 
c concentration 
C cytosine 
cc compound concentration 
CI chemical ionization 
COSY correlation spectroscopy 
CpG C-phosphate-G 
CuAAC copper-catalyzed azide-alkyne cycloaddition 
DAD diode array detector 
DCC N,N‘-dicyclohexylcarbodiimide 
DCM dichloromethane 
DEPT distortionless enhancement by polarization transfer 
DFT density functional theory 
DIAD diisopropyl azodicarboxylate 
DIC N,N‘-diisopropylcarbodiimide 
DMAP 4-(dimethylamino)pyridine 
DMF dimethylformamide 
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Abbreviations 
 
 
 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
DNMT DNA methyltransferase 
DSF differential scanning fluorimetry 
EDG electron donating group 
EI electronic ionization 
ESI electron spray ionization 
EWG electron withdrawing group 
FT Fourier transformed 
G guanine 
GABA -aminobutyric acid 
GP general procedure 
H [number] histone [number] 
HAT histone acetyltransferase 
HDAC histone deacetylase 
HIV human immunodeficiency virus 
HMBC heteronuclear multiple bond coherence 
HMQC heteronuclear multiple quantum coherence 
HPLC high performance liquid chromatography 
HR high resolution 
HTS high throughput screening 
Hz Hertz 
IR infrared  
ITC isothermal titration calorimetry 
K lysine 
Kac -N-acetylated lysine 
Me methyl 
MeCN acetonitrile 
MeOH methanol 
MF molecular formula 
289 
 
Abbreviations 
 
 
 
MLL mixed lineage leukaemia 
mp melting point 
MS mass spectrometry 
MW molecular weight 
NAD(P) nicotine adenine dinucleotide (phosphate) 
NMR nuclear magnetic resonance 
P proline 
PCR polymerase chain reaction 
PDB protein data bank 
PMB para-methoxybenzyl 
ppm parts per million 
R arginine 
r.t. room temperature 
S serine 
SAR structure-activity relationship(s) 
SGC Structural Genomics Consortium 
T threonine 
TBzD triazolobenzodiazepine 
TBzT triazolobenzotriazepine 
THF tetrahydrofuran 
TLC thin layer chromatography 
TMS tetramethylsilane 
UV ultraviolet 
Y tyrosine 
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